Page last updated: 2024-08-18

thiophenes and Hemorrhage

thiophenes has been researched along with Hemorrhage in 425 studies

Research

Studies (425)

Timeframe	Studies, this research(%)	All Research%
pre-1990	6 (1.41)	18.7374
1990's	0 (0.00)	18.2507
2000's	58 (13.65)	29.6817
2010's	359 (84.47)	24.3611
2020's	2 (0.47)	2.80

Authors

Authors	Studies
Cao, X; Gu, J; Li, X; Liu, P; Miao, Y; Sun, D; Xu, Z; Zhang, J	1
Abbasnezhad, A; Abd El-Ghafar, OA; Abhilash, L; Abouzid, KAM; Achberger, AM; Ackerman, S; Akhatayeva, Z; Akin, D; Al-Kaysi, RO; Alakhdar, AA; Alame, M; Aleksic Sabo, V; Alinezhadbalalami, N; Allen, JD; Alonso, JM; Alqatani, S; Alsayed, B; Álvarez Larraondo, M; Alvarez, M; Amini, SB; An, Z; Anasir, MI; Anderson, GH; Andremont, A; Andrés, S; Angel, S; Anigboro, AA; Anini, Y; Antonides, CFJ; Arafa, K; Arafa, RK; Aryal, UK; Asbaghi, O; Assefa, MK; Atyah, M; Avwioroko, OJ; Ayora-Talavera, G; Azpilikueta, A; Azyazov, VN; Ba, YF; Bachmann, KF; Badoual, J; Bae, SJ; Baek, SH; Bahrami, B; Bai, J; Baid-Agrawal, S; Bailey, MR; Baillie, JK; Balani, N; Balcar, VJ; Banica, T; Banks, L; Barb, J; Bardeen, CJ; Barrett, HE; Bartnikowski, N; Bashir, R; Battaglia, M; Bautista-Hernández, V; Becker, B; Beekman, FJ; Benidir, M; Benjelloun, M; Bentley, RF; Bergé, J; Berger, D; Bernsen, MR; Berraondo, P; Bhattacharya, R; Bhayani, SB; Bi, W; Bi, X; Bi, YL; Bi, Z; Bian, K; Biesecker, LG; Billadeau, DD; Blaszczyk, R; Blum, JL; Boachie, R; Boelte, K; Bogers, AJJC; Boileau, I; Bonduelle, C; Bonny, O; Bonsu, JM; Boos, LA; Borges-Argáez, R; Bouchard, PA; Boudot, C; Bourgeade-Delmas, S; Boutet-Robinet, E; Boyle, AJ; Branigan, D; Briones, S; Broniowska, KA; Brossas, JY; Brown, WA; Brzezinska, J; Buitron, G; Burnier, M; Bursulaya, B; Burton, PR; Bush, AA; Busuttil, RW; Cabello-Aguilar, S; Cáceres-Farfán, M; Cacheux, V; Caffrey, PJ; Cai, B; Cai, Q; Cai, S; Cai, Y; Calders, P; Cammarota, G; Campbell, DA; Cancelli, C; Cao, Q; Cao, WH; Cao, X; Capet, M; Capoluongo, E; Carey, ME; Carnero, M; Carrasco, LI; Carreno, J; Carrillo-Reyes, J; Casini, I; Cassar, M; Catalan, G; Cattamanchi, A; Cazares-Granillo, M; Celie, B; Cen, YK; Cena, H; Cerbo, RM; Ceron, E; Cetina-Montejo, L; Chaâbane-Banaoues, R; Chabanet, C; Chace-Donahue, F; Chalfun-Júnior, A; Chan-Balan, R; Chang, CS; Chen, CS; Chen, D; Chen, J; Chen, L; Chen, PN; Chen, Q; Chen, S; Chen, W; Chen, WP; Chen, X; Chen, Z; Cheng, H; Cheng, J; Cheng, Q; Cheng, T; Chi, T; Chianelli, D; Chieppa, M; Child, CJ; Cho, JH; Cho, JY; Chogtu, B; Choi, GH; Choi, J; Choi, M; Choi, NG; Cholu, CO; Chow, ES; Chowdhury, AH; Chu, PC; Chu, Q; Chu, S; Chua, H; Chung, T; Chunyan, L; Church, JS; Civardi, E; Cobiella, J; Colinge, J; Collado, CJ; Collins, TJ; Cong, LM; Conkrite, KL; Cope, SJ; Corbett, JA; Cornet, M; Cornillot, E; Corvaisier, S; Costes-Martineau, V; Courtioux, B; Coussens, M; Covino, M; Criado, A; Cui, J; Cui, Y; Cunitz, BW; Curry, AE; Cussó, L; D'Urzo, AD; D'Urzo, KA; Dabbous, S; Dahlgren, RA; Dai, H; Dai, T; Dai, W; Dalinghaus, M; Dang, S; Davalos, RV; Davidson, H; de Andrea, CE; De Angelis, M; de Blois, E; de Carvalho, PA; De Clercq, E; De Giuseppe, R; de Jong, M; De Langhe, S; De Oliveira, L; de Souza Pinto Lemgruber, R; de Souza, LB; de Swart, J; De Wandele, I; de Woestijne, PCV; Delaney, S; Delorme, M; Delvenne, P; Deng, L; Deng, Z; Denkinger, CM; der Meulen, MHV; Deraeve, C; Desco, M; DeSilva, S; Destere, A; Dhali, A; Di Ciano, P; Dias-Santagata, D; Diskin, SJ; Djè, MK; Doddipatla, S; Doerr, AJ; Dokla, EME; Domiciano, D; Domingo, N; Dong, C; Dong, J; Dong, Q; Dong, S; Dong, X; Dong, Z; Douair, I; Douglas, TA; Doyle, SM; Drain, PK; Du, K; Du, L; Du, Q; Du, S; Duan, C; Duan, H; Duan, J; Duan, S; Duan, W; Dueluzeau, R; Dukic, L; Dunmire, BL; Duvauchelle, T; Dymek, B; Dzwonek, K; Earnest, A; Eckardt, KU; El Ghadraoui, L; El Massoudi, S; Elloumi, F; Elnour, IE; Embarak, S; Ende, M; England, K; Enikeev, D; Enyedy, I; Epple, R; Erickson, GE; Eriksson, J; Erndt-Marino, J; Errachidi, F; Etxeberria, I; Evan, AP; Fairlamb, AH; Falahi, E; Fan, CC; Fan, H; Fan, M; Fan, MZ; Fan, S; Fan, Y; Fang, CS; Fang, J; Fang, X; Fang, Z; Farmany, A; Farooqi, A; Farouk, HO; Fazelipour, S; Feng, D; Feng, J; Feng, JX; Feng, YL; Ferraz, SL; Ferreira, CR; Figenshau, RS; Finn, AV; Fiseha, T; Fleischer, AS; Fogleman, AD; Fontaine, O; Ford, CR; Fouladvand, F; Four, M; Fousteri, G; Francis, JR; Fraser, JF; Frazier, RP; Fu, H; Fu, P; Fu, YJ; Fujishima, A; Fuster, V; Gabilan, JC; Gagliani, N; Gai, QY; Galán-Arriola, C; Gale, P; Galimova, GR; Galkin, A; Gallo, A; Gallo, AA; Gang, DD; Ganschow, S; Gao, C; Gao, F; Gao, GP; Gao, H; Gao, K; Gao, M; Gao, MY; Gao, P; Gao, R; Gao, S; Gao, WJ; Gao, Y; Garbacz, P; García Ruiz, L; Garcia, EM; Garofoli, F; Gasbarrini, A; Gattinoni, L; Gaudig, M; Gbureck, U; Ge, X; Genko, N; Gentile, GL; George, MW; Gerety, GF; Gestwicki, JE; Geusens, PP; Ghassemi, M; Giardina, JD; Giebultowicz, JM; Gifford, CA; Gijsen, FJH; Gilfillan, R; Gilson, E; Gingl, K; Giuliano, C; Glybochko, P; Goessler, W; Gofflot, S; Golab, J; Goldstein, A; Golebiowski, A; Gómez, L; Gómez-Carballo, J; Gonçalves, PEO; Gonzales, R; Gonzalez-Cotto, M; González-Fernández, D; Gonzalez-Lopez de Turiso, F; Goodman, JM; Govinda Raju, S; Grimm, J; Gross, AJ; Gruenheid, S; Gu, C; Gu, FF; Gu, S; Gu, Z; Guest, RL; Gui, C; Gui, J; Guillem, A; Guo, G; Guo, L; Guo, Q; Guo, S; Guo, SW; Guo, W; Guo, Y; Guo, YG; Guo, Z; Guretzky, JA; Haenggi, M; Hahn, MS; Hakkola, J; Halim, AA; Hampel, D; Han, B; Han, BH; Han, D; Han, G; Han, J; Han, LZ; Han, R; Han, S; Han, X; Han, Z; Handley, MA; Hanke, I; Hannongbua, S; Hao, P; Happ, JT; Hara, M; Haraux, F; Hare, JL; Harper, JD; Hartley, AM; Harvey, E; Hashimoto, K; Hassan, HM; Hautajärvi, H; Hayton, TW; He, C; He, H; He, HJ; He, WP; He, Y; He, Z; Hedrick, V; Heffernan, JK; Hegrová, J; Heidarimoghadam, R; Helms, K; Hengphasatporn, K; Henry, D; Herrmann, TRW; Hesson, T; Himmelbauer, MK; Hindle, A; Hoffmann, R; Hogg, N; Hong, KB; Hong, SK; Honjol, Y; Hood, C; Hsi, RS; Hsu, JL; Hu, B; Hu, BC; Hu, D; Hu, H; Hu, J; Hu, K; Hu, M; Hu, MK; Hu, T; Hu, W; Hu, Y; Hu, Z; Hua, S; Huang, H; Huang, J; Huang, L; Huang, M; Huang, P; Huang, X; Huang, Y; Huang, Z; Hukkanen, J; Hung, MC; Huo, X; Hyötyläinen, T; Ianiro, G; Ibanez, B; Imran, M; Ireland, S; Irwin, MS; Ishiguro, H; Jackowski, K; Jackson, C; Jacob, SI; Jahromy, MH; Jakob, SM; Jang, J; Javvaji, PK; Jefferson, KK; Jena, P; Ji, H; Jiang, F; Jiang, GH; Jiang, H; Jiang, J; Jiang, X; Jiang, Z; Jiao, J; Jiménez, A; Jin, X; Jincai, W; Jintao, X; Jo, K; Jofra, T; Johari, Y; Johnson, ACM; Jones, JH; Josephine Fauci, A; Juhl, AK; Jun, S; Kaiser, RI; Kajioka, J; Kajiyama, H; Kalliyil, A; Kalthur, SG; Kamalanathan, M; Kamaldinov, T; Kanaani, L; Kang, D; Kang, J; Kang, S; Känsäkoski, P; Kaplan, DL; Karwan, M; Kasibhatla, S; Kaur, A; Kawazoe, Y; Ke, C; Keyser, J; Khalique, A; Khan, IT; Kharshoum, RM; Kher, R; Kherani, J; Ki, KK; Kikkawa, F; Kikkawa, R; Kim, BT; Kim, EH; Kim, GA; Kim, GD; Kim, HB; Kim, HG; Kim, JS; Kim, MJ; Kim, SI; Kim, SJ; Kim, Y; King, K; Kinyamu-Akunda, J; Kirkkala, T; Kjaer-Sorensen, K; Kleppinger, EL; Kloner, RA; Klopfenstein, TJ; Knappe, D; Knezevic, P; Kobos, LM; Kohli, M; Kolano, L; Kolodgie, FD; Kolte, AP; Koneru, B; Kong, D; Kong, F; Kong, X; Konggidinata, MI; Köpke, M; Koski, KG; Kotsis, F; Köttgen, A; Kouakou-Kouamé, CA; Kraemer, US; Krane, V; Krehbiel, CR; Krenning, BJ; Kretzschmar, D; Ku, KB; Kubota, Y; Kulich, P; Kumar, NG; Kupiec-Weglinski, JW; Lalani, SS; Lan, X; Landfeldt, E; Langenberg, E; Lapauw, B; Larkin, J; Lassoued, MA; Laukhtina, E; Laura Martinez, J; Laveillé, A; Lavela, P; Law, AD; Lazraq, A; Le Foll, B; Lee, BK; Lee, C; Lee, CS; Lee, EJ; Lee, EY; Lee, G; Lee, HY; Lee, JH; Lee, JJ; Lee, JO; Lee, JS; Lee, R; Lei, H; Lei, P; Lellouche, F; Lennerz, JK; Leong, W; Leslie, I; Lessem, E; Levin, M; Levinger, I; Li, C; Li, CW; Li, CX; Li, CY; Li, D; Li, H; Li, HM; Li, J; Li, L; Li, LM; Li, N; Li, S; Li, W; Li, X; Li, XX; Li, Y; Li, Z; Li, ZL; Li, ZX; Lian, Q; Liang, C; Liang, GH; Liang, H; Liang, J; Liang, X; Liao, CX; Liao, R; Ličbinský, R; Lim, YS; Lima, HK; Lin, JG; Lin, L; Lin, S; Lin, WP; Lin, Z; Liso, M; Liu, BX; Liu, C; Liu, H; Liu, J; Liu, M; Liu, Q; Liu, S; Liu, SF; Liu, SL; Liu, T; Liu, W; Liu, X; Liu, XB; Liu, Y; Liu, YY; Liu, Z; Liu, ZQ; Lobo, M; Loitzenbauer, M; López, F; Lopez, G; López, GJ; Lou, Z; Lu, IC; Lu, J; Lu, M; Lu, W; Lu, X; Lu, Y; Luhovyy, BL; Luna-Abanto, J; Luo, J; Luo, K; Luo, L; Luo, M; Luo, W; Luo, X; Luo, XM; Lv, Y; Lv, YQ; Lyu, HD; Lyu, J; Ma, C; Ma, G; Ma, L; Ma, Q; Ma, X; Ma, Y; Macha, SJ; MacLean, E; Mahalapbutr, P; Maina, T; Malfait, F; Malfertheiner, MV; Malzert-Fréon, A; Mansouri, E; Mao, C; Marcellin, E; Marchiori, PER; Marcotte, DJ; Maréchal, A; Maric, N; Maris, JM; Maron, L; Marti, CN; Martínez-Milla, J; Mateo, J; Mather, K; Mathison, CJN; Matthay, MA; Maxwell, CL; Mazier, D; Mazumder, D; Mazurkiewicz, M; Mazzucchelli, TG; McAuley, DF; Mccoy, K; McVicar, DW; Mebel, AM; Mech, A; Meester, EJ; Meiselbach, H; Melero, I; Ménard, G; Meng, X; Mengya, Y; Merle, G; Meunier, B; Mfarrej, B; Mi, K; Migueliz, I; Mikuška, P; Miladi, K; Miletich, R; Millar, JE; Mills, MR; Milne, R; Minute, L; Misiak, M; Mo, F; Modi, A; Mok, F; Molina, C; Mollen, CJ; Molteni, V; Montalto, M; Montet, D; Monti, MC; Moor, MB; Moravec, P; Morsiani, C; Murillo, E; Murugan, P; Muslem, R; Myers, RK; N'guessan, FK; Nabil, H; Nadal, J; Nadeem, M; Nafady, MM; Nafie, MS; Nair, HP; Nakano, R; Nance, J; Naren, N; Neil, CJ; Nelson, J; Nery, FC; Netsch, C; Nguyen, TH; Ni, L; Ni, YX; Nie, W; Nielsen, LK; Nigam, K; Nikolayev, AA; Nishiyama, M; Niu, LL; Niu, PP; Nock, BA; Noer, PR; Noll, G; Noll, S; Norenberg, JP; Nowicka, J; Nutho, B; O'Connor, M; Obonyo, NG; Ochiai, T; Ochoa, MC; Oh, BL; Oh, S; Olczak, J; Olivares, X; Ommurugan, B; Oosthuizen, MC; Operario, D; Orešič, M; Oshima, K; Otano, I; Ou, Y; Owen, TW; Oxvig, C; Pacey, V; Pai, M; Paik, H; Paiva, R; Palmieri, EM; Palpant, N; Pan, L; Pan, Q; Panahi, S; Pang, B; Pang, ZC; Pannecouque, C; Paris, L; Park, D; Park, DJ; Park, E; Park, EC; Park, IH; Park, JH; Park, JI; Park, S; Passmore, MR; Pattaranggoon, NC; Paun, M; Pedersen, S; Pedron, J; Peng, M; Peng, X; Penzhorn, BL; Pérez-Camargo, D; Perez-Maldonado, R; Pérez-Vicente, C; Pham, TD; Pickering, L; Pickersgill, NA; Pinault, E; Pinotsis, N; Plan, M; Pocino, K; Poh, CL; Pons, EDC; Popoff, MR; Porri, D; Pourmand, A; Pratviel, G; Prudente, DO; Qi, H; Qi, N; Qian, LY; Qiao, L; Qiao, Q; Qin, QP; Qiu, N; Qiu, SW; Qu, F; Quan, M; Quigg, A; Raee, E; Raibaud, P; Ramanitrahasimbola, D; Rapoport, L; Rasby, RJ; Rasoanirina, BNV; Raspini, B; Ratner, JR; Razafindrakoto, Z; Redd, MA; Ren, H; Ren, N; Rey, J; Reynolds, CP; Rich, PR; Richards, CJ; Rigol, M; Rimoldi, S; Robert, P; Rodrigues, AE; Roe, JH; Rohde, S; Rokita, JL; Roland, J; Rombaut, L; Ronkainen, J; Rothenberg, SM; Roy, SC; Ruan, Z; Rucker, PV; Rueda, D; Ruhwald, M; Rungrotmongkol, T; Rupert, AS; Rusjan, P; Ryabov, AD; Rysä, J; Saad, NES; Sabioni, P; Sadow, PM; Sahai, N; Salem, HF; Salinas, B; Salonurmi, T; Samé Guerra, D; Sánchez, J; Sanchez-González, J; Sanmamed, MF; Sansores-Peraza, P; Santoro, JC; Santschi, PH; Saritas, T; Sarkisova, Y; Savolainen, MJ; Scherberich, JE; Schlom, DG; Schmelz, EM; Schmid, MC; Schneider, MP; Schumacher, S; Schwartz, JC; Schwartzer, JJ; Schwehr, K; Schweitzer, DH; Scott, ME; Sedky, NK; See Hoe, L; Sejian, V; Selvaraju, S; Sen, SK; Seo, G; Šerý, O; Settles, JA; Sfar, S; Shaffer, J; Shan, GL; Shang, Q; Shannahan, JH; Shao, B; Shao, H; Shao, J; Shao, ZH; Shasha, Y; Shaw, K; Sheeba, V; Shekar, K; Shen, G; Shen, H; Shen, XD; Shen, Y; Sherrell, PC; Shete, PB; Shi, AX; Shi, J; Shi, JH; Shi, S; Shi, X; Shigeta, Y; Shimbo, A; Shin, E; Sikka, N; Silhavy, TJ; Simanon, N; Simard, S; Simon, J; Simon, M; Simpson, SD; Simundic, AM; Since, M; Singh, B; Singhroy, DN; Sinisterra, OT; Smith, EH; Sobreira, TJP; Solanes, N; Somasundar, Y; Sommerer, C; Sonei, A; Song, B; Song, E; Song, J; Song, M; Song, Y; Soo Lee, M; Sorensen, MD; Sournia-Saquet, A; Spaepen, E; Spirk, D; Srivastava, S; Stancill, JS; Stanczak, PS; Starenki, D; Starr, F; Step, DL; Steubl, D; Stigliani, JL; Stráská, J; Sträter, N; Su, ZZ; Sudano, I; Suen, JY; Suh, HJ; Sui, ZY; Suico, JG; Suleiman, K; Sumon, K; Sun, HB; Sun, J; Sun, L; Sun, LL; Sun, M; Sun, Q; Sun, W; Sun, X; Sun, XF; Sun, Y; Sun, YB; Sun, YH; Sun, YN; Sun, Z; Sunada, K; Suzuki, S; Sylvan, JB; Takala, J; Talla, D; Tamir, Z; Tan, SJ; Tanda, S; Tang, H; Tang, J; Tang, LF; Tang, SJ; Tang, Y; Tao, FB; Tappel, R; Taratkin, M; Teijeira, Á; Tellew, JE; Thomas, AM; Thomas, SG; Thomson, SR; Tian, J; Tie, Y; Tirado, JL; Tolonen, A; Tosato, G; Tronnet, A; Tsai, S; Turtoi, A; Turtoi, E; Tvrdoňová, M; Tyagi, A; Tzou, DT; Uddin Ahmad, Z; Urias, E; Usawachintachit, M; Ustriyana, P; Utsumi, F; Vacca, M; Vaculovič, T; Vaidya, SS; Valentin, A; Valgepea, K; van den Berg, P; van den Bergh, JP; van der Heiden, K; van Gaalen, K; Van Gemert, W; van Haard, PMM; van Hest, JCM; Vecchiarelli, E; Večeřa, Z; Venkatesh, R; Verhaeghe, P; Verhagen, HJ; Vetter, JM; Vieira, D; Vilchez-Tschischke, JP; Villena-Gutierrez, R; Villoslada Terrones, V; Vital-Jacome, M; Voelkl, J; Vogel, K; Vogrin, S; Volke, D; von Bahr, V; Vysloužil, J; Wade, TL; Wagner-Gillespie, M; Walsh, SW; Wan, LJ; Wan, SP; Wang, AL; Wang, B; Wang, BY; Wang, C; Wang, D; Wang, F; Wang, H; Wang, HR; Wang, HY; Wang, J; Wang, JY; Wang, K; Wang, L; Wang, LF; Wang, P; Wang, Q; Wang, R; Wang, SF; Wang, SP; Wang, SR; Wang, T; Wang, W; Wang, WP; Wang, X; Wang, XJ; Wang, Y; Wang, YL; Wang, YN; Wáng, YXJ; Wang, Z; Wang, ZF; Wang, ZY; Waning, B; Warner, JM; Washington, SL; Watson, AK; Wei, B; Wei, C; Wei, F; Wei, X; Wei, Y; Wemhoff, AP; Wen, Z; Weng, TT; Wesdemiotis, C; Wheeler, DA; Wildner, M; Wilson, BK; Wirth, LJ; Wissler, M; Wu, F; Wu, G; Wu, J; Wu, KH; Wu, MC; Wu, P; Wu, PK; Wu, S; Wu, W; Wu, X; Wu, XP; Wu, Y; Wyatt, E; Wyllie, S; Xia, Y; Xiao, BH; Xiao, SZ; Xiao, W; Xiao, X; Xiao, Z; Xie, D; Xie, K; Xie, X; Xie, Y; Xie, YF; Xin, S; Xin, Z; Xing, Q; Xing, WQ; Xiong, D; Xiong, X; Xu, C; Xu, D; Xu, F; Xu, G; Xu, H; Xu, J; Xu, JY; Xu, L; Xu, N; Xu, W; Xu, X; Xu, Y; Xu, YM; Xue, H; Xue, J; Xue, Z; Yan, R; Yan, SQ; Yan, W; Yan, X; Yan, Z; Yang, C; Yang, D; Yang, F; Yang, FC; Yang, G; Yang, J; Yang, M; Yang, P; Yang, Q; Yang, R; Yang, S; Yang, SJ; Yang, TWW; Yang, X; Yang, Y; Yang, Z; Yao, C; Yao, L; Yao, LP; Yao, M; Yao, T; Yao, W; Yao, Y; Yaseen, T; Yazdani, V; Ye, J; Ye, S; Yerys, BE; Yi, HWL; Yi, JL; Yin, F; Yin, J; Yin, Y; Yin, Z; Yong, ZP; Yongli, S; Yoo, JS; Yoshikawa, N; You, Q; Yu, B; Yu, CQ; Yu, H; Yu, HG; Yu, J; Yu, L; Yu, Q; Yu, X; Yu, Y; Yu, YK; Yu, Z; Yuan, Q; Yuan, R; Yuan, W; Yuan, X; Yuan, Y; Zager, RA; Zagozdzon, A; Zaller, N; Zang, YP; Zappi, ME; Zelikoff, JT; Zeman, T; Zhai, X; Zhan, P; Zhang, B; Zhang, C; Zhang, G; Zhang, H; Zhang, HB; Zhang, J; Zhang, JS; Zhang, L; Zhang, M; Zhang, Q; Zhang, RX; Zhang, S; Zhang, T; Zhang, W; Zhang, WH; Zhang, X; Zhang, XX; Zhang, Y; Zhang, YQ; Zhang, YW; Zhang, Z; Zhang, ZH; Zhao, D; Zhao, FL; Zhao, K; Zhao, L; Zhao, M; Zhao, R; Zhao, S; Zhao, W; Zhao, WG; Zhao, X; Zhao, Y; Zheng, G; Zheng, J; Zheng, S; Zheng, W; Zheng, Y; Zheng, YG; Zhong, Z; Zhou, C; Zhou, D; Zhou, H; Zhou, HY; Zhou, L; Zhou, Q; Zhou, X; Zhou, Y; Zhou, YL; Zhou, Z; Zhu, J; Zhu, L; Zhu, N; Zhu, X; Zhu, XF; Zhu, Y; Zhu, Z	1
Flamm, SL; Nilles, KM	1
Arias, AS; Gutiérrez, JM; Rucavado, A	1
Jeer, P; Rose, B; Saran, D; Shrivastava, R; Sindali, K; Soueid, H	1
Ageno, W; Ferrari, A; Filippi, A; Imberti, D; Palareti, G; Pengo, V; Rubboli, A; Toni, D	1
Douketis, JD; Faraoni, D; Levy, JH; Samama, CM; Spring, JL	1
Abtan, J; Barthélémy, O; Beygui, F; Brugier, D; Cayla, G; Collet, JP; Kerneis, M; Martin, R; Montalescot, G; O'Connor, SA; Silvain, J; Vignalou, JB	1
Abe, K; Conley, PB; DeGuzman, FR; Hollenbach, SJ; Hutchaleelaha, A; Inagaki, M; Karbarz, MJ; Lee, G; Lu, G; Luan, P; Phillips, DR; Sinha, U	1
Akwaa, F; Spyropoulos, AC	1
Berman, JP; Halperin, JL	1
Lenchus, JD	1
Apostolakis, S; Kasmeridis, C; Lip, GY	1
Adler, D; Beeton, A; Büller, H; de Jong, PR; Haas, S; Hsu, HC; Jacobson, BF; Louw, S; Mer, M; Rowji, P; Schapkaitz, E; Wessels, P	1
Kamphuisen, PW; Lisman, T; Northup, PG; Porte, RJ	1
Wang, H; Wang, WE; Wang, X; Zeng, C	1
Limdi, NA; Thigpen, JL	1
Shan, J; Sun, H	1
Hughes, DA; Pink, J; Pirmohamed, M	1
Harris, K; Mant, J	1
Nutescu, EA	1
Kalus, JS	1
Eisenberg, MJ; Filion, KB; Grandi, SM; Wasserlauf, G	1
Oprea, AD; Popescu, WM	1
Alexopoulos, D; Davlouros, P; Hahalis, G; Perperis, A; Siapika, A; Stavrou, K; Tsoni, E; Xanthopoulou, I	1
Ahmad, Y; Lip, GY	1
Böhm, M; Dichgans, M; Diener, HC; Ell, C; Endres, M; Epple, C; Grond, M; Laufs, U; Nickenig, G; Riess, H; Röther, J; Schellinger, PD; Spannagl, M; Steiner, T; Veltkamp, R	1
Cohen, AT; Spiro, TE; Spyropoulos, AC	1
Alameddine, R; Husari, A	1
Derksen, RJ; Mulder, JW; Mulder, WM	1
Sohne, M; Vink, R	1
de Lemos, JA; Diercks, DB; Hollander, JE; Holmes, DN; Kontos, MC; Mumma, BE; Saucedo, JF; Wiviott, S	1
Dager, WE; Fanikos, J; Gulseth, MP; Nutescu, EA; Smythe, MA; Spinler, SA; Wittkowsky, AK	1
Conde, D; Elissamburu, P; Lalor, N; Rodriguez, L; Trivi, M	1
Cutler, NR; Goldenberg, NA; Halperin, JL; Hiatt, WR; Kessler, CM; Kittelson, JM; Schulman, S; Spyropoulos, AC; Steg, G; Turpie, AG	1
Becker, RC; Berkowitz, SD; Breithardt, G; Califf, RM; Fox, KA; Hacke, W; Halperin, JL; Hankey, GJ; Mahaffey, KW; Nessel, CC; Patel, MR; Piccini, JP; Singer, DE; White, HD; Wojdyla, D	1
Pollack, CV	1
Cameron, C; Coyle, D; Coyle, K; Kelly, S; Lee, K; Steiner, S; Wells, GA	1
Boos, CJ; Camm, AJ; Nam, M	1
Finsterer, J; Stöllberger, C	1
Diener, HC	1
Douketis, J; Lang, ES; Lazo-Langner, A	1
Crowther, MA; Daw, HA; Fawole, A	1
Babatz, J; Beyer-Westendorf, J; Pannach, S	1
Castillo, J; de Andrés, J; Ferrandis, R; Gomar, C; Gómez-Luque, A; Hidalgo, F; Llau, JV; Sierra, P; Torres, LM	1
Ardissino, D; Armstrong, PW; Aylward, PE; Bassand, JP; Boden, WE; Dalby, AJ; Fox, KA; Goodman, SG; Gottlieb, S; Hochman, JS; Martinez, F; McGuire, DK; Ohman, EM; Prabhakaran, D; Roe, MT; Stevens, SR; White, HD; Winters, KJ	1
Chana, F; Llau, JV; Marco, P; Zamorano, JL	1
Al-Majzoub, O; Assiri, A; Donovan, JL; Kanaan, AO; Silva, M	1
Schellong, S	1
Baumann Kreuziger, LM; Reding, MT	1
Li, C; Li, T; Mao, L; Yuan, K	1
Baglin, T	1
Avorn, J	1
Majeed, A; Schulman, S	1
Alessi, MC; Beguin, S; Bonnet, JL; Camoin, L; Cuisset, T; Grosdidier, C; Lambert, M; Loosveld, M; Loundou, AD; Morange, PE; Pankert, M; Quilici, J	1
Gross, L; Massberg, S; Orban, M; Sibbing, D	1
Alexopoulos, D; Angelidis, C; Deftereos, S; Goudevenos, JA; Hahalis, G; Hamilos, M; Kanakakis, I; Ntalas, IV; Parissis, H; Petousis, S; Sitafidis, G; Stefanadis, C; Vavuranakis, M; Xanthopoulou, I	1
Ackman, ML; Bauer, RD; Bell, AD; Cartier, R; Chan, WS; Douketis, J; Mehta, SR; Roussin, A; Schnell, G; Tanguay, JF; Verma, S; Wong, G	1
Angioli, P; Bolognese, L; Cayla, G; Costigan, TM; Dudek, D; Goedicke, J; Goldstein, P; Hamm, C; Jakubowski, JA; Legutko, J; Miller, DL; Montalescot, G; Motovska, Z; Niethammer, M; Silvain, J; Tanguay, JF; ten Berg, JM; Vicaut, E; Visconti, LO; Widimsky, P	1
Albaladejo, P; Blais, N; Cohen, A; de Maistre, E; Fontana, P; Godier, A; Gruel, Y; Llau, JV; Mismetti, P; Pernod, G; Rosencher, N; Samama, CM; Samama, MM; Schved, JF; Sié, P; Susen, S	1
Cameron, C; Carrier, M; Castellucci, LA; Clifford, T; Coyle, D; Gandara, E; Le Gal, G; Rodger, MA; Wells, G; Wells, PS	1
Brunkhorst, R; Foerch, C; Lindhoff-Last, E; Luger, S; Pfeilschifter, W	1
Witt, DM	1
Lu, WX; Qin, L	1
Curkovic, I; Egbring, M; Kullak-Ublick, GA	1
Hosokawa, K; Ogawa, S; Tanaka, KA	1
Bonello, L; Deliargyris, E; Gershlick, A; Hamon, M; Marso, S; Prats, J; Rao, SV; Steg, GP; Valgimigli, M; Verheugt, F; Wang, Y	1
Bay, C; Schwartz, F; Sharifi, M; Skrocki, L	1
Chandler, WL	1
Haas, S; Holberg, G; Jamal, W; Kreutz, R; Lassen, MR; Mantovani, LG; Pattanayak, CW; Schmidt, A; Turpie, AG; van Eickels, M	1
Damman, P; Eriksson, P; Erlinge, D; James, SK; Koul, S; Lagerqvist, B; Varenhorst, C	1
Pazmiño, P	1
Gulseth, M; Hellwig, T	1
Becker, RC; Berkowitz, SD; Breithardt, G; Califf, RM; Fox, KA; Goodman, SG; Hacke, W; Halperin, JL; Hankey, GJ; Mahaffey, KW; Nessel, CC; Paolini, JF; Patel, MR; Piccini, JP; Sherwood, MW; Singer, DE; White, HD; Wojdyla, DM	1
Ragni, MV	1
Dekkers, OM; den Exter, PL; Huisman, MV; Klok, FA; Kooiman, J; van der Hulle, T	1
Fawole, A	1
Aumann, V; Boxberger, N; Hartung, KJ; Heim, MU; Siegemund, A	1
Baker, R; Herrmann, R; Muhammad, S; Phillips, M; Thom, J; Wood, A	1
Akbar Ali, M; Chee, YL; Handa, PK; Lee, LH; Lim, LC; Ng, HJ; Ponnudurai, K; Tan, D; Tay, JC	1
Crowther, MA; Garcia, DA; Siegal, DM	1
Jiang, B; Li, H; Long, A; Mao, Z; Tang, P; Xie, Z; Zhang, L; Zhang, S; Zhang, Y	1
Arntz, HR; Boudriot, E; Garlichs, C; Helms, TM; Hoffmann, S; Ince, H; Klingenheben, T; Schäfer, A; Silber, S; Weil, J; Zugck, C	1
Goto, S; Tomita, A	1
Schulman, S	1
Gasparovic, H; Petricevic, M	1
Alessi, MC; Bonnet, JL; Cuisset, T; Quilici, J	1
Büller, HR; Burton, P; Cohen, AT; Desanctis, YH; Haskell, L; Homering, M; Hu, D; Hull, R; Mebazaa, A; Merli, G; Schellong, S; Spiro, TE; Spyropoulos, AC; Tapson, VF	1
Henke, C; Strasser, RH; Wiedemann, S	1
Jover, E; Tello-Montoliu, A; Valdés, M	1
Aradi, D; Faluközy, J; Horváth, IG; Komócsi, A; Kónyi, A; Magyari, B; Pintér, T; Tornyos, A; Veress, G; Vorobcsuk, A	1
Bollmann, A; Breithardt, OA; Dinov, B; Doering, M; Hindricks, G; Kosiuk, J; Koutalas, E; Nedios, S; Richter, S; Rolf, S; Sommer, P	1
Colombo, P; Klugmann, S; Mafrici, A; Morici, N; Oreglia, JA; Savonitto, S	1
Bohn, RL; Choudhry, NK; Daniel, GW; Gagne, JJ; Liu, J; Patrick, AR; Rassen, JA; Schneeweiss, S; Sridhar, G	1
Bounameaux, H; Fontana, P; Goldhaber, SZ	1
Miller, MP; Nordenholz, KE; Trujillo, TC	1
Fan, JY; Jin, C; Meng, J; Tang, XF; Yang, YJ; Yuan, JQ	1
Albenque, JP; Boveda, S; Combes, N; Combes, S; Hireche, H; Jourda, F; Marijon, E; Morais, J; Providência, R	1
Angiolillo, DJ; Capodanno, D	1
Larsen, TB; Lip, GY; Rasmussen, LH; Skjøth, F	3
Sabouret, P; Taiel-Sartral, M	1
Bode, C; Haas, S; Norrving, B; Turpie, AG	1
Cloutier, M; Coleman, CI; Damaraju, CV; Laliberté, F; Lefebvre, P; Nelson, WW; Olson, WH; Pilon, D; Schein, JR	1
Meddahi, S; Samama, MM	1
Delzor, F; Nanau, RM; Neuman, MG	1
Becker, RC; Berkowitz, SD; Breithardt, G; Califf, RM; Fox, KA; Garg, J; Goodman, SG; Hacke, W; Halperin, JL; Hankey, GJ; Lokhnygina, Y; Mahaffey, KW; Nessel, CC; Patel, MR; Piccini, JP; Singer, DE	1
Giugliano, RP; Reddy, P	1
Abbate, R; Antoniucci, D; Bellandi, B; Carrabba, N; Comito, V; De Luca, G; Gensini, GF; Marcucci, R; Migliorini, A; Parodi, G; Ramazzotti, RN; Valenti, R	1
Berkowitz, SD; Berlin, JA; DiBattiste, PM; Friedman, RJ; Homering, M; Levitan, B; Turpie, AG; Weinstein, RB; Yuan, Z	1
Baumbach, A; Bowles, R; Butler, M; Johnson, TW; Marsden, D; Mumford, A; Mundell, S; Pike, K; Reeves, BC; Rogers, C; Strange, JW	1
Thachil, J	1
Fenger-Eriksen, C; Grove, EL; Münster, AM	1
Bernlochner, I; Braun, S; Hausleiter, J; Kastrati, A; Laugwitz, KL; Massberg, S; Mayer, K; Morath, T; Schulz, S; Schunkert, H; Sibbing, D	1
Boothroyd, DB; Dudley, RA; Garber, AM; Hlatky, MA; Kazi, DS; Mell, MW; Moshkevich, S; Owens, DK; Rhee, C; Shah, RU	1
Delemos, J; Peng, SA; Peterson, ED; Roe, MT; Sherwood, MW; Wang, TY; Wiviott, SD	1
Brighton, TA; Davidson, BL; Gebel, M; Lensing, AW; Lyons, RM; Prins, MH; Rehm, J; Verheijen, S	1
Piccini, JP; Steinberg, BA	1
Asrar ul Haq, M; van Gaal, WJ	1
Jing, JH; Li, J; Shi, ZJ; Zhou, Y	1
Becker, RC; Berkowitz, SD; Breithardt, G; Califf, RM; Fox, KA; Halperin, JL; Hankey, GJ; Harrell, FE; Hellkamp, AS; Lokhnygina, Y; Mahaffey, KW; Nessel, CC; Patel, MR; Piccini, JP; Singer, DE	1
Isshiki, T; Kimura, T; Kitagawa, K; Miyazaki, S; Nakamura, M; Nanto, S; Nishikawa, M; Ogawa, H; Saito, S; Takayama, M; Yokoi, H	1
Bangalore, S; Biondi-Zoccai, G; Cerrato, E; Chatterjee, S; D'Ascenzo, F; DiNicolantonio, JJ; Fuchs, FD; Lavie, CJ; Meier, P; Niazi, AK; Norgard, NB; O'Keefe, JH; Packard, KA; Serebruany, VL	1
Davidson, N; Galloway, SW; Lai, A; Thachil, J	1
Brieger, D	1
Finsterer, J; Stöllberger, C; Valentin, A	1
MacIsaac, A; Xu, B	1
Greene, SL; Koutsogiannis, Z; Wong, A	1
Berkowitz, SD; Castillejos, CF; Goldhaber, SZ; Kubitza, D; Levi, M; Levy, JH; Moore, KT; Patel, MR; Raghoebar, M; Weitz, JI	1
De Servi, S; Goedicke, J; Schirmer, A; Widimsky, P	1
den Exter, PL; Huisman, MV; Klok, FA; Kooiman, J; van der Hoeven, JJ; van der Hulle, T	1
Beyer-Westendorf, J; Ebertz, F; Förster, K; Gelbricht, V; Hänsel, U; Köhler, C; Michalski, F; Pannach, S; Sahin, K; Thieme, C; Tittl, L; Weiss, N; Werth, S	1
Dempfle, CE	1
Hürlimann, D; Noll, G; Noll, S	1
Ossei-Gerning, N; Shivu, GN	1
Evans, RS; Fontaine, GV; Lloyd, JF; Mathews, KD; Stevens, SM; Woller, SC	1
Becker, RC; Breithardt, G; Califf, RM; Fox, KA; Hacke, W; Halperin, JL; Hankey, GJ; Lokhnygina, Y; Mahaffey, KW; Nessel, CC; Paolini, JF; Patel, MR; Piccini, JP; Singer, DE; Wojdyla, DM	1
Lévy, S	1
Curnow, J; Joseph, J; McLintock, C; McRae, S; Nandurkar, H; Tran, H; Wood, P; Young, L	1
Dan, GA; Kaski, JC; Martínez-Rubio, A	1
Büller, HR; Coppens, M; Middeldorp, S; Schulman, S; van Es, N	1
Ammar, S; Buiatti, A; Deisenhofer, I; Dillier, R; Hessling, G; Hofmann, M; Kaess, B; Kathan, S; Kolb, C; Lennerz, C; Pavaci, H; Reents, T; Semmler, V	1
Büller, HR; Cohen, AT; De Sanctis, Y; Haskell, L; Hu, D; Hull, R; Mebazaa, A; Merli, G; Schellong, SW; Spiro, TE; Spyropoulos, AC; Tapson, VF	1
Chatelain, C; Devalet, B; Dogné, JM; Douxfils, J; Larock, AS; Mullier, F; Sennesael, AL; Spinewine, A	1
Alexopoulos, D; Bampouri, T; Gkizas, V; Koniari, I; Kontoprias, K; Perperis, A; Stavrou, K; Vogiatzi, C; Xanthopoulou, I	1
Turpie, AG	1
Gotthardt, DN; Schemmer, P; Stremmel, W; Wannhoff, A; Weiss, KH	1
Costigan, T; Iqbal, K; Lopez-Sendon, J; Ramos, Y; Widimsky, P; Wilcox, R	1
Bae, JP; Effron, MB; Ernst, FR; Faries, DE; Lieu, HD; Lipkin, C; Moretz, C; Zhao, Z	1
Gómez-Outes, A; Lecumberri, R; Suárez-Gea, ML; Terleira-Fernández, AI; Vargas-Castrillón, E	1
Barinov, VE; Boiarintsev, VV; Lobastov, KV; Schastlivtsev, IV	1
Cuisset, T; De Palma, R; James, S; Jüni, P	1
Baumann, M; Ceschi, A; Hasler, K; Hofer, KE; Korte, W; Kupferschmidt, H; Lehmann, T; Rohde, G	1
Alotaibi, G; Alsaleh, K; Mcmurtry, MS; Wu, C	1
Chatterjee, S; Halperin, JL; Herzog, E; Mukherjee, D; Nairooz, R; Sardar, P	1
Fleet, JL; Garg, AX; Lazo-Langner, A; McArthur, E	1
Amin, A; Graham, J; Jing, Y; Lin, J; Lingohr-Smith, M; Trocio, J	1
Baba, Y; Hagii, J; Hitomi, H; Iwata, M; Kamada, T; Matsumoto, S; Metoki, N; Okumura, K; Osanai, T; Saito, S; Sasaki, S; Seino, S; Shiroto, H; Takahashi, K; Tomita, H; Uchizawa, T; Yasujima, M	1
Abendschein, D; Broekman, MJ; Chen, R; Drosopoulos, JH; Jeong, SS; Marcus, AJ; Moeckel, D; Nguyen, A; Robson, SC; Sun, X	1
Kamphuisen, PW	1
Aryal, MR; Badal, M; Chaudhary, A; Donato, AA; Mege, J	1
Amin, A; Lawrence, JH; Makenbaeva, D; Stokes, M; Wiederkehr, D; Wu, N	1
Aylward, PE; Camuglia, AC; Hammett, CJ; Waddell-Smith, KE	1
Steurer, J	1
Baumgartner, H; Becker, RC; Berkowitz, SD; Breithardt, G; Califf, RM; Fox, KA; Hacke, W; Halperin, JL; Hankey, GJ; Hellkamp, AS; Lokhnygina, Y; Mahaffey, KW; Nessel, CC; Patel, MR; Piccini, JP; Singer, DE; Stevens, SR	1
Levy, JH	1
Meddahi, S; Samama, CM; Samama, MM	1
Rudakova, AV; Tatarskiĭ, BA	1
Camm, AJ; Cappato, R; Ezekowitz, MD; Hemmrich, M; Hohnloser, SH; Kirchhof, P; Klein, AL; Lanius, V; Le Heuzey, JY; Ma, CS; Meng, IL; Scanavacca, M; Talajic, M; van Eickels, M; Vardas, PE; Wildgoose, P	1
Bernlochner, I; Braun, S; Hadamitzky, M; Hausleiter, J; Hoppmann, P; Kastrati, A; Laugwitz, KL; Massberg, S; Mayer, K; Mehilli, J; Morath, T; Orban, M; Schulz, S; Schunkert, H; Sibbing, D; Tiroch, K	1
Howell, G; Pluym, M	1
Ikeda, Y; Isshiki, T; Kimura, T; Kitagawa, K; Miyazaki, S; Nakamura, M; Nanto, S; Nishikawa, M; Ogawa, H; Saito, S; Takayama, M; Yokoi, H	1
Baber, U; Mastoris, I; Mehran, R	1
Beyer-Westendorf, J	2
Duart, M; Kauffman, C; Kusumoto, F; Ray, JC; Snipelisky, D; Ung, R	1
Bell, AD; Douketis, J; Eikelboom, J; Liew, A	1
Braunwald, E; Cohen, DJ; Cutlip, DE; Dauerman, HL; Driscoll-Shempp, P; Garratt, KN; Hermiller, J; Holmes, DR; Kandzari, DE; Kereiakes, DJ; Krucoff, MW; Lee, DP; Massaro, JM; Mauri, L; Normand, SL; Pow, TK; Rinaldi, MJ; Simon, DI; Steg, PG; Ver Lee, P; Wiviott, SD; Yeh, RW	1
Belle, L; Boueri, Z; Carrié, D; Cayla, G; Collet, JP; Cuisset, T; Delarche, N; El Mahmoud, R; Elhadad, S; Etienne, CS; Henry, P; Leclercq, F; Montalescot, G; Motreff, P; Pouillot, C; Rangé, G; Silvain, J; Van Belle, E; Varenne, O; Vicaut, E	1
Chatterjee, S; Ghosh, J; Giri, JS; Lavie, CJ; Lip, GY; Mukherjee, D; Sardar, P	1
Davis, EM; Schardt, GL; Schmidt, DP; Uhlmeyer, EM	1
Cairns, JA; Weitz, JI	1
Peacock, WF	1
Armbruster, HL; Berger, RD; Calkins, H; Habibi, M; Khurram, IM; Lindsley, JP; Marine, JE; Moranville, MP; Spragg, DD	1
Andell, P; Björnsson, S; Erlinge, D; Götberg, M; Harnek, J; Koul, S; Martinsson, A; Norström, E; Scherstén, F; Smith, JG	1
Bolognese, L; Brown, E; Collet, JP; Dudek, D; Ecollan, P; Goldstein, P; Hamm, C; LeNarz, L; Miller, DL; Montalescot, G; Tanguay, JF; Ten Berg, J; Vicaut, E; Widimsky, P	2
Dangas, G; Ibáñez, B	1
Broncel, M; Ciastkowska, A; Duraj, I; Gorzelak-Pabiś, P; Szlagowska, L	1
Blann, AD	1
Dublanchet, N; Dutheil, F; Lebreton, A; Milhaud, G; Moustafa, F; Schmidt, J	1
Barra, M; Caldeira, D; Costa, J; Ferreira, JJ; Gonçalves, N; Pinto, FJ	1
Chan, KE; Edelman, ER; Maddux, FW; Thadhani, RI; Wenger, JB	1
Merli, GJ; Weitz, HH	1
Bultas, J; Karetová, D	1
Holper, EM; Luna, M	1
Ansell, JE; Cabral, KP	1
Cohen, AT; Lensing, AW; Müller, K; Pap, ÁF; Prandoni, P; Prins, MH; Tewes, MC	1
Levasseur-Franklin, KE; Liotta, EM; Naidech, AM	1
Ambrosoli, A; Cimminiello, C; Compagnone, C; Fanelli, A; Imberti, D; Ottani, F; Tripodi, A	1
Bultas, J	1
Erkens, PM; Fermann, GJ; Lensing, AW; Pap, ÁF; Prins, MH; Wells, PS	1
Angaran, P; Bell, AD; Berall, M; Bucci, C; Demchuk, AM; Essebag, V; Goldin, L; Goodman, SG; Green, MS; Gregoire, JC; Gross, PL; Heilbron, B; Lin, PJ; Patel, AD; Ramanathan, K; Skanes, A; Tan, MK; Wheeler, BH	1
Oberhofer, E	1
Friedman, RJ; Messerschmidt, C	1
Auer, R; Carballo, D; Gencer, B; Heg, D; Jaguszewski, M; Jakob, P; Jüni, P; Klingenberg, R; Landmesser, U; Lüscher, TF; Mach, F; Maier, W; Matter, CM; Meier, B; Nanchen, D; Räber, L; Rodondi, N; Roffi, M; Stähli, BE; Stefanini, GG; Templin, C; Vogt, P; Windecker, S	1
Bailleul, E; Borrey, D; Caluwé, R; De Bacquer, D; De Vriese, AS; Emmerechts, J; Van Vlem, B; Vandecasteele, SJ	1
Lane, DA; Wood, K	1
Lozano, I; Rondan, J; Vegas, JM	1
Montalescot, G	1
Aronow, WS; Nairooz, R; Sardar, P	1
Gehrie, E; Tormey, C	1
Chen, HB; Huang, BY; Liang, HB; Liu, XW; Xiu, J; Zhang, XL; Zhang, XY	1
Arpey, CJ; Baum, CL; Brewer, JD; Chang, TW; Hochwalt, PC; Hocker, TL; Otley, CC; Roenigk, RK	1
Bolognese, L; Brown, E; Dudek, D; Hamm, C; LeNarz, L; Miller, DL; Montalescot, G; Motovska, Z; Tanguay, JF; Ten Berg, J; Widimsky, P	1
Kreher, S; Riess, H; Sinn, M	1
Chatelain, B; Devalet, B; Dogné, JM; Douxfils, J; Mani, H; Minet, V; Mullier, F	1
Botto, GL; Colonna, P; Troccoli, R	1
Bode, C; Kelm, M; Zeus, T	1
He, Q; Liu, D; Liu, G; Wang, B; Wang, Q; Zhang, L; Zhang, X; Zheng, J; Zhou, Y	1
Gage, BF; Ganti, BR; Lee, ED; Lin, H; Nunley, RM; Venker, BT	1
Bansal, VB; Donovan, A; Gollish, JD; Gomez, D; Murnaghan, JJ; Razmjou, H	1
Alberts, MJ; Hanley, DF; Serebruany, VL	1
Brandt, JT; Farid, NA; Jakubowski, JA; Li, YG; Payne, CD; Salazar, DE; Small, DS; Winters, KJ	1
Agnelli, G; Buller, HR; Cohen, A; Gallus, AS; Lensing, AW; Misselwitz, F; Prins, MH; Raskob, G; Schellong, S; Segers, A	1
Antman, EM; Braunwald, E; Huber, K; Lopez-Sendon, J; McCabe, CH; Morocutti, G; Murphy, SA; Weerakkody, G; Wiviott, SD	1
Lotke, PA	1
De Servi, S; Mariani, G; Mariani, M	1
Kopyleva, O; Serebruany, V; Shalito, I	1
Calatzis, A	1
Crain, EJ; Hua, J; Rehfuss, R; Schumacher, WA; Watson, CA; Wong, PC	1
Samama, CM	2
Arnaout, L; Bellamy, L; Chabbouh, T; Rosencher, N	1
Albaladejo, P	1
Drouet, L	1
Stone, GW	1
Antman, EM; Braunwald, E; Gibson, CM; McCabe, CH; Montalescot, G; Murphy, SA; Wiviott, SD	1
Nurden, AT; Nurden, P; Viallard, JF	1
Gutiérrez, R; Lupi, E; Miranda, MT; Peña, H; Pulido, T; Roquet, I; Rueda, T; Sandoval, J; Santos, E	1
Lassen, MR; Laux, V	1
Bandel, TJ; Bauer, KA; Benson, A; Berkowitz, SD; Cushner, FD; Davidson, BL; Fisher, WD; Gent, M; Kwong, LM; Lassen, MR; Lotke, PA; Misselwitz, F; Turpie, AG	1
Arnaout, L; Bellamy, L; Rosencher, N	1
Marzot, F; Pengo, V	1
Makarov, LM; Serebruany, VL	1
Crain, EJ; Watson, CA; Wong, PC; Xin, B	1
Barnathan, ES; Bordes, P; Braunwald, E; Burton, P; Gibson, CM; Hricak, V; Markov, V; Mega, JL; Misselwitz, F; Mohanavelu, S; Oppenheimer, L; Poulter, R; Witkowski, A	1
Kereiakes, DJ	1
Bhatt, DL	2
Blázquez-Pérez, A; Gómez-Outes, A; Pozo-Hernández, C; Suárez-Gea, ML; Vargas-Castrillón, E	1
Unger, EF	1
Stewart, RA	1
Schrör, K	1
Collet, JP; Montalescot, G	1
Abu-Fadel, M; Norgard, NB	1
Banach, M; Hannam, S; Kowalczyk, M; Mikhailidis, DP; Rysz, J	1
Lazar, LD; Lincoff, AM	1
Guerra, DR; Tcheng, JE	1
Antman, E; Arnold, SV; Braunwald, E; Cohen, DJ; Mahoney, EM; Proskorovsky, I; Wang, K; Wiviott, S	1
Banning, AP; Bedogni, F; Bhindi, R; Biondi Zoccai, GG; Brambilla, N; Lanotte, S; Latini, RA; Laudisa, ML; Pizzocri, S; Testa, L; Valgimigli, M; Van Gaal, WJ	1
Islam, AM; Patel, PM	1
Serebruany, VL	2
Fareed, J; Jeske, WP; Mousa, SA	1
Kolundzic, R; Trkulja, V	1
Carballo, D; Keller, PF; Roffi, M	1
Bauters, C; Bonello, L; Delhaye, C; Lablanche, JM; Lemesle, G; Maluenda, G; Sudre, A	1
Freeman, MK	1
Devabhakthuni, S; Seybert, AL	1
Pakhomov, IaM	1
Aïssaoui, N; Danchin, N	1
Cao, YB; Jiang, YY; Shen, H; Zhang, JD	1
Ageno, W; Rancan, E; Romualdi, E; Siragusa, S	1
Dahl, OE; Huisman, MV; Quinlan, DJ; Schulman, S	1
Cattaneo, M	2
Caglayan, E; Er, F; Erdmann, E; Gassanov, N	1
Cannon, C; Croce, K; Kirshenbaum, J; Manica, A; Marchini, J; Morrow, D; Resnic, F	1
Armani, AM	1
Agnelli, G; Bauersachs, R; Berkowitz, SD; Bounameaux, H; Brenner, B; Buller, HR; Cohen, A; Davidson, BL; Decousus, H; Gallus, AS; Lensing, AW; Misselwitz, F; Piovella, F; Prins, MH; Raskob, GE; Schellong, S; Segers, A; Verhamme, P; Wells, P	1
Minarelli, M; Valgimigli, M	1
Frey, N; Ivandic, B	1
Kwok, CS; Loke, YK	1
Eikelboom, JW; Weitz, JI	1
Gans, RO; Landman, GW	1
Arntz, HR; Boudriot, E; Garlichs, C; Helms, TM; Hoffmann, S; Ince, H; Klingenheben, T; Silber, S; Steiger, H; Weil, J; Zugck, C	1
Scharf, RE	1
Bellemain, A; Collet, JP; Ecollan, P; Montalescot, G; Silvain, J	1
Alexander, D; Jeremias, A	1
Castriota, F; De Luca, G; De Servi, S; Kozinski, M; Kubica, J; Navarese, EP; Schaffer, A; Suriano, P; Verdoia, M	1
Antman, EM; Braunwald, E; Contant, CF; Dalby, AJ; Giugliano, RP; Guo, J; Hochholzer, W; Montalescot, G; Wiviott, SD	1
Fareed, J; Hull, R; Welzel, D	1
Eikelboom, JW; Fitchett, DH; Goodman, SG; Mehta, SR; Quinlan, DJ; Théroux, P; Welsh, RC	1
Ernest, CS; Li, YG; Luo, J; Macias, WL; Ni, L; Riesmeyer, JS; Rohatagi, S; Salazar, DE; Small, DS; Weerakkody, GJ; Wrishko, RE	1
Martin, MT; Nutescu, EA; Spinler, SA	1
Gawaz, M; Geisler, T	1
Alexopoulos, D; Davlouros, P; Dimitropoulos, G; Hahalis, G; Mylona, P; Panagiotou, A; Perperis, A; Tsigkas, G; Xanthopoulou, I	1
Karnon, J; Lu, CY; Sorich, MJ	1
Kazmi, RS; Lwaleed, BA	1
Alber, HF; Frick, M; Huber, K; Pachinger, O	1
Ageno, W; Donadini, MP; Romualdi, E	1
Kwong, LM	1
Becker, RC; Berkowitz, SD; Breithardt, G; Califf, RM; Fox, KA; Garg, J; Hacke, W; Halperin, JL; Hankey, GJ; Mahaffey, KW; Nessel, CC; Pan, G; Paolini, JF; Patel, MR; Piccini, JP; Singer, DE	1
Arya, R; Patel, JP; Roberts, LN	1
Becker, RC; Califf, RM; Fox, KA; Halperin, JL; Hankey, GJ; Mahaffey, KW; Nessel, CC; Paolini, JF; Patel, MR; Piccini, JP; Singer, DE; Wojdyla, D	1
Close, SL; Erlinge, D; Jakubowski, JA; Leishman, AG; Riesmeyer, JS	1
Antoniucci, D; Bellandi, B; Carrabba, N; Grassellini, S; Migliorini, A; Parodi, G; Ramazzotti, E; Valenti, R; Venditti, F	1
Baumbach, A; Davis, A; Edmond, J; Johnson, TW; Kesavan, S; Oriolo, V; Reeves, BC; Smith, D; Strange, JW	1
Heidinger, K; Kemkes-Matthes, B	1
Durand, M; Emmerich, J; Fischer, AM; Godier, A; Le Bonniec, B; Lecompte, T; Marchand-Leroux, C; Miclot, A; Samama, CM	1
Jolobe, OM	1
Cayla, G; Collet, JP; Montalescot, G; O'Connor, SA; Silvain, J	1
Bassand, JP; Bhatt, DL; Bode, C; Braunwald, E; Burton, P; Cohen, M; Cook-Bruns, N; Fox, KA; Gibson, CM; Goto, S; Mega, JL; Murphy, SA; Plotnikov, AN; Schneider, D; Sun, X; Verheugt, FW; Wiviott, SD	1
Basra, SS; Lakkis, NM; Tsai, P	1
Barakoti, M; Neupane, P; Pant, S; Ramesh, KC	1
Collet, JP; De Luca, L; Wouter Jukema, J	1
Dahl, OE; Eriksson, BI; Friedman, RJ; Homering, M; Rosencher, N	1
Li, J; Li, Y; Shi, Z; Wang, J	1
Davies, JE; Francis, DP; Nijjer, SS	1
Parma, Z; Syzdół, M; Tendera, M	1
Mackay, SM; Tcheng, JE	1
Abbate, A; Biondi-Zoccai, G; D'Ascenzo, F; Lotrionte, M; Modena, MG	1
Soff, GA	1
Cohen, A; Drost, P; Marchant, N; Mitchell, S; Orme, M; Rublee, D; Simon, TA; Sutton, A	1
Campbell, JA; Davis, EM; Knezevich, JT; Packard, KA	1
Erdle, S; Harenberg, J; Krämer, R; Marx, S	1
Espada, NG; González, TC; Merino, RG; Nieto, JA	1
Askari, AT; Stephens, JC	1
Agnelli, G; Berkowitz, SD; Bounameaux, H; Büller, HR; Chlumsky, J; Cohen, A; Davidson, BL; Decousus, H; Gallus, AS; Jacobson, BF; Lensin, AW; Minar, E; Misselwitz, F; Prins, MH; Raskob, GE; Schellong, S; Segers, A; Verhamme, P; Wells, P	1
Beitelshees, AL; Daniel Mullins, C; Onukwugha, E; Reese, ES	1
James, S; Varenhorst, C	1
Einecke, D	1
Haas, S; Schellong, SM; Spannagl, M	1
Kline, JA; Yealy, DM	1
Lyseng-Williamson, KA	1
Mustonen, P; Puurunen, M	1
Halperin, JL; Varughese, CJ	1
Lewalter, T	1
Chen, L; Coyle, D; Moertl, D; Steiner, S; Wells, GA	1
Goodnough, LT; Lenarz, LA; Levy, JH; Poston, RS; Short, MA; Smith, PK; Weerakkody, GJ	1
Little, JW	1
Vivancos Mora, J; Ximénez-Carrillo Rico, A; Zapata Wainberg, G	1
Haas, S; Jamal, W; Kreutz, R; Lassen, MR; Mantovani, L; Schmidt, AC; Turpie, AG	1
Ahmad, S; Storey, RF	1
Bessereau, J; Bonello, L; Camoin-Jau, L; Laine, M; Paganelli, F; Sébastien, A	1
Bhatt, DL; Kar, S	1
Ansell, J; Mantha, S	1
Avorn, J; Choudhry, NK; Gagne, JJ; Patrick, AR; Schneeweiss, S	1
Alexander, KP; Foody, JM; Funk, M; Granger, CB; Li, L; Lopes, RD; Peterson, ED; Wang, TY	1
Crippa, L; Falanga, A; Finazzi, G; Manotti, C; Marongiu, F; Moia, M; Palareti, G; Pengo, V; Poli, D; Siragusa, S; Testa, S; Tiraferri, E; Tosetto, A; Tripodi, A	1
Limper, U; Lynch, J	1
Bessereau, J; Bonello, L; Camoin-Jau, L; Collet, F; Dignat-George, F; Jouve, B; Laine, M; Lemesle, G; Maillard, L; Mancini, J; Michelet, P; Paganelli, F; Pansieri, M; Rossi, P; Wittenberg, O	1
Jin, M; Kamrul, R; Kosar, L; Schuster, B	1
Cannon, CP; Kohli, P	1
Douketis, JD; Gerotziafas, G; Kaatz, S; Ortel, TL; Schulman, S; Spyropoulos, AC	1
Dahl, OE; Harenberg, J; Marder, VJ; Marx, S; Schulze, A; Wehling, M; Weiss, C	1
Esmon, CT	1
Kastrati, A	1
Le Heuzey, JY	1
Tripodi, A	1
Becker, RC; Chan, MY; Cyr, D; Kajikawa, M; Lin, M; Lucas, J; Moseley, A; Ortel, TL; Thompson, JW; Ueda, H	1
Wenger, NK	1
McBane, RD; Tafur, A; Wysokinski, WE	1
Arthur, AS; Hoit, DA; Jones, GM; Twilla, JD	1
Berkowitz, SD; Eriksson, BI; Gent, M; Homering, M; Kakkar, AK; Lassen, MR; Turpie, AG	1
Beer, J; Gebhard, C	1
Haschke, M	1
Elias, A; Gaillard, C; Gouin, I; Nguyen, P; Ouvry, P; Pernod, G; Sié, P	1
Graungaard, T; Larsen, TB; Lip, GY; Rasmussen, LH; Skjøth, F	1
Berger, JS; Hochman, JS; Ladapo, JA; Lala, A; Scott Braithwaite, R; Sharma, G	1
Beyer-Westendorf, J; Donath, L; Günther, KP; Hartmann, A; Knoth, H; Kuhlisch, E; Lützner, J; Radke, OC; Stange, T; Tittl, L; Weiss, N; Werth, S	1
Fitchett, DH	1
Cohen, DJ; Jones, PG; Li, Y; Salisbury, AC; Spertus, JA; Wang, K	1
Chatterjee, S; Frankel, R; Ghose, A; Guha, G; Mukherjee, D; Sharma, A	1
Crowther, MA; Siegal, DM	1
Ortel, TL	1
Pawlikowska, Z; Szponar, J	1
Alessi, MC; Beguin, S; Bonnet, JL; Castelli, C; Cuisset, T; Fourcade, L; Gaborit, B; Grosdidier, C; Loosveld, M; Morange, PE; Moro, PJ; Quilici, J; Saut, N	1
Li, HF; Zhao, RL	1
Mazur-Bialy, AI; Undas, A; Wypasek, E; Zdebska, K	1
Fareed, J; Jeske, W; Thethi, I	1
Deitelzweig, SB	1
Betegón Nicolás, L; de Salas-Cansado, M; Gómez Arrayas, I; Gómez Cerezo, JF; Rubio-Terrés, C; Suárez Fernández, C	1
Ganetsky, V; Spinler, SA; Thomas, TF	1
Alessi, MC; Beguin, S; Bonnet, JL; Camoin, L; Cohen, W; Cuisset, T; Gaborit, B; Grosdidier, C; Lambert, M; Loosveld, M; Morange, PE; Moro, PJ; Pankert, M; Quilici, J; Saut, N	1
Hashimoto, M; Jakubowski, J; Ogawa, T; Ohno, K; Sugidachi, A; Tomizawa, A	1
Brem, E; Foran, M; Koyfman, A	1
Büller, HR; Cohen, AT; Haskell, L; Hu, D; Hull, R; Mebazaa, A; Merli, G; Schellong, S; Spiro, TE; Spyropoulos, AC; Tapson, V	1
Escalante, T; Gutiérrez, JM; Moura da Silva, AM; Núñez, J; Rucavado, A; Theakston, RD	1
Escalante, T; Gutiérrez, JM; Rucavado, A	1
Antman, EM; Behounek, BD; Braunwald, E; Carney, RJ; Lazzam, C; McCabe, CH; McKay, RG; Murphy, SA; Weerakkody, G; Winters, KJ; Wiviott, SD	1
Bauer, KA; Fisher, WD; Gent, M; Irwin, MW; Kälebo, P; Kwong, LM; Misselwitz, F; Turpie, AG	1
Borris, L; Dahl, OE; Eriksson, BI; Haas, S; Huisman, MV; Kakkar, AK; Kälebo, P; Misselwitz, F	1
Arbak, P; Balbay, O; Comunoğlu, NU; Erbaş, M; Güler, S; Nihat Annakkaya, A; Silan, C; Uzun, O; Yavuz, O	1
Borris, LC; Dahl, OE; Dierig, C; Eriksson, BI; Haas, S; Huisman, MV; Kakkar, AK; Kälebo, P; Misselwitz, F; Muehlhofer, E	1
Biemond, BJ; Buetehorn, U; Büller, HR; Friederich, PW; Levi, M; Perzborn, E	1
Bauer, KA; Borris, L; Dahl, OE; Eriksson, BI; Fisher, WD; Gent, M; Haas, S; Homering, M; Huisman, MV; Kakkar, AK; Kälebo, P; Kwong, LM; Misselwitz, F; Turpie, AG	1
Eikelboom, JW; Hirsh, J; O'Donnell, M	1
Antman, EM; Ardissino, D; Braunwald, E; De Servi, S; Gibson, CM; Gottlieb, S; McCabe, CH; Montalescot, G; Murphy, SA; Neumann, FJ; Riesmeyer, J; Ruzyllo, W; Weerakkody, G; Wiviott, SD	1
Schaerlig, E	1
Serebruany, V	1
Di Sciascio, G; Pasceri, V; Patti, G	1
Eikelboom, JW; Hankey, GJ; Langton, PE	1
Califf, RM; Fox, KA; Mahaffey, KW; Patel, MR; Piccini, JP	1
Antman, EM; Braunwald, E; Chandna, H; Hasin, Y; Macias, W; McCabe, CH; Murphy, SA; Voitk, J; Widimsky, P; Wiviott, SD	1
Alvarez, W	1
Haber, SL; Riley, AB; Tafreshi, MJ	1
Brommer, EJ	1
Escalante, T; Franceschi, A; Gutiérrez, JM; Rucavado, A	1
Arche, GJ; Drouin, B; Grand, A	1
Hashimoto, H; Hieda, N; Ito, T; Ogawa, K; Okumura, K; Satake, T; Toki, Y	1
Hatsuoka, M; Kashii, A; Sasaki, K; Seiki, M	1
Avello, F; Carmona, J; Criado, A; Juffé, A; Otero, C	1
Oka, N; Washida, H	1

Reviews

174 review(s) available for thiophenes and Hemorrhage

Article	Year
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus	2016
Thrombocytopenia in Chronic Liver Disease: New Management Strategies. Clinics in liver disease, 2020, Volume: 24, Issue:3 Topics: Chronic Disease; Cinnamates; Hemorrhage; Humans; Liver Diseases; Platelet Count; Platelet Transfusion; Receptors, Thrombopoietin; Risk Factors; Surgical Procedures, Operative; Thiazoles; Thiophenes; Thrombocytopenia; Thrombopoiesis	2020
Clinical management of rivaroxaban-treated patients. Expert opinion on pharmacotherapy, 2013, Volume: 14, Issue:5 Topics: Administration, Oral; Animals; Anticoagulants; Atrial Fibrillation; Blood Coagulation; Consensus; Drug Interactions; Drug Substitution; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Humans; Medication Adherence; Morpholines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism	2013
Managing new oral anticoagulants in the perioperative and intensive care unit setting. Anesthesiology, 2013, Volume: 118, Issue:6 Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Critical Care; Dabigatran; Hemorrhage; Humans; Intensive Care Units; Morpholines; Perioperative Care; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Warfarin	2013
Novel oral anticoagulants: a review of the literature and considerations in special clinical situations. Hospital practice (1995), 2013, Volume: 41, Issue:1 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Clinical Trials as Topic; Dabigatran; Drug Approval; Europe; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Therapeutic Equivalency; Thiophenes; United States; United States Food and Drug Administration; Venous Thromboembolism; Warfarin	2013
Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation. Hospital practice (1995), 2013, Volume: 41, Issue:1 Topics: Administration, Oral; Aging; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Comorbidity; Dabigatran; Hemorrhage; Humans; Meta-Analysis as Topic; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Warfarin	2013
A new era of oral anticoagulation in atrial fibrillation: implications in clinical practice. Hospital practice (1995), 2013, Volume: 41, Issue:1 Topics: Administration, Oral; Adult; Age Distribution; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Hemorrhage; Humans; Middle Aged; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Warfarin	2013
Established and new-generation antithrombotic drugs in patients with cirrhosis - possibilities and caveats. Journal of hepatology, 2013, Volume: 59, Issue:2 Topics: Animals; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Disease Progression; Fibrinolytic Agents; Hemorrhage; Heparin; Humans; Liver Cirrhosis; Morpholines; Platelet Aggregation Inhibitors; Rivaroxaban; Thiophenes; Thrombosis; Vitamin K	2013
A transition of P2Y12 antagonists for acute coronary syndrome: benefits, risks and costs. Journal of thrombosis and thrombolysis, 2014, Volume: 37, Issue:2 Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Hemorrhage; Humans; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine	2014
Reversal of oral anticoagulation. Pharmacotherapy, 2013, Volume: 33, Issue:11 Topics: Administration, Oral; Animals; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Hemorrhage; Humans; Morpholines; Rivaroxaban; Thiophenes; Warfarin	2013
Potential impact of new oral anticoagulants on the management of atrial fibrillation-related stroke in primary care. International journal of clinical practice, 2013, Volume: 67, Issue:7 Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Dabigatran; Female; Hemorrhage; Humans; Male; Morpholines; Primary Health Care; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Workload	2013
Meta-analysis of rivaroxaban and bleeding risk. The American journal of cardiology, 2013, Aug-01, Volume: 112, Issue:3 Topics: Cause of Death; Hemorrhage; Humans; Morpholines; Randomized Controlled Trials as Topic; Risk; Rivaroxaban; Thiophenes; Vitamin K	2013
ADP-receptor inhibitors in the perioperative period: the good, the bad, and the ugly. Journal of cardiothoracic and vascular anesthesia, 2013, Volume: 27, Issue:4 Topics: Adenosine; Cardiac Surgical Procedures; Clopidogrel; Hemorrhage; Humans; Perioperative Care; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Surgical Procedures, Operative; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2013
Preventing stroke and systemic embolism in renal patients with atrial fibrillation: focus on anticoagulation. Contributions to nephrology, 2013, Volume: 179 Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Comorbidity; Dabigatran; Disease Management; Embolism; Female; Fibrinolytic Agents; Hemorrhage; Humans; Hypertension; Intracranial Embolism; Male; Morpholines; Patient Selection; Pyrazoles; Pyridones; Renal Insufficiency, Chronic; Risk; Risk Factors; Rivaroxaban; Severity of Illness Index; Stroke; Thiophenes; Thrombophilia; Warfarin	2013
Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban. Clinical research in cardiology : official journal of the German Cardiac Society, 2013, Volume: 102, Issue:6 Topics: Administration, Oral; Animals; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Dose-Response Relationship, Drug; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Renal Insufficiency; Rivaroxaban; Thiophenes	2013
Rivaroxaban: practical considerations for ensuring safety and efficacy. Pharmacotherapy, 2013, Volume: 33, Issue:11 Topics: Administration, Oral; Anticoagulants; Body Weight; Clinical Trials, Phase III as Topic; Hemorrhage; Humans; Morpholines; Rivaroxaban; Thiophenes; Treatment Outcome	2013
Balancing risk and benefit in venous thromboembolism trials: concept for a bivariate endpoint trial design and analytic approach. Journal of thrombosis and haemostasis : JTH, 2013, Volume: 11, Issue:8 Topics: Administration, Oral; Anticoagulants; Hemorrhage; Humans; Morpholines; Randomized Controlled Trials as Topic; Research Design; Risk; Rivaroxaban; Thiophenes; Venous Thromboembolism	2013
Managing bleeding in anticoagulated patients in the emergency care setting. The Journal of emergency medicine, 2013, Volume: 45, Issue:3 Topics: Anticoagulants; Antidotes; Benzimidazoles; beta-Alanine; Dabigatran; Emergency Service, Hospital; Hemorrhage; Hemostasis; Humans; Morpholines; Rivaroxaban; Thiophenes; Warfarin	2013
Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 2013, Volume: 16, Issue:4 Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cardiovascular Diseases; Cost-Benefit Analysis; Dabigatran; Drug Costs; Hemorrhage; Humans; Markov Chains; Middle Aged; Morpholines; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Time Factors; Warfarin	2013
Novel oral anticoagulants and stroke prevention in atrial fibrillation and chronic heart failure. Heart failure reviews, 2014, Volume: 19, Issue:3 Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Chronic Disease; Dabigatran; Drug Monitoring; Heart Failure; Hemorrhage; Humans; Morpholines; Outcome Assessment, Health Care; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Severity of Illness Index; Stroke; Thiophenes; Warfarin	2014
Clinical review: Clinical management of new oral anticoagulants: a structured review with emphasis on the reversal of bleeding complications. Critical care (London, England), 2013, Jun-17, Volume: 17, Issue:3 Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Disease Management; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes	2013
Practical management of bleeding due to the anticoagulants dabigatran, rivaroxaban, and apixaban. Cleveland Clinic journal of medicine, 2013, Volume: 80, Issue:7 Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Dabigatran; Drug Monitoring; Hemorrhage; Hemostatic Techniques; Humans; Morpholines; Perioperative Care; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes	2013
The perioperative management of new direct oral anticoagulants: a question without answers. Thrombosis and haemostasis, 2013, Volume: 110, Issue:3 Topics: Administration, Oral; Aged; Anesthesiology; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Dabigatran; Female; Hemorrhage; Hemostasis; Heparin, Low-Molecular-Weight; Humans; Male; Morpholines; Patient Safety; Perioperative Period; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thromboembolism	2013
Bleeding with dabigatran, rivaroxaban, apixaban. No antidote, and little clinical experience. Prescrire international, 2013, Volume: 22, Issue:139 Topics: Anticoagulants; Antidotes; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Dabigatran; Drug Overdose; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes	2013
[New clinical perspectives in the management of oral direct anticoagulant agents]. Medicina clinica, 2014, Feb-20, Volume: 142, Issue:4 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Elective Surgical Procedures; Emergencies; Factor Xa Inhibitors; Hemorrhage; Humans; Kidney Diseases; Morpholines; Orthopedic Procedures; Postoperative Complications; Premedication; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Risk; Rivaroxaban; Thiophenes; Thrombophilia; Vitamin K	2014
Mixed treatment comparison meta-analysis of aspirin, warfarin, and new anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation. Clinical therapeutics, 2013, Volume: 35, Issue:7 Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Data Interpretation, Statistical; Databases, Bibliographic; Double-Blind Method; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin	2013
Anticoagulation with rivaroxaban: covering a broad spectrum of thromboembolic disease. Expert review of cardiovascular therapy, 2013, Volume: 11, Issue:7 Topics: Administration, Oral; Anticoagulants; Clinical Trials, Phase III as Topic; Clinical Trials, Phase IV as Topic; Drug Monitoring; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Rivaroxaban; Thiophenes; Thromboembolism	2013
Clinical use of new oral anticoagulant drugs: dabigatran and rivaroxaban. British journal of haematology, 2013, Volume: 163, Issue:2 Topics: Administration, Oral; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Embolism; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Rivaroxaban; Stroke; Thiophenes	2013
Bleeding and antidotes in new oral anticoagulants. Best practice & research. Clinical haematology, 2013, Volume: 26, Issue:2 Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Dabigatran; Drug Administration Schedule; Hemorrhage; Hemostatics; Humans; Morpholines; Prothrombin; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiazoles; Thiophenes; Thromboembolism	2013
Focused 2012 update of the Canadian Cardiovascular Society guidelines for the use of antiplatelet therapy. The Canadian journal of cardiology, 2013, Volume: 29, Issue:11 Topics: Acute Coronary Syndrome; Adenosine; Anticoagulants; Aspirin; Clinical Trials as Topic; Clopidogrel; Contraindications; Coronary Artery Bypass; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proton Pump Inhibitors; Secondary Prevention; Stents; Stroke; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine	2013
[Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors. Proposals of the Working Group on Perioperative Haemostasis (GIHP) - March 2013]. Annales francaises d'anesthesie et de reanimation, 2013, Volume: 32, Issue:10 Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Emergencies; Emergency Medical Services; Factor Xa Inhibitors; Hemorrhage; Hemostasis; Humans; Morpholines; Perioperative Care; Rivaroxaban; Surgical Procedures, Operative; Thiophenes; Thrombin	2013
Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network meta-analysis. BMJ (Clinical research ed.), 2013, Aug-30, Volume: 347 Topics: Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Morpholines; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Recurrence; Rivaroxaban; Thiophenes; Venous Thromboembolism; Vitamin K	2013
[Advances in venous thromboembolism]. Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases, 2013, Volume: 36, Issue:5 Topics: Anticoagulants; Hemorrhage; Heparin; Humans; Magnetic Resonance Angiography; Morpholines; Pulmonary Artery; Pulmonary Embolism; Rivaroxaban; Thiophenes; Thrombolytic Therapy; Tomography, X-Ray Computed; Venous Thromboembolism	2013
[Thrombocyte aggregation inhibitors: what are the risks?]. Praxis, 2013, Oct-02, Volume: 102, Issue:20 Topics: Adenosine; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Interactions; Drug Resistance; Drug Therapy, Combination; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Stents; Thiophenes; Ticagrelor; Ticlopidine	2013
Pharmacokinetic and pharmacodynamic drug interactions with new oral anticoagulants: what do they mean for patients with atrial fibrillation? The Annals of pharmacotherapy, 2013, Volume: 47, Issue:11 Topics: Anticoagulants; ATP Binding Cassette Transporter, Subfamily B, Member 1; Atrial Fibrillation; Benzimidazoles; Cytochrome P-450 Enzyme System; Dabigatran; Drug Interactions; Drug Therapy, Combination; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes	2013
The old and new: PCCs, VIIa, and long-lasting clotting factors for hemophilia and other bleeding disorders. Hematology. American Society of Hematology. Education Program, 2013, Volume: 2013 Topics: Antibodies; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Clinical Trials as Topic; Dabigatran; Factor VIIa; Female; Half-Life; Hemophilia A; Hemorrhage; Hemostatics; Humans; Male; Morpholines; Rivaroxaban; RNA Interference; Thiophenes	2013
Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis. Journal of thrombosis and haemostasis : JTH, 2014, Volume: 12, Issue:3 Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Female; Hemorrhage; Humans; Male; Morpholines; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Risk Factors; Rivaroxaban; Thiazoles; Thiophenes; Treatment Outcome; Venous Thromboembolism; Vitamin K	2014
{blacktriangledown} Apixaban and {blacktriangledown} rivaroxaban for stroke prevention in AF. Drug and therapeutics bulletin, 2014, Volume: 52, Issue:1 Topics: Adult; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Embolism; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes	2014
[Differentiated antiplatelet therapy for acute coronary syndromes]. Deutsche medizinische Wochenschrift (1946), 2014, Volume: 139, Issue:4 Topics: Acute Coronary Syndrome; Adenosine; Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Platelet Transfusion; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine	2014
New antithrombotics for secondary prevention of acute coronary syndrome. Clinical cardiology, 2014, Volume: 37, Issue:3 Topics: Acute Coronary Syndrome; Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Coronary Thrombosis; Dabigatran; Hemorrhage; Humans; Imines; Lactones; Morpholines; Platelet Activation; Platelet Aggregation Inhibitors; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Secondary Prevention; Thiophenes; Thrombin	2014
New oral anticoagulant agents - general features and outcomes in subsets of patients. Thrombosis and haemostasis, 2014, Apr-01, Volume: 111, Issue:4 Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Hemorrhage; Humans; Morpholines; Patient Selection; Pyrazoles; Pyridines; Pyridones; Risk; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Treatment Outcome; Venous Thromboembolism; Warfarin	2014
[New antiplatelet drugs in coronary artery disease]. Medicina clinica, 2014, Dec-09, Volume: 143, Issue:11 Topics: Adenosine; Adenosine Monophosphate; Clinical Trials, Phase III as Topic; Coronary Artery Disease; Double-Blind Method; Dyspnea; Hemorrhage; Humans; Multicenter Studies as Topic; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Receptors, Proteinase-Activated; Thiophenes; Ticagrelor; Treatment Outcome	2014
Prasugrel and ticagrelor: is there a winner? Journal of cardiovascular medicine (Hagerstown, Md.), 2014, Volume: 15, Issue:1 Topics: Adenosine; Hemorrhage; Humans; Patient Selection; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Risk Assessment; Risk Factors; Thiophenes; Ticagrelor; Treatment Outcome	2014
Direct oral anticoagulants in the treatment and long-term prevention of venous thrombo-embolism. European heart journal, 2014, Jul-21, Volume: 35, Issue:28 Topics: Acute Disease; Administration, Oral; Antithrombins; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Hemorrhage; Humans; Long-Term Care; Morpholines; Perioperative Care; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Treatment Outcome; Venous Thromboembolism; Vitamin K	2014
Practical considerations in emergency management of bleeding in the setting of target-specific oral anticoagulants. The American journal of emergency medicine, 2014, Volume: 32, Issue:4 Topics: Administration, Oral; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Emergency Treatment; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes	2014
Impact of new oral or intravenous P2Y12 inhibitors and clopidogrel on major ischemic and bleeding events in patients with coronary artery disease: a meta-analysis of randomized trials. Atherosclerosis, 2014, Volume: 233, Issue:2 Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Administration, Oral; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Fibrinolytic Agents; Hemorrhage; Humans; Injections, Intravenous; Multicenter Studies as Topic; Myocardial Infarction; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Randomized Controlled Trials as Topic; Stents; Stroke; Sulfonamides; Thiophenes; Thrombolytic Therapy; Ticagrelor; Ticlopidine	2014
Management of antiplatelet and anticoagulant therapy in patients with atrial fibrillation in the setting of acute coronary syndromes or percutaneous coronary interventions. Circulation. Cardiovascular interventions, 2014, Volume: 7, Issue:1 Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Morpholines; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Postoperative Complications; Prasugrel Hydrochloride; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thrombosis; Ticagrelor	2014
New antiplatelet agents in the treatment of acute coronary syndromes. Archives of cardiovascular diseases, 2014, Volume: 107, Issue:3 Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Clinical Trials as Topic; Clopidogrel; Combined Modality Therapy; Coronary Artery Bypass; Coronary Thrombosis; Diabetes Complications; Hemorrhage; Humans; Multicenter Studies as Topic; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Precision Medicine; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Receptors, Purinergic P2Y12; Renal Insufficiency; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2014
Practical guidance for using rivaroxaban in patients with atrial fibrillation: balancing benefit and risk. Vascular health and risk management, 2014, Volume: 10 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Blood Coagulation; Drug Administration Schedule; Drug Interactions; Drug Substitution; Hemorrhage; Humans; Morpholines; Patient Selection; Perioperative Care; Practice Guidelines as Topic; Preventive Health Services; Risk Assessment; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome	2014
[Pharmacologic and clinical characteristics of direct inhibitors of factor Xa: rivaroxaban, apixaban, edoxaban and betrixaban]. Journal des maladies vasculaires, 2014, Volume: 39, Issue:3 Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Benzamides; Blood Coagulation; Embolism; Factor Xa Inhibitors; Hemorrhage; Hemostatics; Humans; Morpholines; Postoperative Complications; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Thrombophilia; Thrombosis	2014
Efficacy and safety of prasugrel in acute coronary syndrome patients. Clinical biochemistry, 2014, Volume: 47, Issue:7-8 Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine	2014
The role of rivaroxaban in atrial fibrillation and acute coronary syndromes. Journal of cardiovascular pharmacology and therapeutics, 2014, Volume: 19, Issue:6 Topics: Acute Coronary Syndrome; Administration, Oral; Atrial Fibrillation; Blood Coagulation; Cost-Benefit Analysis; Drug Costs; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Practice Guidelines as Topic; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome	2014
The newer direct oral anticoagulants: a practical guide. Clinical medicine (London, England), 2014, Volume: 14, Issue:2 Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Warfarin	2014
New oral anticoagulants: clinical indications, monitoring and treatment of acute bleeding complications. Acta anaesthesiologica Scandinavica, 2014, Volume: 58, Issue:6 Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Dabigatran; Drug Monitoring; Factor Xa Inhibitors; Hemorrhage; Hemostatic Techniques; Hemostatics; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thrombin; Thromboembolism; Thrombophilia	2014
Anticoagulation in atrial fibrillation. BMJ (Clinical research ed.), 2014, Apr-14, Volume: 348 Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Medication Adherence; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Warfarin	2014
Rivaroxaban in acute coronary syndromes--is it prime time? Expert review of cardiovascular therapy, 2014, Volume: 12, Issue:6 Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Rivaroxaban; Thiophenes	2014
Optimal aspirin dose in acute coronary syndromes: an emerging consensus. Future cardiology, 2014, Volume: 10, Issue:2 Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Dose-Response Relationship, Drug; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Secondary Prevention; Thiophenes; Ticagrelor	2014
Anticoagulation: a GP primer on the new oral anticoagulants. Australian family physician, 2014, Volume: 43, Issue:5 Topics: Anticoagulants; Antithrombins; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Dabigatran; Drug Monitoring; Factor Xa Inhibitors; General Practice; Hemorrhage; Humans; Kidney; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism; Warfarin	2014
Meta-analysis of the efficacy and safety of new oral anticoagulants in patients with cancer-associated acute venous thromboembolism. Journal of thrombosis and haemostasis : JTH, 2014, Volume: 12, Issue:7 Topics: Acute Disease; Administration, Oral; Anticoagulants; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Morpholines; Neoplasms; Randomized Controlled Trials as Topic; Recurrence; Risk; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thrombosis	2014
Rivaroxaban in patients with a recent acute coronary syndrome event: integration of trial findings into clinical practice. Vascular health and risk management, 2014, Volume: 10 Topics: Acute Coronary Syndrome; Clinical Trials as Topic; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Platelet Aggregation Inhibitors; Rivaroxaban; Secondary Prevention; Thiophenes; Treatment Outcome	2014
Newer clinically available antithrombotics and their antidotes. Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing, 2014, Volume: 40, Issue:3 Topics: Animals; Antidotes; Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Elective Surgical Procedures; Factor Xa Inhibitors; Hemorrhage; Hemostatics; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism	2014
Rivaroxaban and stroke prevention in patients with atrial fibrillation: new evidence. Expert review of cardiovascular therapy, 2014, Volume: 12, Issue:8 Topics: Administration, Oral; Animals; Anticoagulants; Atrial Fibrillation; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Rivaroxaban; Stroke; Thiophenes; Vitamin K; Warfarin	2014
Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood, 2014, Sep-18, Volume: 124, Issue:12 Topics: Acute Disease; Administration, Oral; Anticoagulants; Benzimidazoles; Clinical Trials, Phase III as Topic; Dabigatran; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Morpholines; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiazoles; Thiophenes; Venous Thromboembolism; Vitamin K	2014
Oral anticoagulant use in addition to antiplatelet therapy for secondary prevention in acute coronary syndrome: current perspectives. Expert review of cardiovascular therapy, 2014, Volume: 12, Issue:8 Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Drug Approval; Drug Therapy, Combination; Hemorrhage; Humans; Morpholines; Platelet Aggregation Inhibitors; Rivaroxaban; Secondary Prevention; Thiophenes	2014
Direct oral anticoagulants in the treatment of acute venous thromboembolism: a systematic review and meta-analysis. Thrombosis research, 2014, Volume: 134, Issue:4 Topics: Administration, Oral; Animals; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Venous Thromboembolism	2014
Dabigatran, rivaroxaban and apixaban for extended venous thromboembolism treatment: network meta-analysis. International angiology : a journal of the International Union of Angiology, 2014, Volume: 33, Issue:4 Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Chi-Square Distribution; Dabigatran; Hemorrhage; Humans; Morpholines; Odds Ratio; Pyrazoles; Pyridones; Recurrence; Risk Assessment; Risk Factors; Rivaroxaban; Thiophenes; Time Factors; Treatment Outcome; Venous Thromboembolism	2014
Novel oral anticoagulants in patients with renal insufficiency: a meta-analysis of randomized trials. The Canadian journal of cardiology, 2014, Volume: 30, Issue:8 Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Renal Insufficiency; Rivaroxaban; Stroke; Thiophenes; Thromboembolism	2014
The potential role of anticoagulant therapy for the secondary prevention of ischemic events post-acute coronary syndrome. Current medical research and opinion, 2014, Volume: 30, Issue:11 Topics: Acute Coronary Syndrome; Anticoagulants; Drug Therapy, Combination; Hemorrhage; Humans; Morpholines; Platelet Aggregation Inhibitors; Rivaroxaban; Secondary Prevention; Thiophenes	2014
Pharmacology and safety of new oral anticoagulants: the challenge of bleeding persists. Clinics in laboratory medicine, 2014, Volume: 34, Issue:3 Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Monitoring; Evidence-Based Medicine; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes	2014
Pharmacology and laboratory testing of the oral Xa inhibitors. Clinics in laboratory medicine, 2014, Volume: 34, Issue:3 Topics: Administration, Oral; Benzamides; Blood Coagulation Tests; Drug Monitoring; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Precision Medicine; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes	2014
Management of hemorrhage with the target-specific oral anticoagulants. Hospital practice (1995), 2014, Volume: 42, Issue:3 Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Transfusion; Charcoal; Dabigatran; Drug Monitoring; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Renal Dialysis; Rivaroxaban; Thiophenes	2014
Balancing ischaemia and bleeding risks with novel oral anticoagulants. Nature reviews. Cardiology, 2014, Volume: 11, Issue:12 Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Ischemia; Morpholines; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Venous Thromboembolism	2014
[Bleeding complications under oral anticoagulation]. Deutsche medizinische Wochenschrift (1946), 2014, Volume: 139, Issue:49 Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Dabigatran; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Thiophenes; Vitamin K	2014
Risk of major bleeding in different indications for new oral anticoagulants: insights from a meta-analysis of approved dosages from 50 randomized trials. International journal of cardiology, 2015, Jan-20, Volume: 179 Topics: Administration, Oral; Antithrombins; Azepines; Benzamides; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Risk; Rivaroxaban; Thiazoles; Thiophenes	2015
Strategies for urgent reversal of target-specific oral anticoagulants. Hospital practice (1995), 2014, Volume: 42, Issue:5 Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Charcoal; Dabigatran; Factor VIIa; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Renal Dialysis; Rivaroxaban; Thiazoles; Thiophenes	2014
Non-vitamin K antagonist oral anticoagulants (NOACs): a view from the laboratory. British journal of biomedical science, 2014, Volume: 71, Issue:4 Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Dose-Response Relationship, Drug; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Thrombosis; Treatment Outcome; Vitamin K	2014
Use of novel antiplatelet agents in acute coronary syndromes. Current atherosclerosis reports, 2015, Volume: 17, Issue:3 Topics: Acute Coronary Syndrome; Animals; Coronary Artery Disease; Hemorrhage; Humans; Myocardial Ischemia; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes	2015
The role of factor Xa inhibitors in venous thromboembolism treatment. Vascular health and risk management, 2015, Volume: 11 Topics: Animals; Blood Coagulation; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Risk Factors; Rivaroxaban; Thiazoles; Thiophenes; Treatment Outcome; Venous Thromboembolism	2015
Reversal of the novel oral anticoagulants dabigatran, rivoraxaban, and apixaban. Current opinion in critical care, 2015, Volume: 21, Issue:2 Topics: Animals; Antidotes; Antithrombins; Benzimidazoles; beta-Alanine; Coagulants; Dabigatran; Factor Xa Inhibitors; Fibrinolytic Agents; Hemorrhage; Humans; Models, Animal; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thromboembolism	2015
Periprocedural management of rivaroxaban-treated patients. Expert opinion on pharmacotherapy, 2015, Volume: 16, Issue:5 Topics: Administration, Oral; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Perioperative Period; Postoperative Complications; Risk; Rivaroxaban; Surgical Procedures, Operative; Thiophenes; Thromboembolism	2015
[Anticoagulant therapy in secondary prevention of coronary events]. Vnitrni lekarstvi, 2014, Volume: 60, Issue:12 Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Clopidogrel; Dabigatran; Hemorrhage; Humans; Morpholines; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyrazoles; Pyridones; Rivaroxaban; Secondary Prevention; Thiophenes; Ticlopidine; Warfarin	2014
Clinical experience with novel oral anticoagulants for thromboprophylaxis after elective hip and knee arthroplasty. Arteriosclerosis, thrombosis, and vascular biology, 2015, Volume: 35, Issue:4 Topics: Administration, Oral; Anticoagulants; Antithrombins; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration Schedule; Elective Surgical Procedures; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Thiophenes; Thromboembolism; Treatment Outcome	2015
Novel oral anticoagulants: efficacy, laboratory measurement, and approaches to emergent reversal. Archives of pathology & laboratory medicine, 2015, Volume: 139, Issue:5 Topics: Administration, Oral; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Drug Monitoring; Factor Xa Inhibitors; Hemorrhage; Humans; Laboratories; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thromboembolism; Treatment Outcome; Warfarin	2015
Meta-Analysis of Randomized Controlled Trials Comparing Risk of Major Adverse Cardiac Events and Bleeding in Patients With Prasugrel Versus Clopidogrel. The American journal of cardiology, 2015, Aug-01, Volume: 116, Issue:3 Topics: Clopidogrel; Coronary Artery Disease; Global Health; Hemorrhage; Humans; Incidence; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Factors; Thiophenes; Ticlopidine	2015
Non-VKA Oral Anticoagulants: Accurate Measurement of Plasma Drug Concentrations. BioMed research international, 2015, Volume: 2015 Topics: Anticoagulants; Blood Coagulation; Dabigatran; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Thiophenes; Thromboembolism	2015
[Prophylaxis of thromboembolism in atrial fibrillation: new oral anticoagulants and left atrial appendage closure]. Deutsche medizinische Wochenschrift (1946), 2015, Volume: 140, Issue:16 Topics: Anticoagulants; Atrial Appendage; Atrial Fibrillation; Atrial Flutter; Benzimidazoles; beta-Alanine; Combined Modality Therapy; Contraindications; Dabigatran; Hemorrhage; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Thiophenes; Thromboembolism; Vitamin K	2015
Safety and Efficacy of New Anticoagulants for the Prevention of Venous Thromboembolism After Hip and Knee Arthroplasty: A Meta-Analysis. The Journal of arthroplasty, 2017, Volume: 32, Issue:2 Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Dabigatran; Enoxaparin; Fondaparinux; Hemorrhage; Humans; Morpholines; Polysaccharides; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism	2017
Prasugrel development - claims and achievements. Thrombosis and haemostasis, 2009, Volume: 101, Issue:1 Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Animals; Aspirin; Blood Platelets; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; Drug Administration Schedule; Drug Discovery; Drug Resistance; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Research Design; Risk Assessment; Stents; Thiophenes; Ticlopidine; Treatment Outcome	2009
[Perioperative venous thromboembolism prophylaxis: short review and recommendations]. Annales francaises d'anesthesie et de reanimation, 2008, Volume: 27 Suppl 3 Topics: Adult; Aged; Anticoagulants; Combined Modality Therapy; Fibrinolytic Agents; Fondaparinux; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Middle Aged; Morpholines; Polysaccharides; Postoperative Complications; Preanesthetic Medication; Pulmonary Embolism; Risk Factors; Rivaroxaban; Stockings, Compression; Thiophenes; Thromboembolism; Thrombophlebitis; Vitamin K	2008
[Rivaroxaban (Xarelto): efficacy and safety]. Annales francaises d'anesthesie et de reanimation, 2008, Volume: 27 Suppl 3 Topics: Administration, Oral; Anticoagulants; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Double-Blind Method; Enoxaparin; Factor Xa Inhibitors; Fibrinolytic Agents; Hematoma, Epidural, Spinal; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Morpholines; Postoperative Complications; Preanesthetic Medication; Rivaroxaban; Thiophenes; Thromboembolism	2008
[Rivaroxaban: mode of action]. Annales francaises d'anesthesie et de reanimation, 2008, Volume: 27 Suppl 3 Topics: Administration, Oral; Anticoagulants; Clinical Trials as Topic; Drug Administration Schedule; Drug Monitoring; Factor Xa Inhibitors; Fibrinolytic Agents; Hemorrhage; Heparin; Heparin, Low-Molecular-Weight; Humans; Molecular Structure; Morpholines; Postoperative Complications; Preanesthetic Medication; Prothrombin Time; Rivaroxaban; Thiophenes; Thrombin; Thromboembolism; Vitamin K; Warfarin	2008
New-generation drugs that stimulate platelet production in chronic immune thrombocytopenic purpura. Lancet (London, England), 2009, May-02, Volume: 373, Issue:9674 Topics: Benzoates; Carrier Proteins; Chronic Disease; Drug Approval; Hemorrhage; Humans; Hydrazines; Megakaryocytes; Methacrylates; Patient Selection; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Safety; Thiazoles; Thiophenes; Thrombopoiesis; Thrombopoietin; Treatment Outcome; United States; United States Food and Drug Administration	2009
Emergence of new oral antithrombotics: a critical appraisal of their clinical potential. Vascular health and risk management, 2008, Volume: 4, Issue:6 Topics: Administration, Oral; Benzimidazoles; Blood Coagulation; Dabigatran; Fibrinolytic Agents; Hemorrhage; History, 20th Century; History, 21st Century; Humans; Medication Adherence; Morpholines; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism	2008
Should new oral anticoagulants replace low-molecular-weight heparin for thromboprophylaxis in orthopaedic surgery? Archives of cardiovascular diseases, 2009, Volume: 102, Issue:4 Topics: Administration, Oral; Anticoagulants; Benzimidazoles; Dabigatran; Drug Administration Schedule; Factor Xa Inhibitors; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Morpholines; Orthopedic Procedures; Prothrombin; Pyridines; Risk Assessment; Rivaroxaban; Thiophenes; Thrombosis; Vitamin K	2009
Prasugrel for the treatment of patients with acute coronary syndrome. Vascular health and risk management, 2009, Volume: 5, Issue:1 Topics: Acute Coronary Syndrome; Administration, Oral; Angioplasty, Balloon, Coronary; Animals; Clinical Trials as Topic; Clopidogrel; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine; Treatment Outcome	2009
Improving adjunctive pharmacotherapy for primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: beyond the HORIZONS-AMI trial. Reviews in cardiovascular medicine, 2009,Spring, Volume: 10, Issue:2 Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Chemotherapy, Adjuvant; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Heparin; Hirudins; Humans; Myocardial Infarction; Peptide Fragments; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Recombinant Proteins; Risk Assessment; Thiophenes; Thrombosis; Ticlopidine; Time Factors; Treatment Outcome	2009
Comparison of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Vascular health and risk management, 2009, Volume: 5 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Assessment; Thiophenes; Thrombosis; Ticlopidine; Treatment Outcome	2009
Ticagrelor--a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors? Medical science monitor : international medical journal of experimental and clinical research, 2009, Volume: 15, Issue:12 Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Biotransformation; Clinical Trials as Topic; Clopidogrel; Hemorrhage; Humans; Lactones; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Pyridines; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor; Ticlopidine	2009
Prasugrel: Clinical development and therapeutic application. Advances in therapy, 2009, Volume: 26, Issue:11 Topics: Acute Coronary Syndrome; Angioplasty; Clopidogrel; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Thiophenes; Thrombosis; Ticlopidine	2009
What is the risk of intensifying platelet inhibition beyond clopidogrel? A systematic review and a critical appraisal of the role of prasugrel. QJM : monthly journal of the Association of Physicians, 2010, Volume: 103, Issue:6 Topics: Clopidogrel; Drug Evaluation, Preclinical; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Randomized Controlled Trials as Topic; Receptors, Purinergic P2; Risk Factors; Thiophenes; Ticlopidine	2010
Preventing serious sequelae after an acute coronary syndrome: the consequences of thrombosis versus bleeding with antiplatelet therapy. Journal of cardiovascular pharmacology, 2010, Volume: 55, Issue:6 Topics: Acute Coronary Syndrome; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Artery Bypass; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Risk Factors; Thiophenes; Thrombosis; Ticlopidine	2010
Antiplatelet therapy prasugrel: a novel platelet ADP P2Y12 receptor antagonist. Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2010, Volume: 16, Issue:2 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials, Phase III as Topic; Clopidogrel; Drug Evaluation, Preclinical; Drug Therapy, Combination; Hemorrhage; Humans; Ischemia; Kidney Failure, Chronic; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Randomized Controlled Trials as Topic; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine	2010
Rivaroxaban vs dabigatran for thromboprophylaxis after joint-replacement surgery: exploratory indirect comparison based on meta-analysis of pivotal clinical trials. Croatian medical journal, 2010, Volume: 51, Issue:2 Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; Dabigatran; Enoxaparin; Hemorrhage; Humans; Morpholines; Postoperative Care; Pyridines; Randomized Controlled Trials as Topic; Rivaroxaban; Safety; Survival Analysis; Thiophenes; Venous Thromboembolism	2010
Diabetes and acute coronary syndrome. Minerva medica, 2010, Volume: 101, Issue:2 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Anticoagulants; Diabetic Angiopathies; Endothelium, Vascular; Hemorrhage; Humans; Hypoglycemic Agents; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes	2010
Dosing strategies for antiplatelet therapy in percutaneous coronary intervention. Hospital practice (1995), 2010, Volume: 38, Issue:2 Topics: Angioplasty, Balloon, Coronary; Aspirin; Clinical Protocols; Clopidogrel; Drug Administration Schedule; Drug Monitoring; Hemorrhage; Humans; Patient Selection; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Risk Assessment; Risk Factors; Thiophenes; Thrombosis; Ticlopidine; Treatment Outcome	2010
Thienopyridine antiplatelet agents: focus on prasugrel. The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists, 2010, Volume: 25, Issue:4 Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Drug Interactions; Drug Resistance; Evidence-Based Medicine; Female; Hemorrhage; Humans; Male; Middle Aged; Patient Selection; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Assessment; Risk Factors; Thiophenes; Thrombosis; Treatment Outcome	2010
Pharmacologic therapy for non ST-segment elevation acute coronary syndromes: focus on antithrombotic therapy. Cardiovascular drugs and therapy, 2010, Volume: 24, Issue:4 Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Disease Management; Drug Synergism; Drug Therapy, Combination; Enoxaparin; Fibrinolytic Agents; Fondaparinux; Hemorrhage; Heparin; Hirudins; Humans; Peptide Fragments; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Polysaccharides; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Recombinant Proteins; Thiophenes; Ticagrelor; Ticlopidine	2010
Rivaroxaban versus enoxaparin for thromboprophylaxis after total hip or knee arthroplasty: a meta-analysis of randomized controlled trials. European journal of clinical pharmacology, 2010, Volume: 66, Issue:11 Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Double-Blind Method; Enoxaparin; Hemorrhage; Humans; Incidence; Morpholines; Multicenter Studies as Topic; Odds Ratio; Primary Prevention; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism	2010
Managing bleeding complications in patients treated with the old and the new anticoagulants. Current pharmaceutical design, 2010, Volume: 16, Issue:31 Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Factor VIIa; Fondaparinux; Hemorrhage; Heparin; Humans; Morpholines; Polysaccharides; Protamines; Recombinant Proteins; Risk Factors; Rivaroxaban; Thiophenes; Vitamin K	2010
The platelet P2Y₁₂ receptor for adenosine diphosphate: congenital and drug-induced defects. Blood, 2011, Feb-17, Volume: 117, Issue:7 Topics: Adenosine; Adenosine Diphosphate; Animals; Blood Platelet Disorders; Blood Platelets; Clopidogrel; Female; Hemorrhage; Humans; Male; Mice; Mutation; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Signal Transduction; Thiophenes; Ticagrelor; Ticlopidine	2011
Prasugrel: an efficacy and safety review of a new antiplatelet therapy option. Critical pathways in cardiology, 2010, Volume: 9, Issue:4 Topics: Acute Coronary Syndrome; American Heart Association; Angioplasty, Balloon, Coronary; Clinical Trials, Phase III as Topic; Clopidogrel; Hemorrhage; Humans; Patient Selection; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Precision Medicine; Proton Pump Inhibitors; Purinergic P2Y Receptor Antagonists; Risk Assessment; Thiophenes; Ticlopidine; Treatment Outcome; United States	2010
[New approaches and indications for the analysis of platelet function in cardiology]. Hamostaseologie, 2011, May-02, Volume: 31, Issue:2 Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Interactions; Hemorrhage; Humans; Piperazines; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine	2011
Dabigatran and rivaroxaban for prevention of venous thromboembolism--systematic review and adjusted indirect comparison. Journal of clinical pharmacy and therapeutics, 2011, Volume: 36, Issue:1 Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Enoxaparin; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Orthopedic Procedures; Postoperative Complications; Pulmonary Embolism; Rivaroxaban; Thiophenes; Venous Thromboembolism; Venous Thrombosis	2011
New anticoagulants: pharmacology and clinical studies. Wiener medizinische Wochenschrift (1946), 2011, Volume: 161, Issue:3-4 Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Biological Availability; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Postoperative Complications; Prothrombin; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism	2011
[Prasugrel for acute and long-term treatment of patients with acute coronary syndromes: what is state-of-the-art?]. Deutsche medizinische Wochenschrift (1946), 2011, Volume: 136, Issue:15 Topics: Acute Coronary Syndrome; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Electrocardiography; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine	2011
Bleeding manifestations of congenital and drug-induced defects of the platelet P2Y12 receptor for adenosine diphosphate. Thrombosis and haemostasis, 2011, Volume: 105 Suppl 1 Topics: Adenosine; Adenosine Diphosphate; Adenosine Monophosphate; Animals; Clinical Trials, Phase III as Topic; Clopidogrel; Hemorrhage; Humans; Piperazines; Platelet Activation; Prasugrel Hydrochloride; Quinazolinones; Receptors, Purinergic P2Y12; Sulfonamides; Thiophenes; Ticagrelor; Ticlopidine	2011
[Myocardial infarction: Role of new antiplatelet agents]. Presse medicale (Paris, France : 1983), 2011, Volume: 40, Issue:6 Topics: Adenosine; Adenosine Monophosphate; Administration, Oral; Clinical Trials as Topic; Clopidogrel; Combined Modality Therapy; Disease Management; Drug Resistance; Fibrinolytic Agents; Hemorrhage; Humans; Injections, Intravenous; Multicenter Studies as Topic; Myocardial Infarction; Myocardial Reperfusion; Myocardial Revascularization; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor; Ticlopidine; Time Factors	2011
Rivaroxaban in the contemporary treatment of acute coronary syndromes. Expert opinion on investigational drugs, 2011, Volume: 20, Issue:6 Topics: Acute Coronary Syndrome; Administration, Oral; Animals; Anticoagulants; Biological Availability; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Practice Guidelines as Topic; Rivaroxaban; Thiophenes	2011
Ischaemic and bleeding complications with new, compared to standard, ADP-antagonist regimens in acute coronary syndromes: a meta-analysis of randomized trials. QJM : monthly journal of the Association of Physicians, 2011, Volume: 104, Issue:7 Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Clopidogrel; Hemorrhage; Humans; Ischemia; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Thiophenes; Ticagrelor; Ticlopidine	2011
Prophylaxis of venous thromboembolism: low molecular weight heparin compared to the selective anticoagulants rivaroxaban, dabigatran and fondaparinux. International angiology : a journal of the International Union of Angiology, 2011, Volume: 30, Issue:3 Topics: Animals; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Evidence-Based Medicine; Fondaparinux; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Morpholines; Polysaccharides; Practice Guidelines as Topic; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism	2011
Implications of variability in definition and reporting of major bleeding in randomized trials of oral P2Y12 inhibitors for acute coronary syndromes. European heart journal, 2011, Volume: 32, Issue:18 Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials, Phase III as Topic; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine	2011
Emerging antiplatelet therapies in percutaneous coronary intervention: a focus on prasugrel. Clinical therapeutics, 2011, Volume: 33, Issue:4 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Clopidogrel; Hemorrhage; Humans; Patient Selection; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Thiophenes; Ticlopidine	2011
New anticoagulants: how to deal with treatment failure and bleeding complications. British journal of clinical pharmacology, 2011, Volume: 72, Issue:4 Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Morpholines; Rivaroxaban; Thiophenes; Thromboembolism; Thrombosis; Treatment Failure	2011
Prasugrel vs. ticagrelor in acute coronary syndromes: which one to choose? Wiener klinische Wochenschrift, 2011, Volume: 123, Issue:15-16 Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Factors; Survival Rate; Thiophenes; Ticagrelor; Ticlopidine	2011
Therapeutic potential of rivaroxaban in the prevention of venous thromboembolism following hip and knee replacement surgery: a review of clinical trial data. Vascular health and risk management, 2011, Volume: 7 Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Clinical Trials as Topic; Evidence-Based Medicine; Fibrinolytic Agents; Hemorrhage; Humans; Morpholines; Risk Assessment; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism	2011
Anticoagulating obese patients in the modern era. British journal of haematology, 2011, Volume: 155, Issue:2 Topics: Acute Coronary Syndrome; Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Double-Blind Method; Factor Xa Inhibitors; Fondaparinux; Hemorrhage; Heparin; Humans; Morpholines; Multicenter Studies as Topic; Obesity; Polysaccharides; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Thrombin; Thrombophilia; Venous Thrombosis; Warfarin	2011
TRITON and beyond: new insights into the profile of prasugrel. Cardiovascular therapeutics, 2012, Volume: 30, Issue:4 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Drug Interactions; Drug Resistance; Evidence-Based Medicine; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Thiophenes; Thrombosis; Time Factors; Treatment Outcome	2012
[New anticoagulants. Characteristics, monitoring and management of bleeding]. Medizinische Klinik, Intensivmedizin und Notfallmedizin, 2011, Volume: 106, Issue:3 Topics: Administration, Oral; Antithrombins; Arthroplasty, Replacement, Hip; Atrial Fibrillation; Benzimidazoles; Blood Coagulation Tests; Critical Care; Dabigatran; Drug Approval; Factor Xa Inhibitors; Fibrinolytic Agents; Hemorrhage; Heparin; Humans; Morpholines; Postoperative Complications; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Thrombophilia; Vitamin K	2011
Antiplatelet options for secondary prevention in acute coronary syndromes. Expert review of cardiovascular therapy, 2011, Volume: 9, Issue:11 Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Risk Factors; Secondary Prevention; Thiophenes; Ticagrelor; Ticlopidine	2011
Safety and efficacy of antiplatelet and antithrombotic therapy in acute coronary syndrome patients with chronic kidney disease. Journal of the American College of Cardiology, 2011, Nov-22, Volume: 58, Issue:22 Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Chronic Disease; Clinical Trials as Topic; Clopidogrel; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Fibrinolytic Agents; Fondaparinux; Hemorrhage; Heparin; Hirudins; Humans; Kidney Diseases; Peptide Fragments; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Polysaccharides; Prasugrel Hydrochloride; Recombinant Proteins; Thiophenes; Ticagrelor; Ticlopidine; Uremia	2011
Antiplatelet therapy in patients with ST-elevation myocardial infarction undergoing myocardial revascularisation: beyond clopidogrel. Current medical research and opinion, 2012, Volume: 28, Issue:2 Topics: Adenosine; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Myocardial Revascularization; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine	2012
Quantitative comparison of clopidogrel 600 mg, prasugrel and ticagrelor, against clopidogrel 300 mg on major adverse cardiovascular events and bleeding in coronary stenting: synthesis of CURRENT-OASIS-7, TRITON-TIMI-38 and PLATO. International journal of cardiology, 2012, Jul-12, Volume: 158, Issue:2 Topics: Adenosine; Animals; Cardiovascular Diseases; Clopidogrel; Hemorrhage; Humans; Piperazines; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine	2012
ARISTOTLE RE-LYs on the ROCKET. What's new in stroke prevention in patients with atrial fibrillation? Cardiology journal, 2012, Volume: 19, Issue:1 Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Evidence-Based Medicine; Hemorrhage; Humans; Morpholines; Patient Selection; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Time Factors; Treatment Outcome; Warfarin	2012
Prasugrel versus clopidogrel antiplatelet therapy after acute coronary syndrome: matching treatments with patients. American journal of cardiovascular drugs : drugs, devices, and other interventions, 2012, Apr-01, Volume: 12, Issue:2 Topics: Acute Coronary Syndrome; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Clopidogrel; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Secondary Prevention; Thiophenes; Ticlopidine	2012
A new generation of oral direct anticoagulants. Arteriosclerosis, thrombosis, and vascular biology, 2012, Volume: 32, Issue:3 Topics: Acute Coronary Syndrome; Administration, Oral; Animals; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Hemorrhage; Humans; Morpholines; Orthopedic Procedures; Pyrazoles; Pyridones; Risk Assessment; Risk Factors; Rivaroxaban; Thiophenes; Thrombosis; Treatment Outcome	2012
The efficacy and safety of pharmacological prophylaxis of venous thromboembolism following elective knee or hip replacement: systematic review and network meta-analysis. Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2012, Volume: 18, Issue:6 Topics: Antithrombins; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Dabigatran; Female; Hemorrhage; Humans; Male; Morpholines; Postoperative Complications; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism	2012
Emerging antiplatelet therapy for coronary artery disease and acute coronary syndrome. Pharmacotherapy, 2012, Volume: 32, Issue:3 Topics: Acute Coronary Syndrome; Adenosine; Animals; Clinical Trials as Topic; Coronary Artery Disease; Hemorrhage; Humans; Imines; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Thiophenes; Thrombosis; Ticagrelor	2012
Acute coronary syndromes: identifying the appropriate patient for prasugrel. Postgraduate medicine, 2012, Volume: 124, Issue:2 Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Patient Selection; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Assessment; Secondary Prevention; Thiophenes; Ticlopidine	2012
Which antiplatelet agent for whom? Which patient populations benefit most from novel antiplatelet agents (ticagrelor, prasugrel)? Current cardiology reports, 2012, Volume: 14, Issue:4 Topics: Acute Coronary Syndrome; Adenosine; Hemorrhage; Humans; Myocardial Ischemia; Patient Selection; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor	2012
Novel oral anticoagulants--key messages for the angiologist. VASA. Zeitschrift fur Gefasskrankheiten, 2012, Volume: 41, Issue:3 Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Drug Monitoring; Evidence-Based Medicine; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Practice Guidelines as Topic; Predictive Value of Tests; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiophenes; Thrombin; Thromboembolism	2012
[New antithrombotic drugs]. Duodecim; laaketieteellinen aikakauskirja, 2012, Volume: 128, Issue:7 Topics: Adenosine; Anticoagulants; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Hemorrhage; Humans; Morpholines; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Ticagrelor; Ticlopidine; Warfarin	2012
Prevention of stroke in patients with atrial fibrillation: anticoagulant and antiplatelet options. Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing, 2012, Volume: 35, Issue:1 Topics: Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Hemorrhage; Humans; Morpholines; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Thrombolytic Therapy; Ticlopidine; Warfarin	2012
[Prophylaxis of stroke and embolisms in atrial fibrillation--what is new in the guidelines?]. MMW Fortschritte der Medizin, 2012, Mar-22, Volume: 154, Issue:5 Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Evidence-Based Medicine; Factor Xa Inhibitors; Guideline Adherence; Hemorrhage; Humans; Intracranial Embolism; Morpholines; Randomized Controlled Trials as Topic; Risk Factors; Rivaroxaban; Stroke; Thiophenes	2012
Network meta-analysis of prasugrel, ticagrelor, high- and standard-dose clopidogrel in patients scheduled for percutaneous coronary interventions. Thrombosis and haemostasis, 2012, Volume: 108, Issue:2 Topics: Acute Coronary Syndrome; Adenosine; Angioplasty; Cardiovascular Diseases; Clopidogrel; Hemorrhage; Humans; Odds Ratio; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Risk; Stents; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2012
New oral anticoagulants: will they replace warfarin? Oral surgery, oral medicine, oral pathology and oral radiology, 2012, Volume: 113, Issue:5 Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Hypersensitivity; Drug Interactions; Factor Xa Inhibitors; Gastritis; Hemorrhage; Humans; Liver; Morpholines; Rivaroxaban; Thiophenes; Thromboembolism	2012
[Clinical management of the new anticoagulants]. Neurologia (Barcelona, Spain), 2012, Volume: 27 Suppl 1 Topics: Administration, Oral; Anticoagulants; Azetidines; Benzimidazoles; Benzylamines; beta-Alanine; Clinical Trials as Topic; Dabigatran; Drug Monitoring; Drugs, Investigational; Hemorrhage; Humans; Morpholines; Multicenter Studies as Topic; Patient Care Planning; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Thrombophilia; Vitamin K	2012
Development and clinical use of prasugrel and ticagrelor. Current pharmaceutical design, 2012, Volume: 18, Issue:33 Topics: Acute Coronary Syndrome; Adenosine; Animals; Aspirin; Blood Platelets; Clopidogrel; Drug Design; Hemorrhage; Hemostasis; Humans; Patient Selection; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2012
Tailoring antiplatelet therapy: a step toward individualized therapy to improve clinical outcome? Current pharmaceutical design, 2012, Volume: 18, Issue:33 Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Blood Platelets; Clopidogrel; Coronary Thrombosis; Drug Interactions; Drug Resistance; Genotype; Hemorrhage; Humans; Patient Selection; Percutaneous Coronary Intervention; Pharmacogenetics; Phenotype; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Precision Medicine; Predictive Value of Tests; Receptors, Purinergic P2Y12; Risk Assessment; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2012
Anticoagulants for the treatment of acute coronary syndrome in the era of new oral agents. Coronary artery disease, 2012, Volume: 23, Issue:6 Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Antithrombins; Aspirin; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Drug Therapy, Combination; Factor Xa Inhibitors; Hemorrhage; Heparin; Humans; Morpholines; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Ticlopidine; Warfarin	2012
An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation. Thrombosis and haemostasis, 2012, Volume: 108, Issue:3 Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Embolism; Factor Xa Inhibitors; Female; Heart Valve Diseases; Hemorrhage; Humans; Ischemic Attack, Transient; Male; Morpholines; Multicenter Studies as Topic; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Secondary Prevention; Severity of Illness Index; Stroke; Thiophenes; Thrombophilia; Vitamin K; Warfarin	2012
Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results. Journal of thrombosis and haemostasis : JTH, 2012, Volume: 10, Issue:10 Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Evidence-Based Medicine; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Patient Safety; Preventive Health Services; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin	2012
Oral anticoagulation in atrial fibrillation: balancing the risk of stroke with the risk of bleed. Canadian family physician Medecin de famille canadien, 2012, Volume: 58, Issue:8 Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Decision Support Techniques; Health Status Indicators; Hemorrhage; Humans; Morpholines; Practice Guidelines as Topic; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Warfarin	2012
Periprocedural antithrombotic and bridging therapy: recommendations for standardized reporting in patients with arterial indications for chronic oral anticoagulant therapy. Journal of thrombosis and haemostasis : JTH, 2012, Volume: 10, Issue:4 Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Elective Surgical Procedures; Factor Xa Inhibitors; Fibrinolytic Agents; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Ischemic Attack, Transient; Medical Records; Morpholines; Perioperative Period; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Thromboembolism	2012
Interpretation of endpoints in a network meta-analysis of new oral anticoagulants following total hip or total knee replacement surgery. Thrombosis and haemostasis, 2012, Volume: 108, Issue:5 Topics: Administration, Oral; Anticoagulants; Antithrombins; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Endpoint Determination; Enoxaparin; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism	2012
What did we learn from new oral anticoagulant treatment? Thrombosis research, 2012, Volume: 130 Suppl 1 Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Drug Interactions; Factor Xa Inhibitors; Half-Life; Hemorrhage; Humans; Metabolic Clearance Rate; Morpholines; Rivaroxaban; Stroke; Thiophenes; Venous Thrombosis	2012
New anti-platelet agents: the end of resistance? Thrombosis research, 2012, Volume: 130 Suppl 1 Topics: Adenosine; Animals; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Drug Design; Drug Resistance; Drug Therapy, Combination; Evidence-Based Medicine; Hemorrhage; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Predictive Value of Tests; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Risk Assessment; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine	2012
Antithrombotic treatment of atrial fibrillation: new insights. Thrombosis research, 2012, Volume: 130 Suppl 1 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Fibrinolytic Agents; Hemorrhage; Humans; Kidney; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Vitamin K	2012
Laboratory tests and the new oral anticoagulants. Thrombosis research, 2012, Volume: 130 Suppl 1 Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Dose-Response Relationship, Drug; Drug Monitoring; Hemorrhage; Humans; Morpholines; Predictive Value of Tests; Pyrazoles; Pyridones; Risk Assessment; Risk Factors; Rivaroxaban; Thiophenes	2012
What's new in antiplatelet and anticoagulant therapy recommendations for unstable angina/non-ST-elevation myocardial infarction: 2012 focused update from the American College of Cardiology Foundation/American Heart Association task force on practice guide Clinical cardiology, 2012, Volume: 35, Issue:11 Topics: Adenosine; Administration, Oral; Angina, Unstable; Anticoagulants; Evidence-Based Medicine; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Assessment; Risk Factors; Thiophenes; Ticagrelor; Treatment Outcome; Warfarin	2012
[Platelet inhibitors in clinical practice]. Therapeutische Umschau. Revue therapeutique, 2012, Volume: 69, Issue:11 Topics: Acute Coronary Syndrome; Adenosine; Biological Availability; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Approval; Drug Interactions; Drug Resistance; Drugs, Investigational; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Factors; Thiophenes; Ticagrelor	2012
[Clinical pharmacological aspects of new oral anticoagulants]. Therapeutische Umschau. Revue therapeutique, 2012, Volume: 69, Issue:11 Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Dabigatran; Dose-Response Relationship, Drug; Drug Interactions; Drug Monitoring; Factor Xa Inhibitors; Hemorrhage; Humans; Metabolic Clearance Rate; Morpholines; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Thiophenes; Thromboembolism; Vitamin K	2012
Potential role of rivaroxaban in patients with acute coronary syndrome. Drug design, development and therapy, 2012, Volume: 6 Topics: Acute Coronary Syndrome; Anticoagulants; Dose-Response Relationship, Drug; Hemorrhage; Humans; Intracranial Hemorrhages; Morpholines; Risk; Rivaroxaban; Thiophenes; Thromboembolism; Thrombosis; Warfarin	2012
Comparing newer oral anti-platelets prasugrel and ticagrelor in reduction of ischemic events-evidence from a network meta-analysis. Journal of thrombosis and thrombolysis, 2013, Volume: 36, Issue:3 Topics: Adenosine; Clopidogrel; Hemorrhage; Humans; Ischemia; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; PubMed; Randomized Controlled Trials as Topic; Stents; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine	2013
Acute management of bleeding in patients on novel oral anticoagulants. European heart journal, 2013, Volume: 34, Issue:7 Topics: Acute Disease; Administration, Oral; Aged; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Dabigatran; Drug Therapy, Combination; Factor Xa Inhibitors; Hemorrhage; Hemostatics; Humans; Morpholines; Plasma; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Renal Dialysis; Renal Insufficiency; Risk Factors; Rivaroxaban; Thiophenes	2013
Perioperative management of patients on chronic antithrombotic therapy. Hematology. American Society of Hematology. Education Program, 2012, Volume: 2012 Topics: Administration, Oral; Aged; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Fibrinolytic Agents; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; International Normalized Ratio; Middle Aged; Morpholines; Perioperative Care; Risk; Rivaroxaban; Thiophenes; Thromboembolism; Thrombosis; Vitamin K	2012
[New anticoagulants--are we prepared?]. Przeglad lekarski, 2012, Volume: 69, Issue:8 Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Prothrombin; Rivaroxaban; Thiophenes; Thromboembolism	2012
Metabolic differences of current thienopyridine antiplatelet agents. Expert opinion on drug metabolism & toxicology, 2013, Volume: 9, Issue:3 Topics: Acute Coronary Syndrome; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Interactions; Fibrinolytic Agents; Hemorrhage; Humans; Inactivation, Metabolic; Pharmacogenetics; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Pyridines; Thiophenes; Ticlopidine	2013
Rivaroxaban: an oral factor Xa inhibitor. Clinical therapeutics, 2013, Volume: 35, Issue:1 Topics: Administration, Oral; Animals; Anticoagulants; Atrial Fibrillation; Blood Coagulation; Factor Xa; Factor Xa Inhibitors; Fibrinolytic Agents; Hemorrhage; Humans; Morpholines; Orthopedic Procedures; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Venous Thromboembolism	2013
Review of recently approved alternatives to anticoagulation with warfarin for emergency clinicians. The Journal of emergency medicine, 2013, Volume: 45, Issue:1 Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Approval; Emergencies; Hemorrhage; Humans; Morpholines; Rivaroxaban; Stroke; Thiophenes; United States; United States Food and Drug Administration; Warfarin	2013
Rivaroxaban for thromboprophylaxis after orthopaedic surgery: pooled analysis of two studies. Thrombosis and haemostasis, 2007, Volume: 97, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Dose-Response Relationship, Drug; Enoxaparin; Female; Fibrinolytic Agents; Hemorrhage; Humans; Incidence; Male; Middle Aged; Morpholines; Phlebography; Pulmonary Embolism; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thrombosis	2007
Beyond unfractionated heparin and warfarin: current and future advances. Circulation, 2007, Jul-31, Volume: 116, Issue:5 Topics: Angina, Unstable; Anticoagulants; Azetidines; Benzimidazoles; Benzylamines; Brain Ischemia; Clinical Trials as Topic; Coumarins; Dabigatran; Factor Xa Inhibitors; Fibrinolytic Agents; Fondaparinux; Forecasting; Hemorrhage; Heparin; Heparin, Low-Molecular-Weight; Hirudins; Humans; Morpholines; Myocardial Infarction; Peptide Fragments; Polysaccharides; Prothrombin; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Rivaroxaban; Thiophenes; Thrombin; Thrombophilia; Thrombosis; Warfarin	2007
Will prasugrel supersede clopidogrel for acute coronary syndromes? The Medical journal of Australia, 2008, Apr-07, Volume: 188, Issue:7 Topics: Acute Coronary Syndrome; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clopidogrel; Coronary Artery Bypass; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Thiophenes; Ticlopidine	2008
Rivaroxaban, an oral direct factor Xa inhibitor. Expert opinion on investigational drugs, 2008, Volume: 17, Issue:6 Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Aged, 80 and over; Animals; Anticoagulants; Atrial Fibrillation; Binding Sites; Clinical Trials as Topic; Comorbidity; Drug Evaluation, Preclinical; Factor Xa; Factor Xa Inhibitors; Fibrinolytic Agents; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Postoperative Complications; Rats; Rivaroxaban; Stroke; Thiophenes; Thrombosis; Warfarin	2008
Prasugrel: a novel antiplatelet agent. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2008, Jun-01, Volume: 65, Issue:11 Topics: Acute Coronary Syndrome; Animals; Clopidogrel; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Thiophenes; Thrombolytic Therapy; Ticlopidine	2008

Trials

73 trial(s) available for thiophenes and Hemorrhage

Article	Year
The Egyptian journal of chest diseases and tuberculosis, 2016, Volume: 65, Issue:1 Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus	2016
Clinical outcomes with rivaroxaban in patients transitioned from vitamin K antagonist therapy: a subgroup analysis of a randomized trial. Annals of internal medicine, 2013, Jun-18, Volume: 158, Issue:12 Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Comparative Effectiveness Research; Embolism; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Morpholines; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Vitamin K; Warfarin	2013
Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel. Circulation, 2013, Aug-20, Volume: 128, Issue:8 Topics: Acute Coronary Syndrome; Age Factors; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Disease Management; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hemorrhage; Humans; Longitudinal Studies; Male; Middle Aged; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Factors; Thiophenes; Ticlopidine; Treatment Outcome	2013
Mixed treatment comparison meta-analysis of aspirin, warfarin, and new anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation. Clinical therapeutics, 2013, Volume: 35, Issue:7 Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Data Interpretation, Statistical; Databases, Bibliographic; Double-Blind Method; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin	2013
Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in Chinese patients with atrial fibrillation. Vascular, 2014, Volume: 22, Issue:4 Topics: Administration, Oral; Aged; Anticoagulants; Asian People; Atrial Fibrillation; China; Double-Blind Method; Embolism; Female; Hemorrhage; Humans; Male; Morpholines; Primary Prevention; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Time Factors; Treatment Outcome; Warfarin	2014
Implementation of contemporary oral antiplatelet treatment guidelines in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a report from the GReek AntiPlatelet rEgistry (GRAPE). International journal of cardiology, 2013, Oct-15, Volume: 168, Issue:6 Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Aged; Clopidogrel; Combined Modality Therapy; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Practolol; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Registries; Thiophenes; Ticagrelor; Ticlopidine	2013
Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. The New England journal of medicine, 2013, Sep-12, Volume: 369, Issue:11 Topics: Acute Coronary Syndrome; Aged; Coronary Angiography; Coronary Artery Bypass; Double-Blind Method; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Prasugrel Hydrochloride; Premedication; Purinergic P2Y Receptor Antagonists; Thiophenes	2013
A non-interventional comparison of rivaroxaban with standard of care for thromboprophylaxis after major orthopaedic surgery in 17,701 patients with propensity score adjustment. Thrombosis and haemostasis, 2014, Volume: 111, Issue:1 Topics: Administration, Oral; Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Cohort Studies; Data Interpretation, Statistical; Enoxaparin; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Odds Ratio; Propensity Score; Risk; Rivaroxaban; Standard of Care; Thiophenes; Time Factors; Treatment Outcome; Venous Thromboembolism	2014
Treatment patterns and outcomes in patients undergoing percutaneous coronary intervention treated with prasugrel or clopidogrel (from the Swedish Coronary Angiography and Angioplasty Registry [SCAAR]). The American journal of cardiology, 2014, Jan-01, Volume: 113, Issue:1 Topics: Acute Coronary Syndrome; Aged; Cause of Death; Clopidogrel; Coronary Angiography; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Hemorrhage; Humans; Incidence; Male; Middle Aged; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Registries; Retrospective Studies; Survival Rate; Sweden; Thiophenes; Ticlopidine; Treatment Outcome	2014
Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation). Journal of the American College of Cardiology, 2014, Mar-11, Volume: 63, Issue:9 Topics: Aged; Anticoagulants; Atrial Fibrillation; Blood Pressure; Embolism; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Patient Safety; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Time Factors; Vitamin K; Warfarin	2014
Efficacy and safety of rivaroxaban versus low-molecular-weight heparin therapy in patients with lower limb fractures. Journal of thrombosis and thrombolysis, 2014, Volume: 38, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Factor Xa Inhibitors; Female; Fractures, Bone; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Incidence; Length of Stay; Lower Extremity; Male; Middle Aged; Morpholines; Postoperative Complications; Retrospective Studies; Rivaroxaban; Thiophenes; Venous Thromboembolism	2014
D-dimer as a predictor of venous thromboembolism in acutely ill, hospitalized patients: a subanalysis of the randomized controlled MAGELLAN trial. Journal of thrombosis and haemostasis : JTH, 2014, Volume: 12, Issue:4 Topics: Acute Disease; Adult; Aged; Anticoagulants; Enoxaparin; Female; Fibrin Fibrinogen Degradation Products; Hemorrhage; Hospitalization; Humans; Male; Middle Aged; Morpholines; Multivariate Analysis; Risk Factors; Rivaroxaban; Thiophenes; Time Factors; Treatment Outcome; Venous Thromboembolism	2014
Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial. European heart journal, 2014, Jul-21, Volume: 35, Issue:28 Topics: Aged; Aged, 80 and over; Anticoagulants; Antifibrinolytic Agents; Atrial Fibrillation; Blood Transfusion; Double-Blind Method; Drug Administration Schedule; Factor Xa Inhibitors; Female; Hemorrhage; Hospitalization; Humans; Male; Morpholines; Plasma; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Vitamin K; Warfarin	2014
Switching from clopidogrel to prasugrel in patients having coronary stent implantation. Journal of thrombosis and thrombolysis, 2014, Volume: 38, Issue:3 Topics: Aged; Aged, 80 and over; Clopidogrel; Coronary Artery Disease; Drug Substitution; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Renal Insufficiency, Chronic; Sex Factors; Stents; Thiophenes; Thrombosis; Ticlopidine	2014
[Case-control study on effect of rivaroxaban on the risk of hidden bleeding after total hip arthroplasty]. Zhongguo gu shang = China journal of orthopaedics and traumatology, 2014, Volume: 27, Issue:1 Topics: Arthroplasty, Replacement, Hip; Case-Control Studies; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Postoperative Complications; Risk; Rivaroxaban; Thiophenes; Time Factors	2014
Relationship between time in therapeutic range and comparative treatment effect of rivaroxaban and warfarin: results from the ROCKET AF trial. Journal of the American Heart Association, 2014, Apr-22, Volume: 3, Issue:2 Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Blood Coagulation; Double-Blind Method; Drug Monitoring; Embolism; Europe; Female; Hemorrhage; Humans; International Normalized Ratio; Male; Middle Aged; Morpholines; North America; Point-of-Care Systems; Predictive Value of Tests; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Time Factors; Treatment Outcome; Warfarin	2014
Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome: the PRASFIT-ACS study. Circulation journal : official journal of the Japanese Circulation Society, 2014, Volume: 78, Issue:7 Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Asian People; Aspirin; Clopidogrel; Drug Therapy, Combination; Follow-Up Studies; Hemorrhage; Humans; Japan; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine; Time Factors	2014
Comparison of three-factor and four-factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers. Journal of thrombosis and haemostasis : JTH, 2014, Volume: 12, Issue:9 Topics: Adolescent; Adult; Anticoagulants; Area Under Curve; Blood Coagulation Factors; Body Mass Index; Drug Administration Schedule; Drug Combinations; Factor IX; Factor VII; Factor X; Female; Healthy Volunteers; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Partial Thromboplastin Time; Prothrombin; Prothrombin Time; Rivaroxaban; Thiophenes; Thrombin; Time Factors; Treatment Outcome; Young Adult	2014
Clinical outcomes for prasugrel versus clopidogrel in patients with unstable angina or non-ST-elevation myocardial infarction: an analysis from the TRITON-TIMI 38 trial. European heart journal. Acute cardiovascular care, 2014, Volume: 3, Issue:4 Topics: Angina, Unstable; Clopidogrel; Double-Blind Method; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Factors; Thiophenes; Ticlopidine; Treatment Outcome	2014
Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry. Blood, 2014, Aug-07, Volume: 124, Issue:6 Topics: Aged; Aged, 80 and over; Anticoagulants; Cohort Studies; Factor Xa Inhibitors; Female; Germany; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Prospective Studies; Registries; Rivaroxaban; Thiophenes; Treatment Outcome; Vitamin K	2014
Major bleeding with dabigatran and rivaroxaban in patients with atrial fibrillation: a real-world setting. Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2014, Volume: 20, Issue:7 Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Databases, Factual; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Medical Records Systems, Computerized; Middle Aged; Morpholines; Rivaroxaban; Thiophenes	2014
Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Circulation, 2014, Jul-08, Volume: 130, Issue:2 Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Vitamin K; Warfarin	2014
Predicting the risk of venous thromboembolism in patients hospitalized with heart failure. Circulation, 2014, Jul-29, Volume: 130, Issue:5 Topics: Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Enoxaparin; Factor Xa Inhibitors; Female; Heart Failure; Hemorrhage; Hospitalization; Humans; Incidence; Male; Middle Aged; Morpholines; Multivariate Analysis; Predictive Value of Tests; Primary Prevention; Risk Factors; Rivaroxaban; Severity of Illness Index; Thiophenes; Venous Thromboembolism	2014
Ticagrelor vs prasugrel one-month maintenance therapy: impact on platelet reactivity and bleeding events. Thrombosis and haemostasis, 2014, Sep-02, Volume: 112, Issue:3 Topics: Acute Coronary Syndrome; Adenosine; Aged; Female; Hemorrhage; Humans; Maintenance Chemotherapy; Male; Middle Aged; Percutaneous Coronary Intervention; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Treatment Outcome	2014
An analysis of TRITON-TIMI 38, based on the 12 month recommended length of therapy in the European label for prasugrel. Current medical research and opinion, 2014, Volume: 30, Issue:11 Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Cohort Studies; Coronary Artery Bypass; Drug Administration Schedule; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Assessment; Stents; Stroke; Thiophenes; Ticlopidine	2014
Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial. European heart journal, 2014, Dec-14, Volume: 35, Issue:47 Topics: Aged; Anticoagulants; Aortic Valve Insufficiency; Atrial Fibrillation; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Mitral Valve Insufficiency; Morpholines; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin	2014
Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. European heart journal, 2014, Dec-14, Volume: 35, Issue:47 Topics: Administration, Oral; Aged; Atrial Fibrillation; Electric Countershock; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Treatment Outcome; Vitamin K	2014
Prasugrel, a third-generation P2Y12 receptor antagonist, in patients with coronary artery disease undergoing elective percutaneous coronary intervention. Circulation journal : official journal of the Japanese Circulation Society, 2014, Volume: 78, Issue:12 Topics: Aged; Brain Ischemia; Clopidogrel; Combined Modality Therapy; Coronary Disease; Cytochrome P-450 CYP2C19; Double-Blind Method; Elective Surgical Procedures; Female; Follow-Up Studies; Gene Frequency; Hemorrhage; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation; Postoperative Complications; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Stents; Thiophenes; Ticlopidine	2014
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. The New England journal of medicine, 2014, Dec-04, Volume: 371, Issue:23 Topics: Aged; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting Stents; Female; Hemorrhage; Humans; Incidence; Male; Middle Aged; Myocardial Ischemia; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Thrombosis; Ticlopidine; Time Factors	2014
Platelet function monitoring in elderly patients on prasugrel after stenting for an acute coronary syndrome: design of the randomized antarctic study. American heart journal, 2014, Volume: 168, Issue:5 Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Drug Monitoring; Hemorrhage; Humans; Myocardial Ischemia; Percutaneous Coronary Intervention; Piperazines; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Stents; Thiophenes; Treatment Outcome	2014
Effect of prasugrel pre-treatment strategy in patients undergoing percutaneous coronary intervention for NSTEMI: the ACCOAST-PCI study. Journal of the American College of Cardiology, 2014, Dec-23, Volume: 64, Issue:24 Topics: Aged; Angiography; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Endpoint Determination; Female; Hemorrhage; Humans; Intraoperative Complications; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Preoperative Care; Risk Assessment; Thiophenes; Treatment Outcome	2014
[Comparison of the safety of rivaroxaban versus dabigatran therapy in patients with persistent atrial fibrillation]. Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 2014, Volume: 37, Issue:221 Topics: Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Female; Gastrointestinal Diseases; Hemorrhage; Humans; Male; Morpholines; Rivaroxaban; Thiophenes; Thromboembolism	2014
Use of prestudy heparin did not influence the efficacy and safety of rivaroxaban in patients treated for symptomatic venous thromboem-bolism in the EINSTEIN DVT and EINSTEIN PE studies. Academic emergency medicine : official journal of the Society for Academic Emergency Medicine, 2015, Volume: 22, Issue:2 Topics: Adult; Aged; Anticoagulants; Enoxaparin; Female; Hemorrhage; Heparin; Humans; Male; Middle Aged; Morpholines; Rivaroxaban; Safety; Thiophenes; Venous Thromboembolism; Vitamin K	2015
Treatment of pulmonary embolism with rivaroxaban: outcomes by simplified Pulmonary Embolism Severity Index score from a post hoc analysis of the EINSTEIN PE study. Academic emergency medicine : official journal of the Society for Academic Emergency Medicine, 2015, Volume: 22, Issue:3 Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Comorbidity; Emergency Service, Hospital; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Predictive Value of Tests; Prognosis; Pulmonary Embolism; Risk; Rivaroxaban; Severity of Illness Index; Thiophenes	2015
Safety profile of prasugrel and clopidogrel in patients with acute coronary syndromes in Switzerland. Heart (British Cardiac Society), 2015, Volume: 101, Issue:11 Topics: Adolescent; Adult; Aged; Cerebrovascular Disorders; Clopidogrel; Drug-Eluting Stents; Female; Guideline Adherence; Hemorrhage; Humans; Length of Stay; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Recurrence; Risk Factors; Thiophenes; Ticlopidine; Treatment Outcome; Young Adult	2015
Dose-finding study of rivaroxaban in hemodialysis patients. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2015, Volume: 66, Issue:1 Topics: Administration, Oral; Area Under Curve; Atrial Fibrillation; Dose-Response Relationship, Drug; Drug Monitoring; Factor Xa Inhibitors; Female; Half-Life; Hemorrhage; Humans; Kidney Failure, Chronic; Male; Morpholines; Renal Dialysis; Rivaroxaban; Thiophenes; Thromboembolism; Thrombophilia	2015
Predictors of bleeding in patients with acute coronary syndromes treated with prasugrel. Heart (British Cardiac Society), 2015, Volume: 101, Issue:15 Topics: Acute Coronary Syndrome; Age Factors; Aged; Chi-Square Distribution; Coronary Artery Bypass; Double-Blind Method; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proportional Hazards Models; Purinergic P2Y Receptor Antagonists; Risk Assessment; Risk Factors; Sex Factors; Thiophenes; Time Factors; Treatment Outcome	2015
[CONKO-011: Evaluation of patient satisfaction with the treatment of acute venous thromboembolism with rivaroxaban or low molecular weight heparin in cancer patients. A randomized phase III study]. Deutsche medizinische Wochenschrift (1946), 2015, Volume: 140 Suppl 1 Topics: Acute Disease; Administration, Oral; Anticoagulants; Factor Xa Inhibitors; Fibrinolytic Agents; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Morpholines; Patient Satisfaction; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism	2015
A Phase IV Study of Thromboembolic and Bleeding Events Following Hip and Knee Arthroplasty Using Oral Factor Xa Inhibitor. The Journal of arthroplasty, 2017, Volume: 32, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Transfusion; Factor Xa Inhibitors; Female; Fibrinolytic Agents; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Prospective Studies; Pulmonary Embolism; Rivaroxaban; Thiophenes; Venous Thromboembolism; Venous Thrombosis; Young Adult	2017
Prasugrel in the poststroke cohort of the TRITON Trial: the clear and present danger. Cerebrovascular diseases (Basel, Switzerland), 2008, Volume: 26, Issue:1 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Double-Blind Method; Hemorrhage; Humans; Ischemic Attack, Transient; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Secondary Prevention; Stents; Stroke; Thiophenes; Ticlopidine; Treatment Outcome	2008
Switching directly to prasugrel from clopidogrel results in greater inhibition of platelet aggregation in aspirin-treated subjects. Platelets, 2008, Volume: 19, Issue:4 Topics: Adenosine Diphosphate; Adult; Aspirin; Clopidogrel; Drug-Related Side Effects and Adverse Reactions; Female; Hemorrhage; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Thiophenes; Ticlopidine	2008
A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study. Blood, 2008, Sep-15, Volume: 112, Issue:6 Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antithrombin III; Dose-Response Relationship, Drug; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Rivaroxaban; Thiophenes; Treatment Outcome; Ultrasonography; Venous Thrombosis	2008
Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial. European heart journal, 2008, Volume: 29, Issue:20 Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Secondary Prevention; Stroke; Thiophenes; Ticlopidine; Treatment Outcome	2008
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet (London, England), 2009, Feb-28, Volume: 373, Issue:9665 Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Method; Endpoint Determination; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine	2009
Interaction of acenocoumarol and sitaxentan in pulmonary arterial hypertension. European journal of clinical investigation, 2009, Volume: 39 Suppl 2 Topics: Acenocoumarol; Adolescent; Adult; Anticoagulants; Antihypertensive Agents; Drug Administration Schedule; Drug Interactions; Endothelin Receptor Antagonists; Female; Hemorrhage; Humans; Hypertension, Pulmonary; International Normalized Ratio; Isoxazoles; Male; Prospective Studies; Survival Analysis; Thiophenes; Young Adult	2009
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet (London, England), 2009, 05-16, Volume: 373, Issue:9676 Topics: Administration, Oral; Aged; Analysis of Variance; Anticoagulants; Arthroplasty, Replacement, Knee; Double-Blind Method; Enoxaparin; Female; Follow-Up Studies; Hemorrhage; Humans; Incidence; Male; Middle Aged; Morpholines; Phlebography; Risk Reduction Behavior; Rivaroxaban; Sensitivity and Specificity; Thiophenes; Treatment Outcome; Venous Thrombosis	2009
Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet (London, England), 2009, Jul-04, Volume: 374, Issue:9683 Topics: Acute Coronary Syndrome; Administration, Oral; Aspirin; Chest Pain; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Morpholines; Myocardial Infarction; Proportional Hazards Models; Pyridines; Recurrence; Risk Reduction Behavior; Rivaroxaban; Safety; Statistics, Nonparametric; Stroke; Thiophenes; Treatment Outcome	2009
Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. American heart journal, 2010, Volume: 159, Issue:3 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Double-Blind Method; Drug Administration Schedule; Embolism; Factor Xa Inhibitors; Fibrinolytic Agents; Follow-Up Studies; Hemorrhage; Humans; Medical Records; Morpholines; Research Design; Risk Factors; Rivaroxaban; Secondary Prevention; Stroke; Thiophenes; Vitamin K; Warfarin	2010
Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: Results of separate pooled analyses of phase III multicenter randomized trials. Circulation. Cardiovascular quality and outcomes, 2010, Volume: 3, Issue:6 Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Dabigatran; Enoxaparin; Follow-Up Studies; Hemorrhage; Humans; Morpholines; Postoperative Complications; Prospective Studies; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism; Withholding Treatment	2010
Oral rivaroxaban for symptomatic venous thromboembolism. The New England journal of medicine, 2010, Dec-23, Volume: 363, Issue:26 Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Injections, Subcutaneous; Intention to Treat Analysis; Kaplan-Meier Estimate; Male; Middle Aged; Morpholines; Pulmonary Embolism; Rivaroxaban; Thiophenes; Venous Thromboembolism; Venous Thrombosis; Vitamin K; Warfarin	2010
Predictors of bleeding and time dependence of association of bleeding with mortality: insights from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel--Thrombolysis in Myocardial Infarction 38 (TRITON- Circulation, 2011, Jun-14, Volume: 123, Issue:23 Topics: Aged; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Predictive Value of Tests; Proportional Hazards Models; Purinergic P2Y Receptor Antagonists; Risk Factors; Thiophenes; Thrombolytic Therapy; Ticlopidine	2011
Relationship between exposure to prasugrel active metabolite and clinical outcomes in the TRITON-TIMI 38 substudy. Journal of clinical pharmacology, 2012, Volume: 52, Issue:6 Topics: Acute Coronary Syndrome; Age Factors; Aged; Biotransformation; Body Weight; Dose-Response Relationship, Drug; Double-Blind Method; Hemorrhage; Humans; Incidence; Male; Models, Biological; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prodrugs; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Severity of Illness Index; Thiophenes; Thrombosis	2012
Oral rivaroxaban after symptomatic venous thromboembolism: the continued treatment study (EINSTEIN-extension study). Expert review of cardiovascular therapy, 2011, Volume: 9, Issue:7 Topics: Administration, Oral; Anticoagulants; Double-Blind Method; Factor Xa Inhibitors; Hemorrhage; Humans; Middle Aged; Morpholines; Risk; Rivaroxaban; Secondary Prevention; Thiophenes; Venous Thromboembolism	2011
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. The New England journal of medicine, 2011, Sep-08, Volume: 365, Issue:10 Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Double-Blind Method; Embolism; Female; Hemorrhage; Humans; Intention to Treat Analysis; Male; Middle Aged; Morpholines; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin	2011
Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. European heart journal, 2011, Volume: 32, Issue:19 Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Double-Blind Method; Embolism; Female; Hemorrhage; Humans; Male; Morpholines; Renal Insufficiency; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin	2011
Residual platelet reactivity, bleedings, and adherence to treatment in patients having coronary stent implantation treated with prasugrel. The American journal of cardiology, 2012, Jan-15, Volume: 109, Issue:2 Topics: Aged; Coronary Artery Disease; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Hemorrhage; Humans; Incidence; Italy; Male; Patient Compliance; Piperazines; Platelet Activation; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Stents; Thiophenes; Treatment Outcome	2012
Rivaroxaban in patients with a recent acute coronary syndrome. The New England journal of medicine, 2012, Jan-05, Volume: 366, Issue:1 Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Incidence; Intracranial Hemorrhages; Kaplan-Meier Estimate; Male; Middle Aged; Morpholines; Rivaroxaban; Secondary Prevention; Thiophenes	2012
Concomitant use of medication with antiplatelet effects in patients receiving either rivaroxaban or enoxaparin after total hip or knee arthroplasty. Thrombosis research, 2012, Volume: 130, Issue:2 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Arthroplasty, Replacement, Knee; Aspirin; Drug Interactions; Enoxaparin; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Platelet Aggregation Inhibitors; Rivaroxaban; Thiophenes; Venous Thromboembolism	2012
[Effect of rivaroxaban on risk of bleeding after total knee arthroplasty]. Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery, 2011, Volume: 25, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Knee; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Rivaroxaban; Thiophenes; Young Adult	2011
Dabigatran, rivaroxaban and apixaban versus enoxaparin for thomboprophylaxis after total knee or hip arthroplasty: pool-analysis of phase III randomized clinical trials. Thrombosis research, 2012, Volume: 130, Issue:2 Topics: Adult; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Dabigatran; Enoxaparin; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism	2012
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. The New England journal of medicine, 2012, 04-05, Volume: 366, Issue:14 Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up Studies; Hemorrhage; Humans; International Normalized Ratio; Kaplan-Meier Estimate; Male; Middle Aged; Morpholines; Pulmonary Embolism; Recurrence; Rivaroxaban; Thiophenes; Treatment Outcome; Vitamin K	2012
Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis. Journal of the American College of Cardiology, 2012, Jul-31, Volume: 60, Issue:5 Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Loss, Surgical; Cause of Death; Chest Tubes; Clopidogrel; Cohort Studies; Combined Modality Therapy; Coronary Artery Bypass; Drug Administration Schedule; Drug Therapy, Combination; Erythrocyte Transfusion; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Recurrence; Retrospective Studies; Risk Adjustment; Thiophenes; Ticlopidine	2012
Plasma proteomics of patients with non-valvular atrial fibrillation on chronic anti-coagulation with warfarin or a direct factor Xa inhibitor. Thrombosis and haemostasis, 2012, Volume: 108, Issue:6 Topics: Aged; Anticoagulants; Atrial Fibrillation; Biomarkers; Blood Proteins; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Morpholines; Proteomics; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Thrombosis; Warfarin	2012
Acute coronary syndrome and rivaroxaban: not so fast... Prescrire international, 2012, Volume: 21, Issue:132 Topics: Acute Coronary Syndrome; Anticoagulants; Double-Blind Method; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Rivaroxaban; Thiophenes	2012
Selecting antiplatelet therapy at the time of percutaneous intervention for an acute coronary syndrome: weighing the benefits and risks of prasugrel versus clopidogrel. Circulation. Cardiovascular quality and outcomes, 2013, Jan-01, Volume: 6, Issue:1 Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Middle Aged; Models, Statistical; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Assessment; Risk Factors; Stroke; Thiophenes; Ticlopidine; Treatment Outcome	2013
Rivaroxaban for thromboprophylaxis in acutely ill medical patients. The New England journal of medicine, 2013, Feb-07, Volume: 368, Issue:6 Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Injections, Subcutaneous; Male; Middle Aged; Morpholines; Rivaroxaban; Thiophenes; Venous Thromboembolism	2013
Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. Circulation, 2005, Jun-28, Volume: 111, Issue:25 Topics: Adolescent; Adult; Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind Method; Female; Hemorrhage; Humans; Incidence; Male; Membrane Proteins; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Pyridines; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine	2005
BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study. Journal of thrombosis and haemostasis : JTH, 2005, Volume: 3, Issue:11 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Antithrombin III; Arthroplasty, Replacement, Knee; Double-Blind Method; Enoxaparin; Hemorrhage; Humans; Incidence; Injections, Subcutaneous; Male; Middle Aged; Morpholines; Rivaroxaban; Thiophenes; Thromboembolism; Venous Thrombosis	2005
Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement. Journal of thrombosis and haemostasis : JTH, 2006, Volume: 4, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Dose-Response Relationship, Drug; Double-Blind Method; Enoxaparin; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Postoperative Complications; Pulmonary Embolism; Rivaroxaban; Thiophenes; Thromboembolism; Venous Thrombosis	2006
A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement. Circulation, 2006, Nov-28, Volume: 114, Issue:22 Topics: Administration, Oral; Adult; Anticoagulants; Arthroplasty, Replacement, Hip; Double-Blind Method; Drug Administration Schedule; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Postmenopause; Postoperative Complications; Rivaroxaban; Safety; Sample Size; Survival Analysis; Thiophenes	2006
Prasugrel versus clopidogrel in patients with acute coronary syndromes. The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20 Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prodrugs; Purinergic P2 Receptor Antagonists; Stroke; Thiophenes; Thrombosis; Ticlopidine	2007
Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolys Journal of the American College of Cardiology, 2008, May-27, Volume: 51, Issue:21 Topics: Acute Coronary Syndrome; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality Therapy; Drug Therapy, Combination; Hemorrhage; Humans; Kaplan-Meier Estimate; Myocardial Infarction; Myocardial Ischemia; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proportional Hazards Models; Purinergic P2 Receptor Antagonists; Stents; Thiophenes; Ticlopidine	2008
The effect of Ticlopidine upon platelet function, haemorrhage and post-operative thrombosis in patients undergoing suprapubic prostatectomy. The Journal of international medical research, 1981, Volume: 9, Issue:3 Topics: Bleeding Time; Hemorrhage; Humans; Male; Platelet Function Tests; Postoperative Complications; Prostatectomy; Pyridines; Random Allocation; Thiophenes; Thrombophlebitis; Ticlopidine	1981

Other Studies

180 other study(ies) available for thiophenes and Hemorrhage

Article	Year
A Pharmacodynamic Study of CN-218, a Novel Antiplatelet and Antithrombotic Agent Primarily Targeting the P2Y Cardiovascular drugs and therapy, 2020, Volume: 34, Issue:1 Topics: Animals; Blood Coagulation; Blood Platelets; Carrageenan; Clopidogrel; Cyclic AMP; Disease Models, Animal; Fibrinolytic Agents; Hemorrhage; Male; Mice; Piperidines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Rats, Wistar; Receptors, Purinergic P2Y12; Thiophenes; Thrombosis	2020
Peptidomimetic hydroxamate metalloproteinase inhibitors abrogate local and systemic toxicity induced by Echis ocellatus (saw-scaled) snake venom. Toxicon : official journal of the International Society on Toxinology, 2017, Jun-15, Volume: 132 Topics: Animals; Cameroon; Dose-Response Relationship, Drug; Ghana; Hemorrhage; Hydroxamic Acids; Lung; Metalloproteases; Mice; Peptidomimetics; Phenylalanine; Snake Bites; Thiophenes; Viper Venoms; Viperidae	2017
Elective hip and knee arthroplasty and the effect of rivaroxaban and enoxaparin thromboprophylaxis on wound healing. European journal of orthopaedic surgery & traumatology : orthopedie traumatologie, 2013, Volume: 23, Issue:4 Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Chemoprevention; Elective Surgical Procedures; Enoxaparin; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Osteoarthritis, Hip; Osteoarthritis, Knee; Outcome and Process Assessment, Health Care; Postoperative Complications; Rivaroxaban; Thiophenes; United Kingdom; Venous Thromboembolism; Wound Healing	2013
Switching acute coronary syndrome patients from prasugrel to clopidogrel. JACC. Cardiovascular interventions, 2013, Volume: 6, Issue:2 Topics: Acute Coronary Syndrome; Aged; Biomarkers; Blood Platelets; Cell Adhesion Molecules; Chi-Square Distribution; Clopidogrel; Drug Resistance; Drug Substitution; Female; Hemorrhage; Humans; Male; Microfilament Proteins; Middle Aged; Phosphoproteins; Phosphorylation; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Registries; Risk Assessment; Risk Factors; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome	2013
A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nature medicine, 2013, Volume: 19, Issue:4 Topics: Animals; Anticoagulants; Antidotes; Benzamides; Dose-Response Relationship, Drug; Enoxaparin; Factor Xa; Factor Xa Inhibitors; Fondaparinux; Hemorrhage; Hemostasis; Male; Mice; Mice, Inbred C57BL; Morpholines; Polysaccharides; Pyrazoles; Pyridines; Pyridones; Rabbits; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Rivaroxaban; Thiophenes	2013
Recent advances in antithrombotic therapy for stroke prevention in patients with atrial fibrillation. Hospital practice (1995), 2013, Volume: 41, Issue:1 Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Comorbidity; Dabigatran; Hemorrhage; Humans; Morpholines; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Warfarin	2013
Venous thromboembolism: prophylactic and therapeutic practice guideline. South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 2013, Feb-15, Volume: 103, Issue:4 Pt 2 Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Chemoprevention; Dabigatran; Disease Management; Dose-Response Relationship, Drug; Drug Delivery Systems; Drug Monitoring; Drug Substitution; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; International Normalized Ratio; Morpholines; Preoperative Care; Risk Assessment; Risk Factors; Rivaroxaban; Secondary Prevention; Thiophenes; Time Factors; Vena Cava Filters; Venous Thromboembolism	2013
The discovery and development of prasugrel. Expert opinion on drug discovery, 2013, Volume: 8, Issue:7 Topics: Animals; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Interactions; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Risk Factors; Thiophenes	2013
Comparative effectiveness of dabigatran, rivaroxaban, apixaban, and warfarin in the management of patients with nonvalvular atrial fibrillation. Clinical pharmacology and therapeutics, 2013, Volume: 94, Issue:2 Topics: Age Factors; Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cardiovascular Diseases; Comorbidity; Computer Simulation; Dabigatran; Female; Hemorrhage; Humans; Male; Morpholines; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Time Factors; Warfarin	2013
New approaches to reversing oral anticoagulant therapy. Introduction. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2013, May-15, Volume: 70, Issue:10 Suppl 1 Topics: Administration, Oral; Anticoagulants; Antifibrinolytic Agents; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Morpholines; Plasma; Primary Prevention; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thromboembolism; Treatment Outcome; Vitamin K 1	2013
Pharmacologic interventions for reversing the effects of oral anticoagulants. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2013, May-15, Volume: 70, Issue:10 Suppl 1 Topics: Administration, Oral; Anticoagulants; Antifibrinolytic Agents; Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Blood Loss, Surgical; Dabigatran; Drug Therapy, Combination; Emergencies; Hemorrhage; Humans; International Normalized Ratio; Morpholines; Plasma; Pyrazoles; Pyridones; Rivaroxaban; Surgical Procedures, Operative; Thiophenes; Thromboembolism; Treatment Outcome; Vitamin K 1; Warfarin	2013
Factors affecting residual platelet aggregation in prasugrel treated patients. Current pharmaceutical design, 2013, Volume: 19, Issue:28 Topics: Acute Coronary Syndrome; Aged; Blood Platelets; Cohort Studies; Drug Resistance; Female; Heart Diseases; Hemorrhage; Humans; Maintenance Chemotherapy; Male; Middle Aged; Models, Biological; Myocardial Ischemia; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Postoperative Complications; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Smoking; Thiophenes	2013
Rivaroxaban for thromboprophylaxis in acutely ill medical patients. The New England journal of medicine, 2013, 05-16, Volume: 368, Issue:20 Topics: Anticoagulants; Enoxaparin; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Morpholines; Thiophenes; Venous Thromboembolism	2013
Rivaroxaban for thromboprophylaxis in acutely ill medical patients. The New England journal of medicine, 2013, 05-16, Volume: 368, Issue:20 Topics: Anticoagulants; Enoxaparin; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Morpholines; Thiophenes; Venous Thromboembolism	2013
Rivaroxaban for thromboprophylaxis in acutely ill medical patients. The New England journal of medicine, 2013, 05-16, Volume: 368, Issue:20 Topics: Anticoagulants; Enoxaparin; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Morpholines; Thiophenes; Venous Thromboembolism	2013
Rivaroxaban for thromboprophylaxis in acutely ill medical patients. The New England journal of medicine, 2013, 05-16, Volume: 368, Issue:20 Topics: Anticoagulants; Enoxaparin; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Morpholines; Thiophenes; Venous Thromboembolism	2013
ED administration of thienopyridines in non-ST-segment elevation myocardial infarction: results from the NCDR. The American journal of emergency medicine, 2013, Volume: 31, Issue:7 Topics: Aged; Clopidogrel; Drug Administration Schedule; Emergency Service, Hospital; Female; Hemorrhage; Hospital Mortality; Humans; Logistic Models; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Registries; Retrospective Studies; Thiophenes; Ticlopidine; Treatment Outcome	2013
Predictors of bleeding in acute coronary syndromes with clopidogrel and prasugrel. The American journal of emergency medicine, 2013, Volume: 31, Issue:8 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Follow-Up Studies; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Factors; Thiophenes; Ticlopidine	2013
Summaries for patients. Rivaroxaban in patients transitioned from vitamin K antagonist therapy. Annals of internal medicine, 2013, Jun-18, Volume: 158, Issue:12 Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Embolism; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Vitamin K; Warfarin	2013
Contra: "New oral anticoagulants should not be used as 1st choice for secondary stroke prevention in atrial fibrillation". Thrombosis and haemostasis, 2013, Volume: 110, Issue:3 Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Middle Aged; Morpholines; Patient Safety; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Secondary Prevention; Stroke; Thiophenes; Warfarin	2013
Pro: "The novel oral anticoagulants should be used as 1st choice for secondary prevention in patients with atrial fibrillation.". Thrombosis and haemostasis, 2013, Volume: 110, Issue:3 Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Diabetes Complications; Female; Hemorrhage; Humans; Hypertension; Male; Middle Aged; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Secondary Prevention; Stroke; Thiophenes; Warfarin	2013
Successful treatment of acute portal vein thrombosis with rivaroxaban. Thrombosis and haemostasis, 2013, Volume: 110, Issue:4 Topics: Acute Disease; Anticoagulants; Disease-Free Survival; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Neovascularization, Physiologic; Portal Vein; Recovery of Function; Regional Blood Flow; Rivaroxaban; Thiophenes; Ultrasonography, Doppler, Duplex; Venous Thrombosis	2013
Management of bleeding associated with dabigatran and rivaroxaban: a survey of current practices. Thrombosis research, 2013, Volume: 132, Issue:2 Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Data Collection; Female; Hemorrhage; Humans; Male; Morpholines; Practice Patterns, Physicians'; Rivaroxaban; Thiophenes	2013
The promise of pharmacoepidemiology in helping clinicians assess drug risk. Circulation, 2013, Aug-13, Volume: 128, Issue:7 Topics: Administration, Oral; Advertising; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Confounding Factors, Epidemiologic; Dabigatran; Decision Making; Evidence-Based Medicine; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Pharmacoepidemiology; Product Surveillance, Postmarketing; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Research Design; Risk Assessment; Rivaroxaban; Therapeutic Equivalency; Thiophenes; United States; United States Food and Drug Administration; Warfarin	2013
Clinical implications of very low on-treatment platelet reactivity in patients treated with thienopyridine: the POBA study (predictor of bleedings with antiplatelet drugs). JACC. Cardiovascular interventions, 2013, Volume: 6, Issue:8 Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Area Under Curve; Biomarkers; Cell Adhesion Molecules; Clopidogrel; Coronary Thrombosis; Drug Resistance; Female; Hemorrhage; Humans; Logistic Models; Male; Microfilament Proteins; Middle Aged; Multivariate Analysis; Odds Ratio; Percutaneous Coronary Intervention; Phosphoproteins; Phosphorylation; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Risk Assessment; Risk Factors; ROC Curve; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome	2013
Bleeding and thrombosis risk matters: how long can we stick to the one-size-fits-all strategy of platelet inhibition? JACC. Cardiovascular interventions, 2013, Volume: 6, Issue:8 Topics: Acute Coronary Syndrome; Clopidogrel; Female; Hemorrhage; Humans; Male; Percutaneous Coronary Intervention; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine	2013
The gap between trial data and clinical practice -- an analysis of case reports on bleeding complications occurring under dabigatran and rivaroxaban anticoagulation. Cerebrovascular diseases (Basel, Switzerland), 2013, Volume: 36, Issue:2 Topics: Aged; Aged, 80 and over; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin	2013
Review: rivaroxaban causes less fatal bleeding, but does not reduce mortality, compared with VKAs. Annals of internal medicine, 2013, Sep-17, Volume: 159, Issue:6 Topics: Hemorrhage; Humans; Morpholines; Thiophenes	2013
Influences of hemodilution and anticoagulation on antiplatelet P2Y12 therapy: in vitro whole blood perfusion model. Journal of cardiothoracic and vascular anesthesia, 2013, Volume: 27, Issue:6 Topics: Adult; Anticoagulants; Fibrinolytic Agents; Hemodilution; Hemorrhage; Humans; Perfusion; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes	2013
Comparison of bivalirudin versus heparin(s) during percutaneous coronary interventions in patients receiving prasugrel: a propensity-matched study. Clinical cardiology, 2014, Volume: 37, Issue:1 Topics: Aged; Anticoagulants; Blood Transfusion; Chi-Square Distribution; Drug Therapy, Combination; Female; Hemorrhage; Heparin; Hirudins; Hospital Mortality; Humans; Length of Stay; Male; Middle Aged; Odds Ratio; Peptide Fragments; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Propensity Score; Recombinant Proteins; Retrospective Studies; Risk Factors; Thiophenes; Time Factors; Treatment Outcome; United States	2014
Safe-dose thrombolysis plus rivaroxaban for moderate and severe pulmonary embolism: drip, drug, and discharge. Clinical cardiology, 2014, Volume: 37, Issue:2 Topics: Administration, Oral; Aged; Drug Administration Schedule; Drug Therapy, Combination; Female; Fibrinolytic Agents; Hemorrhage; Heparin; Humans; Infusions, Intravenous; Length of Stay; Male; Middle Aged; Morpholines; Patient Discharge; Pulmonary Embolism; Recurrence; Risk Factors; Rivaroxaban; Severity of Illness Index; Thiophenes; Thrombolytic Therapy; Time Factors; Treatment Outcome	2014
Anticoagulation without monitoring. American journal of clinical pathology, 2013, Volume: 140, Issue:5 Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Monitoring; Hemorrhage; Heparin; Humans; Morpholines; Pharmacovigilance; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thrombosis; Warfarin	2013
Renal risk stratification with the new oral anticoagulants (July 2013). Cleveland Clinic journal of medicine, 2013, Volume: 80, Issue:11 Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Thiophenes	2013
In reply. Cleveland Clinic journal of medicine, 2013, Volume: 80, Issue:11 Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Thiophenes	2013
[Experience with rivaroxaban and dabigatran]. Hamostaseologie, 2013, Volume: 33 Suppl 1 Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Drug Therapy, Combination; Female; Hemorrhage; Humans; Morpholines; Protein C Deficiency; Rivaroxaban; Thiophenes; Treatment Outcome; Young Adult	2013
Thrombin generation using the calibrated automated thrombinoscope to assess reversibility of dabigatran and rivaroxaban. Thrombosis and haemostasis, 2014, May-05, Volume: 111, Issue:5 Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Atrial Fibrillation; Automation, Laboratory; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Dabigatran; Equipment and Supplies; Factor VII; Hemorrhage; Humans; Morpholines; Postoperative Complications; Rivaroxaban; Stroke; Thiophenes; Thrombelastography; Thrombin; Thrombin Time; Venous Thrombosis; Withholding Treatment	2014
Consensus recommendations for preventing and managing bleeding complications associated with novel oral anticoagulants in singapore. Annals of the Academy of Medicine, Singapore, 2013, Volume: 42, Issue:11 Topics: Administration, Oral; Anticoagulants; Benzimidazoles; Consensus; Dabigatran; Hemorrhage; Humans; Singapore; Thiophenes	2013
How I treat target-specific oral anticoagulant-associated bleeding. Blood, 2014, Feb-20, Volume: 123, Issue:8 Topics: Administration, Oral; Anticoagulants; Antifibrinolytic Agents; Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Dabigatran; Drug Monitoring; Factor VIIa; Hemorrhage; Hemostatics; Humans; Morpholines; Pyrazoles; Pyridones; Recombinant Proteins; Renal Dialysis; Rivaroxaban; Thiophenes	2014
P2Y12-based platelet function assays should be complemented with cyclooxygenase-dependent testing in framing the therapeutic windows for dual antiplatelet therapy. JACC. Cardiovascular interventions, 2014, Volume: 7, Issue:1 Topics: Acute Coronary Syndrome; Female; Hemorrhage; Humans; Male; Percutaneous Coronary Intervention; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Thiophenes; Ticlopidine	2014
Reply: P2Y12-Based platelet function assays should be complemented with cyclooxygenase-dependent testing in framing the therapeutic windows for dual antiplatelet therapy. JACC. Cardiovascular interventions, 2014, Volume: 7, Issue:1 Topics: Acute Coronary Syndrome; Female; Hemorrhage; Humans; Male; Percutaneous Coronary Intervention; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Thiophenes; Ticlopidine	2014
Acute dysphagia after myocardial infarction: an unusual complication of anticoagulation therapy. Kardiologia polska, 2014, Volume: 72, Issue:1 Topics: Anticoagulants; Aspirin; Cysts; Deglutition Disorders; Electrocardiography; Fibrinolytic Agents; Hematoma; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Prasugrel Hydrochloride; Premedication; Stents; Tenecteplase; Thiophenes; Thyroid Diseases; Thyroidectomy; Tissue Plasminogen Activator	2014
Optimizing P2Y12 receptor inhibition in patients with acute coronary syndrome on the basis of platelet function testing: impact of prasugrel and high-dose clopidogrel. Journal of the American College of Cardiology, 2014, Mar-25, Volume: 63, Issue:11 Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Cause of Death; Clopidogrel; Combined Modality Therapy; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Function Tests; Prasugrel Hydrochloride; Predictive Value of Tests; Proportional Hazards Models; Prospective Studies; Purinergic P2Y Receptor Antagonists; Registries; Risk Assessment; Severity of Illness Index; Stents; Stroke; Survival Rate; Thiophenes; Thrombosis; Ticlopidine; Treatment Outcome	2014
Treatment with novel oral anticoagulants in a real-world cohort of patients undergoing cardiac rhythm device implantations. Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2014, Volume: 16, Issue:7 Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cardiac Pacing, Artificial; Dabigatran; Defibrillators, Implantable; Electric Countershock; Female; Germany; Hematoma; Hemorrhage; Humans; Incidence; Male; Middle Aged; Morpholines; Pacemaker, Artificial; Prospective Studies; Prosthesis Design; Prosthesis Implantation; Risk Factors; Rivaroxaban; Thiophenes; Thromboembolism; Time Factors; Treatment Outcome	2014
Near-real-time monitoring of new drugs: an application comparing prasugrel versus clopidogrel. Drug safety, 2014, Volume: 37, Issue:3 Topics: Aged; Clopidogrel; Cohort Studies; Databases, Factual; Electronic Health Records; Female; Hemorrhage; Humans; Ischemia; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Product Surveillance, Postmarketing; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine	2014
Rivaroxaban and dabigatran in patients undergoing catheter ablation of atrial fibrillation. Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2014, Volume: 16, Issue:8 Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Drug Prescriptions; Drug Utilization Review; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Portugal; Practice Patterns, Physicians'; Prospective Studies; Risk Assessment; Risk Factors; Rivaroxaban; Thiophenes; Thromboembolism; Time Factors; Treatment Outcome	2014
Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis. Thrombosis and haemostasis, 2014, May-05, Volume: 111, Issue:5 Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Myocardial Infarction; Precision Medicine; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Survival Analysis; Thiazoles; Thiophenes; Treatment Outcome	2014
Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients. Current medical research and opinion, 2014, Volume: 30, Issue:7 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Comparative Effectiveness Research; Embolism; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Propensity Score; Proportional Hazards Models; Retrospective Studies; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin; Young Adult	2014
Benefit-risk assessment of rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee arthroplasty. Vascular health and risk management, 2014, Volume: 10 Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Enoxaparin; Hemorrhage; Humans; Morpholines; Patient Selection; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Rivaroxaban; Thiophenes; Time Factors; Treatment Outcome; Venous Thromboembolism	2014
Point of care platelet activity measurement in primary PCI [PINPOINT-PPCI]: a protocol paper. BMC cardiovascular disorders, 2014, Apr-04, Volume: 14 Topics: Blood Platelets; Clinical Protocols; Coronary Thrombosis; Drug Monitoring; Drug Therapy, Combination; England; Hemorrhage; Hirudins; Humans; Myocardial Infarction; Peptide Fragments; Percutaneous Coronary Intervention; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Point-of-Care Systems; Prasugrel Hydrochloride; Predictive Value of Tests; Prospective Studies; Recombinant Proteins; Research Design; Thiophenes; Time Factors; Treatment Outcome	2014
A comparative cohort study on personalised antiplatelet therapy in PCI-treated patients with high on-clopidogrel platelet reactivity. Results of the ISAR-HPR registry. Thrombosis and haemostasis, 2014, Volume: 112, Issue:2 Topics: Aged; Aged, 80 and over; Blood Platelets; Case-Control Studies; Clopidogrel; Coronary Thrombosis; Drug Resistance; Drug Substitution; Female; Germany; Hemorrhage; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Precision Medicine; Predictive Value of Tests; Proportional Hazards Models; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Registries; Risk Factors; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome	2014
Cost-effectiveness of genotype-guided and dual antiplatelet therapies in acute coronary syndrome. Annals of internal medicine, 2014, Feb-18, Volume: 160, Issue:4 Topics: Acute Coronary Syndrome; Adenosine; Alleles; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Coronary Thrombosis; Cost-Benefit Analysis; Cytochrome P-450 CYP2C19; Decision Support Techniques; Direct Service Costs; Drug Therapy, Combination; Drugs, Generic; Genotype; Hemorrhage; Humans; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prasugrel Hydrochloride; Quality-Adjusted Life Years; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine	2014
Early clopidogrel versus prasugrel use among contemporary STEMI and NSTEMI patients in the US: insights from the National Cardiovascular Data Registry. Journal of the American Heart Association, 2014, Apr-14, Volume: 3, Issue:2 Topics: Aged; Clopidogrel; Drug Administration Schedule; Drug Utilization Review; Female; Guideline Adherence; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Practice Patterns, Physicians'; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Registries; Retrospective Studies; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome; United States	2014
Bleeding risk of patients with acute venous thromboembolism taking nonsteroidal anti-inflammatory drugs or aspirin. JAMA internal medicine, 2014, Volume: 174, Issue:6 Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Drug Therapy, Combination; Enoxaparin; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Prospective Studies; Randomized Controlled Trials as Topic; Risk Assessment; Rivaroxaban; Thiophenes; Venous Thromboembolism	2014
Perioperative management of patients on new oral anticoagulants. The British journal of surgery, 2014, Volume: 101, Issue:7 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Biological Availability; Clinical Trials as Topic; Dabigatran; Drug Monitoring; Elective Surgical Procedures; Emergencies; Half-Life; Hemorrhage; Humans; Medication Adherence; Morpholines; Preoperative Care; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Time Factors; Warfarin	2014
Severe bleeding after jugular central venous line insertion in a patient under rivaroxaban. Anaesthesia and intensive care, 2014, Volume: 42, Issue:3 Topics: Aged; Aged, 80 and over; Anticoagulants; Catheterization, Central Venous; Female; Hemorrhage; Humans; Jugular Veins; Morpholines; Rivaroxaban; Thiophenes	2014
Life-threatening haemorrhagic pericarditis associated with rivaroxaban. International journal of cardiology, 2014, Jun-15, Volume: 174, Issue:2 Topics: Aged; Factor Xa Inhibitors; Hemorrhage; Humans; Male; Morpholines; Pericarditis; Rivaroxaban; Thiophenes	2014
Pulmonary haemorrhage from therapeutic rivaroxaban use: chest radiograph consolidation is not always infection! Emergency medicine Australasia : EMA, 2014, Volume: 26, Issue:3 Topics: Aged; Diagnosis, Differential; Factor Xa Inhibitors; Hemorrhage; Humans; Lung Diseases; Male; Morpholines; Pneumonia; Radiography; Rivaroxaban; Thiophenes	2014
Direct oral anticoagulants--pharmacology, drug interactions, and side effects. Seminars in hematology, 2014, Volume: 51, Issue:2 Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Drug Monitoring; Half-Life; Hemorrhage; Humans; Kidney; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Thromboembolism	2014
Direct oral anticoagulants in atrial fibrillation. Seminars in hematology, 2014, Volume: 51, Issue:2 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Embolism; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Warfarin	2014
New oral anticoagulants: a practical guide on prescription, laboratory testing and peri-procedural/bleeding management. Australasian Society of Thrombosis and Haemostasis. Internal medicine journal, 2014, Volume: 44, Issue:6 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Blood Loss, Surgical; Contraindications; Dabigatran; Drug Interactions; Drug Monitoring; Drug Substitution; Elective Surgical Procedures; Emergencies; Hematoma, Epidural, Spinal; Hemorrhage; Humans; Kidney Diseases; Liver Diseases; Morpholines; Patient Selection; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Thrombophilia	2014
Safety of continuous periprocedural rivaroxaban for patients undergoing left atrial catheter ablation procedures. Circulation. Arrhythmia and electrophysiology, 2014, Volume: 7, Issue:4 Topics: Aged; Anticoagulants; Atrial Fibrillation; Catheter Ablation; Chi-Square Distribution; Drug Administration Schedule; Female; Germany; Heart Atria; Hemorrhage; Humans; Logistic Models; Male; Middle Aged; Morpholines; Multivariate Analysis; Odds Ratio; Phenprocoumon; Registries; Retrospective Studies; Risk Factors; Rivaroxaban; Sex Factors; Thiophenes; Thromboembolism; Time Factors; Treatment Outcome	2014
Appropriateness of prescribing dabigatran etexilate and rivaroxaban in patients with nonvalvular atrial fibrillation: a prospective study. The Annals of pharmacotherapy, 2014, Volume: 48, Issue:10 Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Female; Hemorrhage; Humans; Inappropriate Prescribing; Male; Middle Aged; Morpholines; Prospective Studies; Pyridines; Rivaroxaban; Thiophenes	2014
Increased levels of rivaroxaban in patients after liver transplantation treated with cyclosporine A. Transplantation, 2014, Jul-27, Volume: 98, Issue:2 Topics: Aged; Anticoagulants; Cyclosporine; Drug Interactions; Drug Monitoring; Female; Hemorrhage; Humans; Immunosuppressive Agents; Liver Transplantation; Male; Middle Aged; Morpholines; Retrospective Studies; Risk Factors; Rivaroxaban; Tacrolimus; Thiophenes	2014
Real-world observations with prasugrel compared to clopidogrel in acute coronary syndrome patients treated with percutaneous coronary intervention in the United States. Current medical research and opinion, 2014, Volume: 30, Issue:11 Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Female; Hemorrhage; Hospitalization; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Stents; Stroke; Thiophenes; Ticlopidine; Treatment Outcome; United States	2014
[Treatment of acute deep vein thrombosis with new oral anticoagulant rivaroxaban: the first experience]. Khirurgiia, 2014, Issue:6 Topics: Acute Disease; Adult; Aged; Anticoagulants; Blood Coagulation; Dose-Response Relationship, Drug; Drug Monitoring; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Moscow; Prospective Studies; Rivaroxaban; Secondary Prevention; Thiophenes; Time Factors; Treatment Outcome; Venous Thrombosis	2014
Will this trial change my practice? ACCOAST - early loading with a novel P2Y12 inhibitor in patients with an acute coronary syndrome. EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2014, Volume: 10, Issue:3 Topics: Acute Coronary Syndrome; Drug Administration Schedule; Evidence-Based Medicine; Hemorrhage; Humans; Multicenter Studies as Topic; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Practice Patterns, Physicians'; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Receptors, Purinergic P2Y12; Risk Factors; Thiophenes; Time Factors; Treatment Outcome	2014
Massive human rivaroxaban overdose. Thrombosis and haemostasis, 2014, Volume: 112, Issue:4 Topics: Administration, Oral; Chromatography, High Pressure Liquid; Drug Overdose; Factor Xa; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Rivaroxaban; Suicide, Attempted; Tandem Mass Spectrometry; Thiophenes; Treatment Outcome; Venous Thromboembolism; Venous Thrombosis	2014
Rivaroxaban vs. low molecular weight heparin for the prevention of venous thromboembolism after hip or knee arthroplasty: a cohort study. Journal of thrombosis and haemostasis : JTH, 2014, Volume: 12, Issue:10 Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty; Arthroplasty, Replacement, Knee; Factor Xa Inhibitors; Female; Hemorrhage; Heparin, Low-Molecular-Weight; Hip; Humans; Male; Molecular Weight; Morpholines; Ontario; Retrospective Studies; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism	2014
Evaluation of medical costs associated with use of new oral anticoagulants compared with standard therapy among venous thromboembolism patients. Journal of medical economics, 2014, Volume: 17, Issue:11 Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Fees, Pharmaceutical; Health Expenditures; Hemorrhage; Humans; Models, Econometric; Monte Carlo Method; Morpholines; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiazoles; Thiophenes; Venous Thromboembolism	2014
Characteristics of intracerebral hemorrhage during rivaroxaban treatment: comparison with those during warfarin. Stroke, 2014, Volume: 45, Issue:9 Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cerebral Hemorrhage; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Retrospective Studies; Risk; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin	2014
Optimizing human apyrase to treat arterial thrombosis and limit reperfusion injury without increasing bleeding risk. Science translational medicine, 2014, Aug-06, Volume: 6, Issue:248 Topics: Adenosine Diphosphate; Animals; Apyrase; Clopidogrel; Coronary Circulation; Dogs; Fibrinolysis; Hemorrhage; Humans; Mice, Inbred C57BL; Myocardial Infarction; Myocardial Reperfusion Injury; Piperazines; Platelet Aggregation; Prasugrel Hydrochloride; Risk Factors; Thiophenes; Thrombosis; Ticlopidine; Time Factors; Tissue Plasminogen Activator; Treatment Outcome; Vascular Patency	2014
Gaining experience with the NOACs. Blood, 2014, Aug-07, Volume: 124, Issue:6 Topics: Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Morpholines; Rivaroxaban; Thiophenes	2014
Evaluation of Trends of Inpatient Hospitalisation for Significant Haemorrhage in Patients Anticoagulated for Atrial Fibrillation before and after the Release of Novel Anticoagulants. Heart, lung & circulation, 2015, Volume: 24, Issue:1 Topics: Age Factors; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort Studies; Dabigatran; Female; Hemorrhage; Hospitalization; Humans; Male; Morpholines; Rivaroxaban; Thiophenes; Vitamin K	2015
Estimated medical cost reductions associated with use of novel oral anticoagulants vs warfarin in a real-world non-valvular atrial fibrillation patient population. Journal of medical economics, 2014, Volume: 17, Issue:11 Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Health Expenditures; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Warfarin	2014
[New oral anticoagulants are as safe in elderly patients as conventional drugs]. Praxis, 2014, Aug-20, Volume: 103, Issue:17 Topics: Administration, Oral; Age Factors; Aged; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Treatment Outcome	2014
[Cost-effectiveness of apixaban compared to other new oral anticoagulants in patients with non-valvular atrial fibrillation]. Kardiologiia, 2014, Volume: 54, Issue:7 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation; Cost-Benefit Analysis; Dabigatran; Drug Monitoring; Hemorrhage; Humans; Models, Statistical; Morpholines; Myocardial Infarction; Prognosis; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Russia; Stroke; Thiophenes; Warfarin	2014
Prasugrel vs clopidogrel in cardiogenic shock patients undergoing primary PCI for acute myocardial infarction. Results of the ISAR-SHOCK registry. Thrombosis and haemostasis, 2014, Volume: 112, Issue:6 Topics: Aged; Aged, 80 and over; Blood Platelets; Clopidogrel; Coronary Thrombosis; Female; Germany; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Predictive Value of Tests; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Recurrence; Registries; Risk Factors; Shock, Cardiogenic; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome	2014
A comparison of bleeding complications between warfarin, dabigatran, and rivaroxaban in patients undergoing cryoballoon ablation. Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing, 2014, Volume: 41, Issue:3 Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Comorbidity; Cryosurgery; Dabigatran; Female; Hemorrhage; Humans; Incidence; Male; Morpholines; Retrospective Studies; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin	2014
Approach to the new oral anticoagulants in family practice: part 2: addressing frequently asked questions. Canadian family physician Medecin de famille canadien, 2014, Volume: 60, Issue:11 Topics: Acute Disease; Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Family Practice; Hemorrhage; Humans; Morpholines; Preoperative Care; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Time Factors; Venous Thromboembolism	2014
Transition from apixaban to warfarin--addressing excess stroke, systemic embolism, and major bleeding. American heart journal, 2015, Volume: 169, Issue:1 Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; International Normalized Ratio; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Vitamin K; Warfarin	2015
Managing bleeding and emergency reversal of newer oral anticoagulants: a review for primary care providers. Hospital practice (1995), 2014, Volume: 42, Issue:4 Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Hospitalization; Humans; Morpholines; Primary Health Care; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes	2014
Safety of novel oral anticoagulants compared with uninterrupted warfarin for catheter ablation of atrial fibrillation. The Annals of pharmacotherapy, 2015, Volume: 49, Issue:3 Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Drug Administration Schedule; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin	2015
A pharmacodynamic comparison of 5 anti-platelet protocols in patients with ST-elevation myocardial infarction undergoing primary PCI. BMC cardiovascular disorders, 2014, Dec-16, Volume: 14 Topics: Adenosine; Aged; Blood Platelets; Clinical Protocols; Clopidogrel; Drug Administration Schedule; Electrocardiography; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Thiophenes; Ticagrelor; Ticlopidine	2014
Prasugrel in NSTEMI: loading after seeing. Journal of the American College of Cardiology, 2014, Dec-23, Volume: 64, Issue:24 Topics: Female; Hemorrhage; Humans; Intraoperative Complications; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Prasugrel Hydrochloride; Thiophenes	2014
[Retrospective study about 73 consecutive patients treated by direct oral anticoagulant and admitted to an emergency room]. Journal des maladies vasculaires, 2015, Volume: 40, Issue:1 Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Emergency Service, Hospital; Female; France; Hemorrhage; History, Ancient; Hospitalization; Humans; Male; Morpholines; Retrospective Studies; Risk Factors; Rivaroxaban; Stroke; Thiophenes	2015
Pericardial bleeding risk with non-vitamin K oral anticoagulants: a meta-analysis. International journal of cardiology, 2015, Mar-01, Volume: 182 Topics: Factor Xa Inhibitors; Hemorrhage; Humans; Male; Morpholines; Pericarditis; Thiophenes	2015
Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis. Circulation, 2015, Mar-17, Volume: 131, Issue:11 Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Databases, Factual; Dose-Response Relationship, Drug; Drug Utilization; Female; Hemorrhage; Hospitalization; Humans; Kidney; Kidney Failure, Chronic; Male; Matched-Pair Analysis; Middle Aged; Morpholines; Poisson Distribution; Practice Patterns, Physicians'; Renal Dialysis; Retrospective Studies; Risk; Rivaroxaban; Stroke; Thiophenes; Warfarin	2015
Web Exclusives. The consult guys--too close for comfort? For how long must I stop this anticoagulant for an epidural? Annals of internal medicine, 2015, 01-20, Volume: 162, Issue:2 Topics: Adrenal Cortex Hormones; Aged; Anticoagulants; Drug Administration Schedule; Female; Hemorrhage; Humans; Injections, Epidural; Morpholines; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Warfarin; Withholding Treatment	2015
[Extended options of anticoagulant treatment in thromboembolism]. Vnitrni lekarstvi, 2014, Volume: 60, Issue:11 Topics: Administration, Oral; Aged; Antithrombins; Benzimidazoles; beta-Alanine; Czech Republic; Dabigatran; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Pulmonary Embolism; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thromboembolism; Venous Thrombosis	2014
Risk stratification and stroke prevention therapy care gaps in Canadian atrial fibrillation patients (from the Co-ordinated National Network to Engage Physicians in the Care and Treatment of Patients With Atrial Fibrillation chart audit). The American journal of cardiology, 2015, Mar-01, Volume: 115, Issue:5 Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Canada; Dabigatran; Hemorrhage; Humans; Male; Medical Audit; Morpholines; Predictive Value of Tests; Primary Health Care; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Warfarin	2015
[New oral anticoagulants in venous thromboembolism. General practice information on switching, monitoring, pausing]. MMW Fortschritte der Medizin, 2015, Jan-19, Volume: 157, Issue:1 Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Monitoring; Drug Substitution; Half-Life; Hemorrhage; Humans; Kidney Function Tests; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Thromboembolism; Warfarin	2015
Cardiology patient page. Patient guide for taking the non-vitamin K antagonist oral anticoagulants for atrial fibrillation. Circulation, 2015, Apr-21, Volume: 131, Issue:16 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Contraindications; Dabigatran; Drug Interactions; Drug Monitoring; Drug Substitution; Female; Hemorrhage; Humans; Kidney Diseases; Kidney Function Tests; Male; Morpholines; Pyrazoles; Pyridines; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Thrombophilia	2015
Has Prasugrel Been Compared Correctly With Clopidogrel in Non-ST-Segment Elevation Acute Coronary Syndrome? Journal of the American College of Cardiology, 2015, Apr-28, Volume: 65, Issue:16 Topics: Female; Hemorrhage; Humans; Intraoperative Complications; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Thiophenes	2015
Reply: Has Prasugrel Been Compared Correctly With Clopidogrel in Non-ST-Segment Elevation Acute Coronary Syndrome? Journal of the American College of Cardiology, 2015, Apr-28, Volume: 65, Issue:16 Topics: Female; Hemorrhage; Humans; Intraoperative Complications; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Thiophenes	2015
Not All NSTEMIs Are Created Equal. Journal of the American College of Cardiology, 2015, Apr-28, Volume: 65, Issue:16 Topics: Female; Hemorrhage; Humans; Intraoperative Complications; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Thiophenes	2015
Reply: Not All NSTEMIs Are Created Equal. Journal of the American College of Cardiology, 2015, Apr-28, Volume: 65, Issue:16 Topics: Female; Hemorrhage; Humans; Intraoperative Complications; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Thiophenes	2015
Rivaroxaban 2.5 mg. No justification for using this anticoagulant after an acute coronary syndrome. Prescrire international, 2014, Volume: 23, Issue:153 Topics: Acute Coronary Syndrome; Administration, Oral; Drug Dosage Calculations; Drug Therapy, Combination; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Patient Selection; Platelet Aggregation Inhibitors; Recurrence; Risk Assessment; Risk Factors; Rivaroxaban; Secondary Prevention; Thiophenes; Treatment Outcome	2014
Complications With New Oral Anticoagulants Dabigatran and Rivaroxaban in Cutaneous Surgery. Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 2015, Volume: 41, Issue:7 Topics: Administration, Oral; Aged; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Dermatologic Surgical Procedures; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Minnesota; Mohs Surgery; Morpholines; Retrospective Studies; Risk Factors; Rivaroxaban; Skin Diseases; Thiophenes	2015
[The X-VeRT study]. Giornale italiano di cardiologia (2006), 2015, Volume: 16, Issue:6 Topics: Adult; Aged; Anticoagulants; Atrial Fibrillation; Electric Countershock; Embolism; Factor Xa Inhibitors; Heart Diseases; Hemorrhage; Humans; International Normalized Ratio; Middle Aged; Morpholines; Multicenter Studies as Topic; Myocardial Infarction; Prospective Studies; Randomized Controlled Trials as Topic; Research Design; Risk; Rivaroxaban; Stroke; Thiophenes; Thrombophilia; Time Factors; Treatment Outcome; Vitamin K; Warfarin	2015
Protective effects of batimastat against hemorrhagic injuries in delayed jellyfish envenomation syndrome models. Toxicon : official journal of the International Society on Toxinology, 2015, Dec-15, Volume: 108 Topics: Angiography; Animals; Bites and Stings; Cnidarian Venoms; Hemorrhage; In Situ Nick-End Labeling; Kidney; Liver; Male; Metalloproteases; Mice; Necrosis; Phenylalanine; Protective Agents; Rats; Rats, Sprague-Dawley; Scyphozoa; Syndrome; Thiophenes; X-Ray Microtomography	2015
Letter to the Editor "Gender related aspects of bleeding with rivaroxaban in venous thromboembolism - Potential for pitfalls": A comment to "Impact of gender on safety and efficacy of rivaroxaban in adolescents & young adults with venous thromboembolism" Thrombosis research, 2016, Volume: 148 Topics: Adult; Anticoagulants; Enoxaparin; Hemorrhage; Humans; Morpholines; Rivaroxaban; Thiophenes; Thrombosis; Venous Thromboembolism	2016
Rivaroxaban for thromboprophylaxis. The New England journal of medicine, 2008, Nov-13, Volume: 359, Issue:20 Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Enoxaparin; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Pulmonary Embolism; Risk; Rivaroxaban; Thiophenes; Venous Thromboembolism	2008
Efficacy and safety of prasugrel compared with clopidogrel in patients with acute coronary syndromes: results of TRITON-TIMI 38 trials. Expert review of cardiovascular therapy, 2009, Volume: 7, Issue:1 Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Clinical Trials, Phase III as Topic; Clopidogrel; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Randomized Controlled Trials as Topic; Thiophenes; Ticlopidine	2009
Another view on prasugrel. Thrombosis and haemostasis, 2009, Volume: 101, Issue:1 Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Animals; Aspirin; Blood Platelets; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; Drug Administration Schedule; Drug Resistance; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Research Design; Risk Assessment; Stents; Thiophenes; Ticlopidine; Treatment Outcome	2009
Clopidogrel versus prasugrel in rabbits. Effects on thrombosis, haemostasis, platelet function and response variability. Thrombosis and haemostasis, 2009, Volume: 101, Issue:1 Topics: Adenosine Diphosphate; Administration, Oral; Animals; Binding, Competitive; Bleeding Time; Clopidogrel; Disease Models, Animal; Dose-Response Relationship, Drug; Fibrinolytic Agents; Hemorrhage; Hemostasis; Male; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Rabbits; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Thionucleotides; Thiophenes; Thrombosis; Ticlopidine	2009
[Summary and perspectives. Rivaroxaban]. Annales francaises d'anesthesie et de reanimation, 2008, Volume: 27 Suppl 3 Topics: Administration, Oral; Aged; Anticoagulants; Clinical Trials, Phase III as Topic; Comorbidity; Enoxaparin; Factor Xa Inhibitors; Fibrinolytic Agents; Hemorrhage; Humans; Kidney Failure, Chronic; Morpholines; Obesity; Postoperative Complications; Preanesthetic Medication; Rivaroxaban; Thiophenes; Thromboembolism; Thrombophilia; Venous Thrombosis	2008
Ischaemia versus bleeding: the art of clinical decision-making. Lancet (London, England), 2009, Feb-28, Volume: 373, Issue:9665 Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Disease; Decision Making; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Randomized Controlled Trials as Topic; Thiophenes; Ticlopidine	2009
Future of oral antiplatelet therapy: four challenged hypotheses. Thrombosis and haemostasis, 2009, Volume: 101, Issue:6 Topics: Adenosine; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Cost-Benefit Analysis; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Prognosis; Purinergic P2 Receptor Antagonists; Pyridines; Risk Assessment; Survival Rate; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2009
Favorable therapeutic index of the direct factor Xa inhibitors, apixaban and rivaroxaban, compared with the thrombin inhibitor dabigatran in rabbits. Journal of thrombosis and haemostasis : JTH, 2009, Volume: 7, Issue:8 Topics: Animals; Benzimidazoles; Blood Coagulation Tests; Dabigatran; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Fibrinolytic Agents; Hemorrhage; Morpholines; Pyrazoles; Pyridines; Pyridones; Rabbits; Rivaroxaban; Thiophenes; Thrombin; Venous Thrombosis	2009
Prasugrel in clinical practice. The New England journal of medicine, 2009, Sep-03, Volume: 361, Issue:10 Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Combined Modality Therapy; Coronary Thrombosis; Drug Administration Schedule; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Secondary Prevention; Stents; Thiophenes	2009
Rivaroxaban versus enoxaparin after total knee arthroplasty. Lancet (London, England), 2009, Aug-29, Volume: 374, Issue:9691 Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Enoxaparin; Hemorrhage; Humans; Morpholines; Randomized Controlled Trials as Topic; Research Design; Risk Factors; Rivaroxaban; Safety; Thiophenes; Venous Thrombosis	2009
Weighing benefits and risks--the FDA's review of prasugrel. The New England journal of medicine, 2009, Sep-03, Volume: 361, Issue:10 Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Causality; Clinical Trials as Topic; Combined Modality Therapy; Coronary Thrombosis; Drug Administration Schedule; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction; Neoplasms; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; United States; United States Food and Drug Administration	2009
Underestimation of the effect of bleeding in clinical trials. Lancet (London, England), 2009, Oct-03, Volume: 374, Issue:9696 Topics: Acute Coronary Syndrome; Clinical Trials, Phase II as Topic; Data Interpretation, Statistical; Hemorrhage; Humans; Morpholines; Research Design; Rivaroxaban; Thiophenes; Treatment Outcome; Young Adult	2009
[Prasugrel or clopidogrel in patients with coronary intervention]. Der Internist, 2009, Volume: 50, Issue:11 Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Coronary Artery Bypass; Double-Blind Method; Endpoint Determination; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Thiophenes; Ticlopidine	2009
Prasugrel: new drug. After angioplasty and stenting: continue to use aspirin + clopidogrel. Prescrire international, 2009, Volume: 18, Issue:103 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Drug-Eluting Stents; Europe; Hemorrhage; Humans; Ischemic Attack, Transient; Myocardial Infarction; Neoplasms; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Randomized Controlled Trials as Topic; Receptors, Purinergic P2; Recurrence; Stents; Stroke; Thiophenes; Ticlopidine; Treatment Outcome	2009
P2Y12 inhibitors: thienopyridines and direct oral inhibitors. Hamostaseologie, 2009, Volume: 29, Issue:4 Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Aspirin; Atherosclerosis; Coronary Artery Bypass; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Postoperative Complications; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Stroke; Thiophenes; Ticagrelor	2009
Prasugrel for acute coronary syndromes: faster, more potent, but higher bleeding risk. Cleveland Clinic journal of medicine, 2009, Volume: 76, Issue:12 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Hemorrhage; Humans; Patient Selection; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine	2009
Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasug Circulation, 2010, Jan-05, Volume: 121, Issue:1 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Combined Modality Therapy; Cost-Benefit Analysis; Databases, Factual; Drug Costs; Follow-Up Studies; Hemorrhage; Hospitalization; Humans; Life Expectancy; Multicenter Studies as Topic; Myocardial Infarction; Outcome and Process Assessment, Health Care; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Stroke; Thiophenes; Thrombolytic Therapy; Ticlopidine; United States	2010
Delays of event adjudication in the TRITON trial. Cardiology, 2010, Volume: 115, Issue:3 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Cerebral Infarction; Clopidogrel; Coronary Restenosis; Data Collection; Disease-Free Survival; Hemorrhage; Myocardial Infarction; Observer Variation; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Reproducibility of Results; Research Design; Stents; Thiophenes; Ticlopidine; Treatment Outcome; United States; United States Food and Drug Administration	2010
Oral antiplatelet therapy for the management of acute coronary syndromes: defining the role of prasugrel. Critical care nurse, 2011, Volume: 31, Issue:1 Topics: Acute Coronary Syndrome; Administration, Oral; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Factors; Thiophenes; Thrombosis; Treatment Outcome	2011
[Comparison of effects of prasugrel and clopidogrel in patients with acute coronary syndrome, subjected to percutaneous coronary intervention: TRITON-TIMI 38 trial]. Kardiologiia, 2010, Volume: 50, Issue:6 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Drug-Eluting Stents; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Stroke; Thiophenes; Thrombosis; Ticlopidine; Treatment Outcome	2010
[Prophylaxis of thrombembolic diseases with rivaroxaban]. Deutsche medizinische Wochenschrift (1946), 2010, Volume: 135, Issue:44 Topics: Administration, Oral; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Biological Availability; Dose-Response Relationship, Drug; Drug Interactions; Factor Xa Inhibitors; Fibrinolytic Agents; Hemorrhage; Humans; International Normalized Ratio; Metabolic Clearance Rate; Morpholines; Partial Thromboplastin Time; Postoperative Complications; Protein Binding; Prothrombin Time; Rivaroxaban; Thiophenes; Thromboembolism	2010
An algorithm for use of prasugrel (effient) in patients undergoing cardiac catheterization and percutaneous coronary intervention. Critical pathways in cardiology, 2010, Volume: 9, Issue:4 Topics: Angioplasty, Balloon, Coronary; Cardiac Catheterization; Clinical Protocols; Clinical Trials as Topic; Clopidogrel; Comparative Effectiveness Research; Guidelines as Topic; Hemorrhage; Humans; Myocardial Infarction; Patient Care Planning; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Assessment; Standard of Care; Thiophenes; Thrombolytic Therapy; Ticlopidine; Treatment Outcome	2010
Antiplatelet and antithrombotic treatment after primary percutaneous coronary intervention: balancing safety and efficacy. American heart journal, 2010, Volume: 160, Issue:6 Suppl Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Administration Schedule; Fibrinolytic Agents; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Assessment; Safety; Secondary Prevention; Thiophenes; Ticlopidine; Treatment Outcome; Warfarin	2010
New oral anticoagulants for thromboprophylaxis in patients having hip or knee arthroplasty. BMJ (Clinical research ed.), 2011, Jan-18, Volume: 342 Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; Cost-Benefit Analysis; Dabigatran; Drug Interactions; Hemorrhage; Humans; Kidney Diseases; Morpholines; Pyridines; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism	2011
Oral rivaroxaban for symptomatic venous thromboembolism. The New England journal of medicine, 2011, 03-24, Volume: 364, Issue:12 Topics: Acute Disease; Administration, Oral; Anticoagulants; Enoxaparin; Hemorrhage; Humans; Morpholines; Pulmonary Embolism; Recurrence; Risk Assessment; Rivaroxaban; Thiophenes; Venous Thrombosis	2011
[Do genetic factors reduce the effects of clopidogrel?]. Deutsche medizinische Wochenschrift (1946), 2011, Volume: 136, Issue:15 Topics: Adenosine; Clopidogrel; Cytochrome P-450 Enzyme System; Genetic Variation; Genotype; Hemorrhage; Humans; Isoenzymes; Pharmacogenetics; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2011
[Current and future therapies for prophylaxis of thromboembolism in atrial fibrillation]. MMW Fortschritte der Medizin, 2011, Apr-14, Volume: 153, Issue:15 Topics: Anticoagulants; Antithrombin Proteins; Atrial Fibrillation; Benzimidazoles; Dabigatran; Drug Therapy, Combination; Factor Xa Inhibitors; Fibrinolytic Agents; Guideline Adherence; Hemorrhage; Humans; Intracranial Embolism; Morpholines; Platelet Aggregation Inhibitors; Pyrazoles; Pyridines; Pyridones; Risk Factors; Rivaroxaban; Thiophenes; Vitamin K	2011
Prevalence of contraindications and conditions for precaution for prasugrel administration in a real world acute coronary syndrome population. Journal of thrombosis and thrombolysis, 2011, Volume: 32, Issue:3 Topics: Acute Coronary Syndrome; Age Factors; Aged; Aged, 80 and over; Diabetes Mellitus; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Piperazines; Prasugrel Hydrochloride; Prevalence; Prospective Studies; Purinergic P2Y Receptor Antagonists; Risk Factors; Stroke; Thiophenes	2011
The importance of high-quality evidence of the long-term impact of nonfatal events used in randomized controlled trials: a case study of prasugrel. Clinical pharmacology and therapeutics, 2011, Volume: 90, Issue:1 Topics: Drug-Related Side Effects and Adverse Reactions; Evidence-Based Medicine; Follow-Up Studies; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Research Design; Terminology as Topic; Thiophenes	2011
Prasugrel and bivalirudin for primary angioplasty: early results on stent thrombosis and bleeding. International journal of cardiology, 2011, Dec-01, Volume: 153, Issue:2 Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Cohort Studies; Drug Therapy, Combination; Female; Hemorrhage; Hirudins; Humans; Male; Middle Aged; Peptide Fragments; Piperazines; Prasugrel Hydrochloride; Recombinant Proteins; Stents; Thiophenes; Thrombosis; Time Factors	2011
Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model. Anesthesiology, 2012, Volume: 116, Issue:1 Topics: Anesthesia; Animals; Anticoagulants; Bleeding Time; Blood Coagulation Tests; Blood Pressure; Body Temperature; Dose-Response Relationship, Drug; Factor VIIa; Hemorrhage; Liver; Male; Monitoring, Physiologic; Morpholines; Prothrombin; Rabbits; Recombinant Proteins; Respiration, Artificial; Rivaroxaban; Spleen; Thiophenes; Thrombelastography; Thrombin; Thrombosis	2012
Lack of an antagonist to reverse the action of dabigatran. QJM : monthly journal of the Association of Physicians, 2012, Volume: 105, Issue:2 Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Dabigatran; Hemorrhage; Humans; Morpholines; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Warfarin	2012
Post percutaneous coronary intervention antiplatelet therapy: current perceptions, prospects and perplexity. Cardiology journal, 2011, Volume: 18, Issue:6 Topics: Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Clopidogrel; Coronary Restenosis; Drug Resistance; Drug Therapy, Combination; Drug-Eluting Stents; Hemorrhage; Humans; Metals; Patient Selection; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prosthesis Design; Risk Assessment; Risk Factors; Stents; Tetrazoles; Thiophenes; Thrombosis; Ticlopidine; Treatment Outcome	2011
I recently heard that there are alternative medications to the blood thinner warfarin. What are they, and how are they different? DukeMedicine healthnews, 2012, Volume: 18, Issue:1 Topics: Anticoagulants; Benzimidazoles; Cardiovascular Diseases; Dabigatran; Drug Approval; Drug Interactions; Food-Drug Interactions; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Warfarin	2012
Prasugrel during primary percutaneous coronary intervention: evidence from clinical data. Current vascular pharmacology, 2012, Volume: 10, Issue:4 Topics: Angioplasty, Balloon, Coronary; Arrhythmias, Cardiac; Combined Modality Therapy; Evidence-Based Medicine; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Precision Medicine; Purinergic P2Y Receptor Antagonists; Stents; Thiophenes; Thrombosis	2012
Determination of rivaroxaban in human plasma samples. Seminars in thrombosis and hemostasis, 2012, Volume: 38, Issue:2 Topics: Blood Coagulation; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Partial Thromboplastin Time; Prothrombin Time; Rivaroxaban; Thiophenes; Venous Thrombosis	2012
Cost-effectiveness of cytochrome P450 2C19 genotype screening for selection of antiplatelet therapy with clopidogrel or prasugrel. Pharmacotherapy, 2012, Volume: 32, Issue:4 Topics: Acute Coronary Syndrome; Aryl Hydrocarbon Hydroxylases; Cardiovascular Diseases; Clopidogrel; Computer Simulation; Cost-Benefit Analysis; Cytochrome P-450 CYP2C19; Decision Trees; Drugs, Generic; Genotype; Hemorrhage; Humans; Models, Economic; Models, Statistical; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Thrombolytic Therapy; Ticlopidine	2012
[Therapy of pulmonary embolism. Rivaroxaban is superior to standard therapy]. MMW Fortschritte der Medizin, 2012, Apr-19, Volume: 154, Issue:7 Topics: Anticoagulants; Hemorrhage; Humans; Morpholines; Pulmonary Embolism; Randomized Controlled Trials as Topic; Rivaroxaban; Secondary Prevention; Thiophenes; Venous Thrombosis	2012
Venous thromboembolism: EINSTEIN transforms anticoagulant therapy in acute PE. Nature reviews. Cardiology, 2012, May-08, Volume: 9, Issue:7 Topics: Acute Disease; Anticoagulants; Evidence-Based Medicine; Hemorrhage; Humans; Morpholines; Pulmonary Embolism; Randomized Controlled Trials as Topic; Recurrence; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism	2012
Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation. Journal of the American College of Cardiology, 2012, Aug-21, Volume: 60, Issue:8 Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Clinical Trials, Phase III as Topic; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Odds Ratio; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome	2012
Prasugrel: a guide to its use in patients with acute coronary syndromes undergoing percutaneous coronary intervention in the US. American journal of cardiovascular drugs : drugs, devices, and other interventions, 2012, Jun-01, Volume: 12, Issue:3 Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Clopidogrel; Economics, Pharmaceutical; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Factors; Thiophenes; Thrombosis; Ticlopidine; United States	2012
Rationale and design of XAMOS: noninterventional study of rivaroxaban for prophylaxis of venous thromboembolism after major hip and knee surgery. Vascular health and risk management, 2012, Volume: 8 Topics: Anticoagulants; Hemorrhage; Hip Joint; Humans; Knee Joint; Morpholines; Orthopedic Procedures; Registries; Research Design; Rivaroxaban; Thiophenes; Time Factors; Treatment Outcome; Venous Thromboembolism	2012
Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation. Circulation. Cardiovascular quality and outcomes, 2012, Jul-01, Volume: 5, Issue:4 Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Embolism; Evidence-Based Medicine; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Time Factors; Treatment Outcome; Warfarin	2012
Atrial fibrillation and acute myocardial infarction: antithrombotic therapy and outcomes. The American journal of medicine, 2012, Volume: 125, Issue:9 Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Comorbidity; Drug Therapy, Combination; Female; Fibrinolytic Agents; Hemorrhage; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Patient Discharge; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Research Design; Risk Assessment; Stroke; Thiophenes; Ticlopidine; Treatment Outcome; Warfarin	2012
A potent alternative to clopidogrel emerges. Prasugrel appears to lower heart attack risk for patients with acute coronary syndrome. Heart advisor, 2010, Volume: 13, Issue:5 Topics: Acute Coronary Syndrome; Clopidogrel; Drug Dosage Calculations; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine	2010
[Removal of epidural catheter under dual antiplatelet therapy following acute coronary syndrome : scenario without special consideration to the current guidelines on epidural regional anesthesia]. Der Anaesthesist, 2012, Volume: 61, Issue:8 Topics: Acute Coronary Syndrome; Analgesia, Epidural; Aspirin; Catheterization; Clopidogrel; Digestive System Surgical Procedures; Drug Interactions; Hemorrhage; Humans; Male; Middle Aged; Pain, Postoperative; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Risk; Thiophenes; Ticlopidine	2012
Relationship between post-treatment platelet reactivity and ischemic and bleeding events at 1-year follow-up in patients receiving prasugrel. Journal of thrombosis and haemostasis : JTH, 2012, Volume: 10, Issue:10 Topics: Acute Coronary Syndrome; Blood Platelets; Cell Adhesion Molecules; Coronary Thrombosis; Female; Follow-Up Studies; France; Hemorrhage; Humans; Kaplan-Meier Estimate; Linear Models; Male; Microfilament Proteins; Middle Aged; Multivariate Analysis; Myocardial Ischemia; Odds Ratio; Percutaneous Coronary Intervention; Phosphoproteins; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Predictive Value of Tests; Proportional Hazards Models; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Risk Assessment; Risk Factors; Thiophenes; Time Factors; Treatment Outcome	2012
Danger ahead: watch out for indirect comparisons! Journal of the American College of Cardiology, 2012, Aug-21, Volume: 60, Issue:8 Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Female; Hemorrhage; Humans; Male; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiophenes	2012
Periprocedural anticoagulant management. Hospital practice (1995), 2012, Volume: 40, Issue:3 Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Coronary Restenosis; Dabigatran; Heart Valve Prosthesis; Hemorrhage; Humans; Morpholines; Neoplasms; Perioperative Care; Risk Assessment; Rivaroxaban; Stents; Thiophenes; Venous Thromboembolism; Warfarin	2012
Prevention of stent thrombosis with reduced dose of prasugrel in two patients undergoing treatment of cerebral aneurysms with pipeline embolisation devices. BMJ case reports, 2012, Oct-26, Volume: 2012 Topics: Blood Platelets; Clopidogrel; Embolization, Therapeutic; Female; Hemorrhage; Humans; Intracranial Aneurysm; Intracranial Thrombosis; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Stents; Thiophenes; Ticlopidine; Treatment Outcome	2012
The effects of rivaroxaban on the complications of surgery after total hip or knee replacement: results from the RECORD programme. The Journal of bone and joint surgery. British volume, 2012, Volume: 94, Issue:11 Topics: Anticoagulants; Arthroplasty, Replacement, Ankle; Arthroplasty, Replacement, Knee; Clinical Trials, Phase III as Topic; Enoxaparin; Hemarthrosis; Hemorrhage; Humans; Morpholines; Postoperative Complications; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism	2012
[Questions--answers on the use of rivaroxaban for the treatment of venous thromboembolic disease]. Journal des maladies vasculaires, 2012, Volume: 37, Issue:6 Topics: Age Factors; Anticoagulants; Drug Interactions; Factor Xa; France; Hemorrhage; Humans; Morpholines; Pulmonary Embolism; Risk Factors; Rivaroxaban; Thiophenes; Venous Thromboembolism; Venous Thrombosis; Vitamins	2012
Primary and secondary prevention with new oral anticoagulant drugs for stroke prevention in atrial fibrillation: indirect comparison analysis. BMJ (Clinical research ed.), 2012, Nov-05, Volume: 345 Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Clinical Trials, Phase III as Topic; Comparative Effectiveness Research; Dabigatran; Dose-Response Relationship, Drug; Drug Monitoring; Female; Hemorrhage; Humans; Male; Morpholines; Pharmacovigilance; Primary Prevention; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Secondary Prevention; Stroke; Thiophenes; Warfarin	2012
Genetic testing in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a cost-effectiveness analysis. Journal of thrombosis and haemostasis : JTH, 2013, Volume: 11, Issue:1 Topics: Acute Coronary Syndrome; Aryl Hydrocarbon Hydroxylases; Cerebrovascular Disorders; Clopidogrel; Computer Simulation; Cost-Benefit Analysis; Cytochrome P-450 CYP2C19; Decision Support Techniques; Disease-Free Survival; Drug Costs; Gene Frequency; Genetic Predisposition to Disease; Genetic Testing; Health Care Costs; Hemorrhage; Humans; Insurance, Health, Reimbursement; Kaplan-Meier Estimate; Markov Chains; Medicare; Models, Economic; Myocardial Infarction; Percutaneous Coronary Intervention; Pharmacogenetics; Phenotype; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Predictive Value of Tests; Quality-Adjusted Life Years; Risk Assessment; Risk Factors; Thiophenes; Thrombosis; Ticlopidine; Time Factors; Treatment Outcome; United States	2013
Efficacy and safety of thromboprophylaxis with low-molecular-weight heparin or rivaroxaban in hip and knee replacement surgery: findings from the ORTHO-TEP registry. Thrombosis and haemostasis, 2013, Volume: 109, Issue:1 Topics: Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Transfusion; Female; Fibrinolytic Agents; Germany; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Kaplan-Meier Estimate; Length of Stay; Logistic Models; Male; Middle Aged; Morpholines; Multivariate Analysis; Odds Ratio; Proportional Hazards Models; Registries; Retrospective Studies; Risk Factors; Rivaroxaban; Thiophenes; Thromboembolism; Time Factors; Treatment Outcome; Venous Thrombosis	2013
CYP2C192 and 17 alleles have a significant impact on platelet response and bleeding risk in patients treated with prasugrel after acute coronary syndrome. JACC. Cardiovascular interventions, 2012, Volume: 5, Issue:12 Topics: Acute Coronary Syndrome; Alleles; Aryl Hydrocarbon Hydroxylases; Blood Platelets; Cytochrome P-450 CYP2C19; Female; Hemorrhage; Humans; Male; Middle Aged; Piperazines; Postoperative Complications; Prasugrel Hydrochloride; Prospective Studies; Risk Factors; Thiophenes	2012
Reply: To PMID 22575324. Journal of the American College of Cardiology, 2013, Feb-05, Volume: 61, Issue:5 Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Female; Hemorrhage; Humans; Male; Morpholines; Pyrazoles; Pyridines; Pyridones; Stroke; Thiophenes	2013
Lack of stroke subtype information may hinder indirect comparison between the ROCKET-AF and other trials of new oral anticoagulants. Journal of the American College of Cardiology, 2013, Feb-05, Volume: 61, Issue:5 Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Female; Hemorrhage; Humans; Male; Morpholines; Pyrazoles; Pyridines; Pyridones; Stroke; Thiophenes	2013
Repeated bleeding complications during therapy with vitamin K antagonists in a patient with the VKORC12A and the CYP2C93/3 alleles: genetic testing to support switching to new oral anticoagulants. Thrombosis research, 2013, Volume: 131, Issue:3* Topics: Administration, Oral; Adult; Anticoagulants; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C9; Exons; Female; Genetic Predisposition to Disease; Genetic Testing; Genotype; Haplotypes; Hemorrhage; Humans; Hypertension; Mixed Function Oxygenases; Morpholines; Mutation; Poland; Rivaroxaban; Thiophenes; Vitamin K; Vitamin K Epoxide Reductases; Warfarin	2013
Transitions of care in anticoagulation management for patients with atrial fibrillation. Hospital practice (1995), 2012, Volume: 40, Issue:4 Topics: Administration, Oral; Aftercare; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Continuity of Patient Care; Dabigatran; Drug Monitoring; Drug Substitution; Emergencies; Hemorrhage; Humans; Morpholines; Patient Education as Topic; Rivaroxaban; Stroke; Thiophenes; Warfarin	2012
[Budgetary impact for the National Health System of apixaban prophylaxis of venous thromboembolism in patients undergoing total knee or hip replacement]. Revista espanola de salud publica, 2012, Volume: 86, Issue:6 Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Budgets; Cost Control; Dabigatran; Enoxaparin; Female; Fibrinolytic Agents; Fondaparinux; Hemorrhage; Humans; Morpholines; Polysaccharides; Pulmonary Embolism; Pyrazoles; Pyridones; Rivaroxaban; Spain; State Medicine; Thiophenes; Venous Thromboembolism	2012
Effect of CYP2C192 and 17 genetic variants on platelet response to clopidogrel and prasugrel maintenance dose and relation to bleeding complications. The American journal of cardiology, 2013, Apr-01, Volume: 111, Issue:7 Topics: Acute Coronary Syndrome; Alleles; Aryl Hydrocarbon Hydroxylases; Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Genetic Variation; Genotype; Hemorrhage; Humans; Male; Microfilament Proteins; Middle Aged; Myocardial Infarction; Phosphoproteins; Piperazines; Polymerase Chain Reaction; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Risk Factors; Thiophenes; Ticlopidine; Treatment Outcome	2013
A comparison of the pharmacological profiles of prasugrel and ticagrelor assessed by platelet aggregation, thrombus formation and haemostasis in rats. British journal of pharmacology, 2013, Volume: 169, Issue:1 Topics: Adenosine; Animals; Blood Coagulation Tests; Dose-Response Relationship, Drug; Hemorrhage; Hemostasis; Male; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prodrugs; Purinergic P2Y Receptor Antagonists; Rats; Rats, Sprague-Dawley; Risk; Thiophenes; Thrombosis; Ticagrelor	2013
Pulmonary hemorrhage induced by jararhagin, a metalloproteinase from Bothrops jararaca snake venom. Toxicology and applied pharmacology, 2003, Nov-15, Volume: 193, Issue:1 Topics: alpha-Macroglobulins; Animals; Blood Coagulation; Bothrops; Bothrops jararaca Venom; Crotalid Venoms; Hemorrhage; Lung Diseases; Metalloendopeptidases; Mice; Microscopy, Electron; Phenylalanine; Platelet Aggregation Inhibitors; Protease Inhibitors; Thiophenes; Tissue Distribution	2003
Effect of the metalloproteinase inhibitor batimastat in the systemic toxicity induced by Bothrops asper snake venom: understanding the role of metalloproteinases in envenomation. Toxicon : official journal of the International Society on Toxinology, 2004, Mar-15, Volume: 43, Issue:4 Topics: Animals; Blood Coagulation; Bothrops; Costa Rica; Crotalid Venoms; Dose-Response Relationship, Drug; Drug Interactions; Factor X; Hemorrhage; Histological Techniques; Lethal Dose 50; Lung; Metalloendopeptidases; Mice; Phenylalanine; Prothrombin; Snake Bites; Thiophenes; Time Factors	2004
Hypobaric-hypoxia-induced pulmonary damage in rats ameliorated by antioxidant erdosteine. Acta histochemica, 2006, Volume: 108, Issue:1 Topics: Animals; Antibodies, Monoclonal; Antioxidants; Atmosphere Exposure Chambers; Atmospheric Pressure; Endothelial Cells; Hematocrit; Hemorrhage; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Hypoxia; Immunohistochemistry; Lung; Malondialdehyde; Pulmonary Artery; Random Allocation; Rats; Thioglycolates; Thiophenes	2006
Prevention and treatment of experimental thrombosis in rabbits with rivaroxaban (BAY 597939)--an oral, direct factor Xa inhibitor. Thrombosis and haemostasis, 2007, Volume: 97, Issue:3 Topics: Administration, Oral; Animals; Anticoagulants; Blood Coagulation Tests; Disease Models, Animal; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Fibrinolytic Agents; Fondaparinux; Hemorrhage; Humans; Infusions, Intravenous; Injections, Intravenous; Jugular Veins; Ligation; Morpholines; Nadroparin; Polysaccharides; Rabbits; Random Allocation; Rivaroxaban; Thiophenes; Thromboplastin; Venous Thrombosis	2007
Intensifying platelet inhibition--navigating between Scylla and Charybdis. The New England journal of medicine, 2007, Nov-15, Volume: 357, Issue:20 Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Ischemia; Piperazines; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine	2007
[Prasugrel versus clopidogrel. From the American Heart Association meeting, 2007]. Revue medicale suisse, 2008, Feb-13, Volume: 4, Issue:144 Topics: Clopidogrel; Congresses as Topic; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticlopidine	2008
Prasugrel versus clopidogrel. The New England journal of medicine, 2008, Mar-20, Volume: 358, Issue:12 Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Stents; Stroke; Thiophenes; Ticlopidine	2008
Prasugrel versus clopidogrel. The New England journal of medicine, 2008, Mar-20, Volume: 358, Issue:12 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk; Thiophenes; Ticlopidine	2008
Bleeding risks with prasugrel in the TRITON trial: good news ... bad news. Cardiology, 2008, Volume: 111, Issue:4 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Drug Therapy, Combination; Hematemesis; Hematuria; Hemorrhage; Humans; Intracranial Hemorrhages; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Thiophenes; Ticlopidine	2008
For better or for worse: the future of antiplatelet therapy. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2008, Jun-01, Volume: 65, Issue:11 Topics: Acute Coronary Syndrome; Clopidogrel; Coronary Disease; Forecasting; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Stroke; Thiophenes; Thrombolytic Therapy; Thrombosis; Ticlopidine	2008
Effectiveness of batimastat, a synthetic inhibitor of matrix metalloproteinases, in neutralizing local tissue damage induced by BaP1, a hemorrhagic metalloproteinase from the venom of the snake bothrops asper. Biochemical pharmacology, 2000, Jul-15, Volume: 60, Issue:2 Topics: Animals; Bothrops; Carbon-Oxygen Lyases; Crotalid Venoms; Deoxyribonuclease IV (Phage T4-Induced); DNA-(Apurinic or Apyrimidinic Site) Lyase; Drug Interactions; Edema; Hemorrhage; Matrix Metalloproteinase Inhibitors; Metalloendopeptidases; Mice; Phenylalanine; Protease Inhibitors; Thiophenes	2000
[Potentialization of the anticoagulant action of antivitamin K by thienylic acid]. La Nouvelle presse medicale, 1977, Sep-17, Volume: 6, Issue:30 Topics: Acenocoumarol; Aged; Drug Synergism; Gastrointestinal Hemorrhage; Glycolates; Hemorrhage; Humans; Male; Phenoxyacetates; Thiophenes	1977
Protective effects of a thromboxane synthetase inhibitor, a thromboxane antagonist, a lipoxygenase inhibitor and a leukotriene C4, D4 antagonist on myocardial injury caused by acute myocardial infarction in the canine heart. Japanese circulation journal, 1989, Volume: 53, Issue:9 Topics: Animals; Arrhythmias, Cardiac; Benzoquinones; Cardiomyopathies; Chromones; Coronary Disease; Dogs; Hemorrhage; Lipoxygenase Inhibitors; Male; Myocardial Infarction; Myocardium; Neutrophils; Quinones; SRS-A; Thiophenes; Thromboxane A2; Thromboxane-A Synthase	1989
Hemostatic effects of microfibrillar collagen hemostat (MCH) in experimental coagulopathy model and its mechanism of hemostasis. Thrombosis research, 1986, May-01, Volume: 42, Issue:3 Topics: Animals; Aspirin; Blood Coagulation Disorders; Cattle; Collagen; Dogs; Hemorrhage; Hemostatic Techniques; Hemostatics; Heparin; Spleen; Thiophenes; Thrombocytopenia; Ticlopidine; Warfarin	1986
Ticlopidine as a hemorrhagic risk factor in coronary surgery. Drug intelligence & clinical pharmacy, 1985, Volume: 19, Issue:9 Topics: Adult; Coronary Disease; Female; Hemorrhage; Humans; Male; Platelet Aggregation; Platelet Count; Postoperative Complications; Retrospective Studies; Risk; Thiophenes; Ticlopidine	1985
[Effect of tiemonium iodide (Visceralgine) on the ureteral contractile activities and its clinical use in urology]. Hinyokika kiyo. Acta urologica Japonica, 1970, Volume: 16, Issue:10 Topics: Adult; Aged; Female; Hemorrhage; Humans; Injections, Intramuscular; Iodides; Male; Middle Aged; Morpholines; Muscle Contraction; Parasympatholytics; Prostatic Hyperplasia; Prostatic Neoplasms; Quaternary Ammonium Compounds; Thiophenes; Tuberculosis, Renal; Ureter; Urologic Diseases; Uterine Neoplasms	1970